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ABSTRACT 
 
Kellie Adrienne Park 
 
CELLULAR MECHANISMS MEDIATING THE ACTIONS OF NERVE GROWTH 
FACTOR IN SENSORY NEURONS 
 
 Nerve growth factor (NGF) is a neurotrophin upregulated with injury and 
inflammation. Peripheral administration of NGF causes hyperalgesia and 
allodynia in animals. Blocking NGF signaling reverses these effects. At the 
cellular level, chronic exposure of sensory neurons to NGF enhances expression 
the neurotransmitter, calcitonin gene-related peptide (CGRP). Acute exposure to 
NGF increases capsaicin-evoked CGRP release from sensory neurons in culture. 
Thus, NGF increases peptide release from neurons by: (1) increasing expression 
of peptides, and/or (2) altering their sensitivity. The increase in peptide outflow by 
either mechanism could contribute to development of hyperalgesia and allodynia. 
The signaling cascades mediating the actions of NGF in sensory neurons are 
unclear. Therefore, experiments were designed to determine which pathways 
regulate changes in iCGRP content and evoked release from primary sensory 
neurons in culture.  
 The Ras/MEK/ERK cascade was identified as a possible regulator of 
iCGRP expression in response to NGF. To test this pathway, it was manipulated 
in neurons by (1) expression of dominant negative or constitutively active 
isoforms of Ras, (2) farnesyltransferase inhibition, (3) manipulation of the 
RasGAP, synGAP, and (4) blocking MEK activity. When the pathway was 
blocked, the NGF-induced increase in iCGRP expression was attenuated. When 
the Ras pathway was activated, iCGRP expression increased. These data 
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indicate that Ras, and downstream signaling kinases, MEK and ERK, regulate 
the NGF-induced increases in CGRP in sensory neurons.  
 To determine which pathway(s) regulate the increase in capsaicin-evoked 
iCGRP release upon brief exposure to NGF, the Ras/MEK/ERK pathway was 
manipulated as described above, and pharmacological inhibitors of the PI3 
kinase, PLC, and Src kinase pathways were used.  There were no differences 
observed in NGF-sensitization when the Ras and PI3 kinase pathways were 
inhibited, suggesting these two pathways were not involved. However, when the 
Src kinase inhibitor PP2 was used, the NGF-induced increase in release was 
completely blocked. Furthermore, the PKC inhibitor, BIM, also inhibited the 
sensitization by NGF. This data indicate Src and PKC regulate of sensitivity of 
sensory neurons in response to brief exposure to NGF. Thus, there is differential 
regulation of iCGRP content and evoked release from sensory neurons in 
response to NGF.  
 
 
 
 
Michael R. Vasko, Ph.D., Chairperson 
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 INTRODUCTION 
 
Pain Perception and Pain Pathways in Normal Mammalian Physiology 
 
Physiological Pain Perception 
 Pain is a sensory modality defined by the International Association for the Study 
of Pain® (IASP) as “an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage…”  (IASP Task Force on Taxonomy, 1994). Pain is a 
prevalent symptom of an acute injury and of many chronic disease. It affects 
approximately one quarter of the US population (75 million individuals) each year and is 
one of the most common symptoms that causes people to seek medical attention 
(Brownlee and Schrof, 1997; Gureje et al., 1998; Goodman, 2003; Woolf, 2004). Pain 
can be either acute (defined as pain for less than three months), persistent 
(defined as three to six months), or chronic (greater than six months) (Bonica JJ 
and Loeser JD, 1990; Portenoy RK and Kanner RM, 1996).  
 Pain results from a noxious stimulus and from injury to somatic and/or 
visceral tissues. Pain is not uniform, but has many different qualities (Portenoy 
RK and Kanner RM, 1996). For instance, pain resulting from activation of somatic 
primary sensory neurons is usually well-localized. Somatic pain is usually 
described as stabbing, lancinating (lightening-like), aching, squeezing, or 
throbbing. Pain resulting from visceral primary sensory neurons is not well-
localized due in past to fewer nociceptors per volume of tissue, and is often 
described as diffuse and is usually dull, achy, or cramping. If visceral pain is 
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 sharp or stabbing, the pain usually results from organs with capsules, or 
coverings of fiberous tissue that are heavily innervated (Bonica JJ and Loeser 
JD, 1990).   
 
Dorsal Root Ganglion Neurons 
 The cell bodies of primary sensory neurons, which are responsible transducing 
sensory input from the cutaneous and visceral sites to the spinal cord are located 
in dorsal root ganglia. These ganglia are found in the intervertebral foramen of the 
vertebral column. These cells are the basis for sensing light touch, vibration, 
position in space, themosensation, itch, and nociception. Different subsets of 
neurons transduce each of these modalities, although some neurons are 
polymodal.  
 A specific subset of sensory neurons, nociceptors, or neurons that 
transduce noxious stimuli into electrical and chemical signals are the focus of this 
thesis (Besson and Chaouch, 1987). Under non-pathological conditions, this subset of 
sensory neurons has the ability to respond to noxious thermal, chemical, or 
mechanical stimuli. These neurons have small diameter cell bodies whose axons are 
lightly myelinated (A-δ fibers) or unmyelinated axons (C-fibers). Besides the presence of 
myelin, the definitive way to distinguish between these two types of nociceptive neurons 
is by conduction velocity: C-fiber action potentials travel at 0.2-1.5m/s, whereas A-δ 
fiber action potentials travel much faster at 5-30m/s (Kandel and Schwartz, 2000).  
 Primary sensory neurons are pseudounipolar. They have two fused processes 
that form a single bifurcating axon as it leaves the cell body. The peripheral 
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 branch of the axon innervates cutaneous tissues and viscera. The peripheral 
ends of the axon terminate in a branching pattern in structures such as the 
dermis and epidermis of the skin. The central branch travels proximally and 
synapses on second order neurons in the dorsal horn of the spinal cord. 
 The peripheral ends of nociceptive neurons are referred to as “free 
endings” because they are unmyelinated and uncoupled to specialized 
structures. This distinguishes nociceptive neurons from non-nociceptive neurons. 
Non-nociceptive sensory neurons have special sensory organs, such as Pacinian 
corpuscles and Meissner’s corpuscles, at their peripheral endings which 
transduce mechanical stimuli such as pressure and light touch (Shepherd, 1994).  
 Stimuli that cause primary nociceptive neurons to generate action 
potentials are harmful to tissues. These stimuli include temperatures greater than 
43˚C, high mechanical pressure, and chemical activators, such as hydrogen ions 
(low pH). Individual nociceptive neurons may respond to specific stimuli (i.e., only 
respond to mechanical or thermal stimulation), or may respond to multiple types 
of stimuli (i.e., mechanical, thermal, and chemical stimuli) (Lang et al., 1990). 
Neurons that respond to multiple types of stimuli are generally C-fibers and are 
termed polymodal.  
 The mechanisms by which noxious stimuli active nociceptive neurons 
continue to be studied. Some types are noxious stimuli are known to activate 
specific types of receptors, such as the transient receptor potential/vanilloid 1 
(TRPV1) receptor on the cell surface of neurons. TRPV1 a non-selective cation 
channel activated by heat (>43˚C), protons, and by capsaicin, the active 
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 ingredient in hot chili peppers (Caterina et al., 1997; Tominaga and Caterina, 
2004). When the channel is activated by a stimulus, it allows the influx of Na+ and 
Ca2+. If the influx of ions is sufficient to cause the neuron to depolarize, it can 
release neurotransmitters to signal to the second order neurons. Upon 
depolarization, action potentials are generated and travel the length of the axon. 
Once the action potential reaches the central neuronal endings, they cause 
voltage sensitive Ca2+ channels open to allow cations to enter. Calcium entry into 
the neuronal ending causes fusion of synaptic vesicles to the membrane. The 
neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP) 
and other transmitters, such as glutamate, are released into the extracellular 
space within the spinal cord (Li et al., 1996; Kandel and Schwartz, 2000). Within 
the spinal cord, CGRP and SP interact with receptors on the second order 
neurons of the dorsal spinal cord (dorsal horn neurons). Dorsal horn neurons 
may depolarize and from these neurons nociceptive signals travel on to higher 
brain regions, such as the thalamus, periaqueductal gray, reticular formation, and 
the somatosensory cortex of the cerebrum discussed below.     
 
The Spinal Cord and Higher Brain Regions in Pain Signaling 
 The gray matter of the spinal cord is divided into 10 lamina that are 
numbered dorsally to ventrally. The sensory neurons that conduct nociceptive 
signals terminate on lamina I, II and V of the dorsal horn. Spinal cord neurons in 
lamina I, also called the lamina marginalis, receive input mostly from Aδ-type 
primary sensory neurons. The axons of the neurons of the spinal cord then cross 
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 over to the contralateral side, and travel rostrally to the thalamus and on to the 
cerebral somatosensory cortex. This pathway is referred to as the 
neospinothalamic tract. This tract transmits noxious stimuli to the brain rapidly, 
and pain is perceived immediately such as pain upon contact with a hot stove. 
Spinal neurons of lamina II, also referred to as the substantia gelatinosa, receive 
inputs mostly from the C-type primary sensory neurons. Axons from these spinal 
neurons also cross to the contralateral side of the spinal cord, but they terminate 
rostrally in areas of the brainstem such as the medulla and pons. This pathway is 
referred to as the paleospinothalamic tract. This tract transmits pain that is 
characterized as burning, aching, and poorly localized pain. This tract is 
associated with pain that develops slowly and  is perceived longer after the 
immediate pain of an injury ceases (Simone et al., 1989; Baumann et al., 1991).   
 
Neurotransmitters in Pain Signaling 
 The primary neurotransmitters released by small diameter sensory neurons are 
excitatory amino acids (EAAs) and the neuropeptides, SP and CGRP (Budai, 2000). 
Several lines of evidence support the notion that neurotransmitters are involved in 
nociceptive signaling in mammals. First, studies show that peripheral noxious 
stimulation of sensory neurons, such as  intense pinching of skin, causes release of SP 
and CGRP into the dorsal horn of the spinal cord (Kuraishi et al., 1985; Holzer, 1988). 
Secondly, injection of SP into the intrathecal space at the level of the lumbar spinal cord 
causes a concentration-dependent increase in mechanical hyperalgesia (Matsumura et 
al., 1985). Thirdly, administration of antagonists at the receptors for these neuropeptides 
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 reduces allodynia induced by capsaicin (Sun et al., 2003; Sun et al., 2004). Fourthly, 
expression of the neuropeptides is limited to the small- and medium- diameter sensory 
neurons of the dorsal root ganglion, which correlates to the subset of neurons 
responsible for transducing noxious stimuli (Pohl et al., 1990; Hiruma et al., 2000).  
 There also are many studies that delineate the mechanisms by which these 
neurotransmitters signal to second order neurons. Once EEAs are released from 
primary sensory neurons, they interact with either ionotropic or metabotropic receptors 
of the spinal neurons. The ionotropic glutamate receptors are the N-methyl-D-
aspartate (NMDA) receptors, (R,S)-α-amino-3-hydroxy-5-methylisoxazole-4-
propionate (AMPA) receptors, and kainic acid (KA) receptors. When bound to 
agonist, these channels to open and allow influx of Na+ and efflux of K+. In 
addition, activated NMDA receptors cause Ca2+ entry into the cell. Ionotropic 
receptor activation and sufficient flux of ions into spinal neurons causes their 
depolarization.   
 The EEAs released from primary sensory neurons also activate 
metabotropic glutamate receptors. The metabotropic glutamate receptors consist 
of a family of G protein-coupled receptors and are divided into groups I, II, and III. 
The divisions are based on amino acid sequence homology to one another, on 
which ligands they bind, and on which G protein they activate. The group I 
metabotropic receptors are coupled to the activation of the enzyme 
phospholipase-C β (PLC-β), which increases intracellular phosphoinositides and 
the release of Ca2+ from intracellular stores, whereas group II and III 
metabotropic receptors are linked to the inhibition of adenylyl cyclase and the 
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 decrease of cAMP (Budai and Larson, 1998). The metabotropic receptors are 
thought to be important in nociceptive signaling as they are localized to small 
diameter primary sensory neurons. Furthermore, when the receptors are 
activated, they increase sensitivity to noxious heat in behavioral studies and 
prolong hypersensitivity induced by CFA injection into the paw (Bhave and 
Gereau, 2004; Adwanikar et al., 2004).  
 In addition to the release of glutamate, other important neurotransmitters 
such as substance P (SP) and calcitonin gene-related peptide (CGRP), are 
released from sensory neurons once they are activated. Substance P is a 
tachykinin derived from an mRNA transcript which is spliced to generate SP and 
another tachykinin, neurokinin A. When released from the terminals of sensory 
neurons, these two peptides bind to two different GPCRs localized on dorsal 
horn neurons that are linked to the PLC signaling pathway (Helke et al., 1986; 
Guard and Watson, 1987; Helke et al., 1990; Severini et al., 2002). Activation of 
this pathway in neurons increases intracellular Ca2+ concentration and activates 
protein kinase C (PKC).  
 Calcitonin gene-related peptide (CGRP) also is a transmitter involved in 
signaling the presence of noxious stimuli. Like SP, CGRP binds to G protein-
coupled receptors on spinal neurons when it is released from sensory neurons. 
There are at least three known types of CGRP receptors: CGRP receptor 1 and 2 
and an atypical type (Quirion et al., 1992; van et al., 1997). Based on 
pharmacological studies in spinal neurons, CGRP receptor 1 is the likely 
mediator of nociceptive signaling (Sun et al., 2004). In spinal neurons, CGRP 
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 binds to its receptor and activates adenylyl cyclase to increase cAMP (Parsons 
and Seybold, 1997). The binding of CGRP to its receptors does not cause 
significant depolarization, but augments the response of spinal neurons to EAAs 
through activation of signaling molecules like PKA (Sun et al., 2004). 
Interestingly, CGRP receptors also are present on primary sensory neurons 
themselves. In nodose ganglion neurons, activation of the CGRP receptor alters 
Ca2+ currents (Wiley et al., 1992). Also, treatment of dorsal root ganglion neurons 
with CGRP increases tetrodotoxin resistant sodium currents, indicating the 
neuropeptide is potentiating neuronal activity (Natura et al., 2005). These data 
suggest that CGRP signals in an autocrine manner to primary sensory neurons 
to modulate their function.  
 The importance of CGRP and SP in relation to one another in nociceptive 
signaling is not known. It is unclear if they are released differentially under 
specific circumstances in vivo. In studies where CGRP and SP are quantified 
simultaneously, the peptide neurotransmitters display similar trends in the 
outcomes measured. For instance, the two neuropeptides are generally co-
expressed in the same neurons (Zhang et al., 1995).  Furthermore, alterations in 
expression and release of these two neurotransmitter peptides in neurons appear 
to be similar after various treatments, such as decreased expression in neurons 
from diabetic mice or increased release after incubation with various 
inflammatory mediators  (Lindsay et al., 1989; Sango et al., 1994; Zhang et al., 
1995; Barber and Vasko, 1996; Frayer et al., 1999; Belanger et al., 2002). 
However, a notable exception was published by Bowles et. al. They found that 
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 animals injected with nerve growth factor (NGF, 0.1mg/kg) for 7 days increased 
the level of CGRP release but not SP release into the spinal cord (Bowles et al., 
2004). These data may indicate that CGRP is the relevant neuropeptide effector 
that mediates the responses to NGF in animals when they are treated 
systemically with NGF.  
 
Sensitization of Neurons in the Pain Pathway 
 
Peripheral sensitization and central sensitization 
 Detection of noxious stimuli is necessary for survival. However, too much 
activity in the nociceptive pathways can also be detrimental. The development of 
persistent or chronic types of pain that occur in the absence of a noxious 
stimulus or even in the absence of systemic pathology is referred to as 
pathological pain. Pathological pain serves no purpose that is understood to date 
and it causes a great deal of suffering and decreased quality of life (Woolf and 
Decosterd, 1999).   
 Pathological pain develops from alterations at all levels of nociceptive 
signaling, including changes in the activity of primary sensory neurons, the 
activity of neurons in the spinal cord, and activity of neurons in brain(Costigan 
and Woolf, 2000; Julius and Basbaum, 2001). In general, when neurons become 
more responsive to a noxious stimulus, they are sensitized (Castellucci and 
Kandel, 1976; Lewin et al., 1993; Hingtgen and Vasko, 1994; Stucky et al., 1998; 
Devor, 2006). When primary nociceptive neurons are sensitized, they respond to 
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 lower intensity or non-noxious stimuli, such as heat below 43˚C or lower 
threshold mechanical stimuli. Sensitization can result in pain perception in the 
absence of any noxious stimulus if the threshold for activation of the neurons 
occurs at physiological temperatures or pH.  
 The pathological consequences of increased sensitivity of nociceptive 
neurons is the development of hyperalgesia and/or allodynia (Basbaum, 1999; 
Richardson and Vasko, 2002). The IASP defines hyperalgesia as “an increased 
response to a stimulus that is normally painful,” while allodynia is “pain due to a stimulus 
which does not normally provoke pain” (IASP Task Force on Taxonomy, 1994). 
Examples of these two conditions are common. For instance, passive or active 
movement of a joint, such as the knee, is usually non-painful. In an individual with 
arthritis of the knee, it is thought that neurons surrounding the inflamed joint are 
sensitized and thus simple movement evokes a painful sensation. In another example, 
a pin prick of the skin is usually painful. However, a pin prick to inflamed skin results in a 
more intense pain sensation than normally experienced. This is an example of 
hyperalgesia.   
 The allodynia and hyperalgesia observed in humans can be reproduced in 
animals. Injection of inflammatory mediators into the knee joint of rats causes a 
sustained inflammation. This inflammation causes a decrease in the nociceptive 
thresholds with passive movement of the joint (Coggeshall et al., 1983; Schaible et al., 
1987; Schaible et al., 1990; Donaldson et al., 1995). There is an increase in the activity 
of primary sensory neurons innervating the inflamed joint compared to non-inflamed 
animals with a concomitant increase in activity of dorsal horn nociceptive neurons.  
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 While highlighting the increased activity of neurons from these animals, these studies 
also demonstrate that the modulation of responsiveness to a stimulus can occur in 
neurons of the peripheral or central nervous system (Woolf, 2004).  
 Peripheral sensitization refers specifically to the hypersensitivity of primary 
sensory neurons (Levine JD and Reichling DB, 1999). This hypersensitivity can 
result from exposure of the sensory neuron to a sensitizing agent (Hingtgen et al., 
1995; Evans et al., 1996; Nicol et al., 1997; Southall and Vasko, 2001). Sensitizing 
agents, which are often inflammatory mediators such as prostaglandins and 
bradykinin, bind to receptors on the surface of cellular membranes, and activate 
intracellular signaling cascades. Activation of the signaling cascades causes 
transcriptional alterations in proteins or post-translational modifications of ion 
channels and other proteins that regulate the sensitivity to a stimulus.  
 At least two post-translational mechanisms have been shown to regulate 
the sensitivity of sensory neurons in response to inflammatory mediators 
(Planells-Cases et al., 2005). First, the increased capsaicin sensitivity of sensory 
neurons in response to NGF may result, in part, from a change in the 
phosphorylation state of TRPV1 that alters the receptor’s localization in the cell. 
This was proposed by Zhang et al. They propose that NGF activates PI3 kinase, 
which then interacts with another kinase, Src, which phosphorylates TRPV1 
(Zhang et al., 2005). Upon phosphorylation, TRPV1 moves from intracellular 
vesicles to the surface of membranes. This change increases sensitivity to 
capsaicin. Also, phosphorylation of the TRPV1 channel by specific kinases alters 
the capsaicin-evoked currents. Jin et al. showed that capsaicin-currents in dorsal 
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 root ganglion neurons could be blocked by inhibition of Src kinase or enhanced 
by inhibition of phosphatases (Jin et al., 2004). These results demonstrate the 
importance of the phosphorylation state of ion channels in regulating sensitivity of 
cells to a stimulus.  
 With respect to translational changes, neurons also can be sensitized as a 
result of an increased expression of proteins, such as increases in sodium 
channels and TRPV1, or a decreases in expression of some potassium channel 
subtypes (Winter et al., 1988; Okuse et al., 1997; Gould, III et al., 1998; Waxman 
et al., 1999; Ji et al., 2002; Jiang et al., 2003). For instance, the expression of 
sodium channels, Nav1.8 and 1.9, which are localized on small diameter primary 
sensory neurons, are increased with nerve injury (Waxman et al., 2000). Overall, 
the altered expression of receptors and/or ion channels at the surface of 
membranes in response to inflammatory mediators or neuronal injury can cause 
neurons to be more excitable to a given stimulus.  
 Neurons localized in the dorsal spinal cord also can become sensitized, 
and this phenomenon is termed central sensitization (Woolf, 1983; Ji et al., 
2003). High frequency firing from peripheral nociceptive neurons can increase 
the firing rate of dorsal horn neurons. Multiple mechanisms are thought to 
regulate this sensitization, including increases in NMDA receptors at the 
membrane. As with increased TRPV1 or sodium channels at the surface of 
primary sensory neurons, an increased density of NMDA receptors will increase 
the responsiveness of spinal neurons to glutamate (Woolf, 1983; Ji et al., 2003).  
Inflammation and sensitization 
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  The physiology of inflammation is complex. With acute and chronic 
inflammation, there is increased vascular permeability and extravasation of 
leukocytes, including polymorphonuclear cells (PMNs) and macrophages 
(Springer et al., 2003). With acute inflammation, the purpose of leukocyte 
invasion is to defend against infection and to resolve tissue damage. With 
chronic types of inflammation, it is less clear why white blood cells are invading 
tissues. The extravasation of leukocytes and their inappropriate activation in 
tissues leads to complications of chronic inflammation, including edema, loss of 
function, and pain.    
 Chronic inflammation, such as rheumatoid arthritis, is characterized by 
hyperalgesia and allodynia. The hyperalgesia and allodynia may result from 
sensitization of the primary sensory neurons that innervate the tissues with 
ongoing chronic inflammation. However, the exact cellular mechanisms mediating 
the changes in sensitivity of sensory neurons in response to inflammation are not 
known. The neuronal signal transduction cascades that predominate in regulating these 
effects have not been determined.  
 With inflammation, there is release of endogenous chemicals, including 
but not limited to serotonin, histamine, acetylcholine, bradykinin, prostaglandins, 
cytokines, and nerve growth factor (NGF) from the tissues. These inflammatory 
mediators are derived from multiple cell types such as lymphocytes, 
keratinocytes, and neurons themselves. These substances activate and sensitize 
nociceptors in a paracrine or autocrine fashion (Falcini et al., 1996; Basbaum, 1999; 
Woolf and Salter, 2000; Richardson and Vasko, 2002; Obata et al., 2002).  
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  Animal models of inflammatory pain have helped to build concepts that 
explain the mechanisms of development of hyperalgesia and allodynia. A 
common method to induce inflammatory pain is injection of an immunogenic or 
inflammatory mediator, such as Complete Freund’s Adjuvant (CFA), formalin, 
endotoxin, PGE2 or NGF, into the paw of mice or rats (Ferreira et al., 1978; 
Donnerer et al., 1993; Woolf et al., 1994; Honore et al., 2000). After various 
times, ranging from minutes to days, the nociceptive behaviors in the animal are 
measured. These behavioral measurements test allodynia or hyperalgesia. Von 
Frey hairs are commonly used to quantify allodynia and mechanical hyperalgesia 
(Reeh et al., 1986; Ahlgren and Levine, 1993; Ahlgren et al., 1997). The hairs are 
stiff nylon fibers that poke the surface of the inflamed paw. The fibers bend when 
a calibrated force is applied to the paw. When the animal withdraws the paw, it is 
assumed that the force is noxious. A decrease in the amount of force needed to 
cause paw withdraw indicates development of mechanical allodynia. A force that 
once was non-painful prior to injection now has become painful.  
 Thermal hyperalgesia is tested in a similar manner to mechanical 
hyperalgesia. The paw is injected with an inflammatory mediator. A source of 
heat, such as an intense beam of light, is imposed on the paw of the animal. The 
latency for withdraw of the paw is measured. If the time for withdraw decreases 
significantly, the assumption is the animal has developed thermal hyperalgesia.  
 
Nerve Growth Factor 
  
 14
  Many types of inflammatory mediators cause hyperalgesia and allodynia 
(Hong and Abbott, 1994). While the relative importance of each of these 
mediators in inflammatory pain is not known, NGF recently has moved to the 
forefront. Nerve growth factor was discovered in the 1950s by Levi-Montalcini et 
al. as a trophic factor essential for the survival of sensory and sympathetic 
neurons (Levi-Montalcini, 1964; Levi-Montalcini et al., 1996; Aloe, 2004). In 
laboratory animals and humans, NGF is upregulated with inflammation  (Lewin 
and Mendell, 1994; Woolf et al., 1994; Safieh-Garabedian et al., 1995; Falcini et 
al., 1996; Nonogaki et al., 1996). Nerve growth factor can be produced by a 
variety of cells in the body. These cells include keratinocytes, melanocytes, 
smooth muscle cells, salivary glands, thyroid and parathyroid tissues, and 
reproductive tissues (Levi-Montalcini et al., 1996). Leukocytes, such as mast 
cells, monocytes, macrophages, and T-lymphocytes also produce NGF, which 
implicate this growth factor in immune and inflammatory functions (Leon et al., 
1994; Lambiase et al., 1995; Lambiase et al., 1995; Bonini et al., 1996). During 
injury, Schwann cells produce increased levels of NGF in the peripheral nervous 
system (Lindholm et al., 1987).  
 Multiple studies correlate NGF and inflammation. Synovial fluid aspirated 
from the joints of adults with rheumatoid arthritis have detectable levels of NGF, 
where fluid from non-inflamed joints do not (Aloe et al., 1992). Similarly in 
children, elevated serum NGF is directly correlated to the severity of juvenile 
chronic arthritis (Falcini et al., 1996). Finally, NGF regulates the expression of 
neuropeptides SP and CGRP both in vitro and in vivo suggesting that NGF may 
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 be linked to nociceptive signaling (Lindsay and Harmar, 1989; Verge et al., 1995; 
Ruiz and Banos, 2005).  
 In in vitro studies, injection of NGF into the forearm of adult humans 
induces hypersensitivity to noxious stimuli (Petty et al., 1994). Cutaneous 
injection of NGF into rats also causes the development of hypersensitivity (Lewin 
et al., 1993). Injection of bacterial endotoxin causes a dose dependent increase 
in serum NGF in rats (Safieh-Garabedian et al., 2002). There is upregulation of 
the SP content of dorsal root ganglion neurons  4-5 days after CFA injection into 
the paw (Donnerer et al., 1992), and the thermal hyperalgesia that develops in 
the paw with CFA-injection is reduced when signaling by NGF signaling is 
neurtralized by NGF blocking antibody (Woolf et al., 1994). These studies 
together demonstrate that NGF is increased with inflammation and is regulating 
the sensitivity of sensory neurons. A current major unresolved issue is which 
cellular mechanisms and neuronal signaling cascades regulate the increase 
neuronal sensitivity in response to NGF.  
 
Nerve growth factor sensitization of sensory neurons in vivo 
 NGF is synthesized as a proneurotrophin. The mature, fully active protein 
is a homodimer composed of two13kDa peptides,   which is referred to as beta-
NGF (McDonald et al., 1991; McDonald and Blundell, 1991). The naturally 
occurring form of NGF is referred to as 7S NGF. It is a multimeric protein with 
two alpha, one beta and two gamma subunits. Often the 2.5S form will be used in 
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 experiments. This form is 9 amino acids shorter than the beta form and lacks the 
other subunits of the multimer. 
 It is well-established that NGF regulates the expression of  neuropeptides in 
sensory neurons both in vitro and in vivo (Lindsay and Harmar, 1989; Lindsay and 
Harmar, 1989; Noguchi et al., 1995; Verge et al., 1996; Schuligoi and Amann, 1998; 
Miki et al., 1998; Fehrenbacher, 2005). Injection of 0.1 mg/kg NGF subcutaneously into 
rats for 7 days increases the CGRP immunoreactivity in dorsal root ganglion neurons 
(Verge et al., 1995). When the sciatic nerve is transected, SP and CGRP 
immunoreactivity decrease, but intrathecal administration of NGF reverses the 
decrease presumably by increasing their transcription (Verge et al., 1995). NGF 
treatment of rat paws increases SP and CGRP expression in dorsal root ganglion 
neurons innervating inflamed tissues (Donnerer et al., 1992).   Finally, treatment of 
neurons in culture with NGF increases neuropeptide expression in dorsal root ganglion 
neurons (Lindsay and Harmar, 1989; Fehrenbacher, 2005). 
 In addition to its actions on neuropeptide expression, there is evidence that NGF 
also increases the sensitivity of sensory neurons. This increase is not based on 
translational changes, but on post-translational modifications of proteins in cells. Shu 
and Mendell demonstrated that the decreased response in firing cause by successive 
capsaicin stimulation of neurons could be reversed by 10 minute treatment with NGF 
(Shu and Mendell, 1999). Bonnington and McNaughton measured changes in 
intracellular Ca2+ concentrations in response to NGF (Bonnington and McNaughton, 
2003). They found after 2 minute exposure of sensory neurons to NGF there was an 
increase in the Ca2+ entry upon stimulation.  Zhang and Nicol demonstrated that a brief 
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 exposure of neurons to NGF increased the number of actions potentials measured in 
response to a ramp of depolarizing current (Zhang and Nicol, 2004). A study by 
Fehrenbacher showed that brief exposure to NGF increases the capsaicin-evoked 
release of iCGRP from neurons in culture (Fehrenbacher, 2005). These results show 
that acute administration of NGF sensitizes senosry neurons and the time course of 
action implies signaling through some post-translational mechanisms.  
 Based on the concept of a dichotomy between NGF-induced changes in post-
translational events and changes in transcription, a model emerges that may explain at 
least two ways by which NGF can alter the release of neuropeptides from sensory 
neurons (Fig. 1).  Figure 1 demonstrates a primary sensory neuronal ending, a synaptic 
cleft, and the membrane of a dorsal horn neuron, onto which the sensory neuron is 
releasing a reproducible amount of neuropeptide. With long term exposure to NGF, 
neurons express more neuropeptide, and this has been confrimed in the literature (see 
above, and left panel Fig. 1). With more neuropeptide packaged into vesicles, a 
depolarizing stimulus would result in an increased release of neuropeptide into the 
synaptic cleft. Malcangio et. al. provided proof of this concept (Malcangio et al., 1997). 
Animals were treated with NGF for two weeks, and the evoked release of 
neuropeptides was measured. They demonstrated a significant increase in the amount 
of CGRP released from the dorsal horn of the spinal cord. Fehrenbacher et. al. obtained 
similar results in vitro when dorsal root ganglion neurons were exposed to NGF for 7 
days,  and released more iCGRP when exposed to capsaicin (Fehrenbacher, 2005).  
 The right panel of Figure 1 illustrates the effect of acute exposure to NGF where 
there is also an increased evoked-release of neuropeptides from sensory neurons that 
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 is not a result of altered content. This concept is based on the findings of Fehrenbacher 
(Fehrenbacher, 2005) that when measuring release as a percentage of total content, 
NGF still augments capsaicin-evoked releasef. The exact signaling cascades that 
regulate these changes in content and stimulated release of neuropeptides in response 
to NGF are not known. Consequently determining the signaling  pathways that control 
the changes in sensitivity of sensory neurons to NGF is the focus of this thesis.   
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Figure 1.   Model representing two possible mechanisms for increased release of 
neuropeptide in response to NGF exposure. The left panel represents a sensory 
neuronal ending filled with vesicles signaling to the cell surface of a second order 
neuron before (top) and after (bottom) NGF exposure for 7 days. After days of exposure 
to NGF, there is increased expression and therefore increased cellular content. When 
sensory neurons are exposed to a noxious stimulus, there is an increased release of 
peptides (Fehrenbacher, 2005; Malcangio et al., 1997). The right panel represents what 
occurs in a sensory neuron exposed to NGF for 10 minutes, and then stimulated with 
capsaicin. Upon stimulation, the neurons release more peptide, or they are sensitized. 
This sensitization cannot be a results of alterations in content as 10 minutes exposure 
to NGF does not change CGRP expression. Therefore, there is both an acute and 
chronic effect of the neurotrophin on sensory neurons.         
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   Nerve growth factor receptors 
Nerve growth factor has two known membrane receptors, the TrkA and p75 
receptors (Fig. 2). Both  receptor types are found on primary sensory neurons of 
adult animals (Verge et al., 1989; Bothwell, 1995; Kaplan and Miller, 1997). 
Nearly all (92%) of sensory neurons that express CGRP also express the TrkA 
receptor (Averill et al., 1995). NGF binds to the extracellular portion of these 
receptors to elicit its effects. Once bound to ligand, the NGF receptors alter cell 
function through intracellular signaling via a variety of different cascades 
described below. 
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Figure 2. Possible signal transduction cascades activated in sensory neurons by 
NGF. 
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 TrkA receptor and downstream signaling cascades 
 The TrkA receptor for NGF is a tyrosine kinase receptor (Kaplan et al., 
1991; Kaplan et al., 1991; Kaplan et al., 1991). The active receptor is a 
homodimer, and each subunit contains an extracellular ligand-binding domain, a 
transmembrane domain, and an intracellular catalytic domain (Martin-Zanca et 
al., 1986). Upon NGF binding, the receptors dimerize and transphosphorylate 
tyrosine residues of its partner to activate the kinase domain on each molecule. 
The kinase domain autophosphorylates specific tyrosine residues that act as 
binding sites for adapter proteins and enzymes described in detail below. These 
adapter proteins trigger the activation of signaling molecules in the cell 
(Cunningham et al., 1997). The TrkA receptor actives multiple downstream 
cascades in neurons, including the Ras/MEK/ER pathway, the  
phosphatidylinositol 3-Kinase (PI3 kinase) pathway, the phospholipase C (PLC) 
pathway, and Src kinase signaling (Sofroniew et al., 2001).   
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  Ras/MEK/ERK signaling 
 
 One consequence of activation of the TrkA receptor is an increase in the 
activity of the small G-protein, Ras, with subsequent phosphorylation of the MAP 
kinase, ERK (Kaplan and Miller, 1997; Katz and McCormick, 1997). The pathway 
is activated when tyrosine residue Y490 of the cytoplasmic domain of TrkA is 
autophosphorylated after NGF binding to the receptor. Once phosphorylated, the 
adapter proteins, Shc, Grb-2, and Son of Sevenless (Sos) are recruited to the 
receptor complex at the near the membrane surface (Basu et al., 1994). Sos is a 
guanine nucleotide exchange factor which binds RasGDP and exchanges the 
low-energy GDP for GTP to activate Ras (Katz and McCormick, 1997). Once Ras 
is bound to GTP (RasGTP) it binds and activates a series of downstream 
kinases. It first activates Raf, a serine/threonine kinase. This kinase, in turn, 
phosphorylates and activates MEK, which then phosphorylates and activates 
ERK. This kinase has numerous functions in the cell, including regulation of 
transcription of many types of proteins in the cell (Katz and McCormick, 1997). 
ERK is implicated in the regulation of the sensitivity of sensory neurons (Aley et 
al., 2001; Zhuang et al., 2004). 
 The Ras pathway has been implicated in regulation of acute sensitizing 
effects of NGF. Bron et al. examined the effects of the combination of NGF and 
GDNF only in sensory neurons cultured without NGF for 4-5 days (Bron et al., 
2003). After 15 minutes of exposure to the neurotrophin, NGF, they observed 
increased cell-surface TRPV1, increased pERK levels as measured by 
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 immunoreactivity, and increased cobalt uptake in neurons exposed to capsaicin. 
This increase was blocked by dominant negative Ras. The increases in TRPV1 
immunoreactivity and pERK level in neurons also if the neurons were incubated 
with a MEK inhibitor (U0126). Conversely, the increase in these two parameters 
could be reproduced by expression of constitutively active Ras (12V) into their 
neuronal preparation.  
 In the work by Aley et al., they injected epinephrine into the paws of rats to 
induce hyperalgesia (Aley et al., 2001). After hyperalgesia developed, the 
authors extracted the dorsal root ganglion neurons from the animals and used 
immunohistochemistry to measure the level of ERK phosphorylation in the cells. 
They found an increased level of phosphorylation of the ERK 1 and 2 in cells 
after minutes of exposure to the sensitizing agent. Furthermore, they found that 
animals develop hyperalgesia during this time, which can be blocked by MEK 
inhibitors. In these experiments they use NGF as the positive control to 
demonstrate that after 5 minutes exposure to 50 ng/ml NGF there is a rapid rise 
in ERK phosphorylation. What is not clear from this study is whether ERK and 
MEK regulate the acute development of hyperalgesia in response to NGF. 
 Zhuang et al. studied the development of hyperalgesia in the presence of 
NGF (Zhuang et al., 2004). They showed that 15 minutes after NGF injection into 
the paw, the animals developed hyerpalgesia as measured by paw withdrawal 
latency. The time to paw withdrawl from a noxious stimulus decreased if 
hyperalgesia had developed. However, if they pretreated the area of the paw 
before injection of NGF with an ERK inhibitor PD 98050 (10 μg), they are able to 
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 block the development of hyperalgesia. While the results from these experiments 
are interesting, they are not well-controlled. For instance, the authors did not use 
this concentration of ERK inhibitor injected into the paw alone, and then test for 
paw withdrawal latency. Therefore, it is not clear that the differences are a result 
of the drug or of inhibition of NGF-induced increases in ERK activity.    
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  PI3 kinase signaling 
 
 A second signaling cascade linked to TrkA signaling is the PI3 kinase 
pathway (Alessi et al., 1997).  PI3 kinases are heterodimers composed of an 85-
kDa regulatory subunit and a 110 kDa catalytic subunit. When NGF binds to the 
TrkA receptor, the regulatory subunit of PI3 kinase binds directly to the 
cytoplasmic domain of the neurotrophin receptor. The regulatory domain recruits 
its catalytic domain to the membrane. Once at the membrane, PI3 kinase 
phosphorylates phosphoinositides to produce phosphoinositide-3,4-diphosphate 
(PI-3,4-P2) or phosphoinositide-3,4,5-triphosphate (PI-3,4,5-P3). These two 
phospholipids recruit Akt, a serine/threonine kinase, to the membrane (Stephens 
et al., 1998). In addition to Akt, PI-3,4-P2 and PI-3,4,5-P3 recruit 3-
phosphoinositide-dependent kinase (PDK1) to the membrane. PDK1 
phosphorylates and activates Akt (Alessi et al., 1997).  
 The PI3 kinase pathway is implicated in regulation of sensitivity of sensory 
neurons by NGF (Bonnington and McNaughton, 2003; Zhuang et al., 2004; 
Zhang et al., 2005). PI3 kinase is expressed in sensory neurons from adult 
animals (Bartlett et al., 1999) and PI3 kinase is activated by NGF (Reynolds et 
al., 1998). In the study by Bonnington and McNaughton, they used neurons from 
neotnatal mice, and measured the percentage of cells that were sensitized with 
100 ng/ml NGF for 2 minutes. The endpoint measured was the ratio of Ca2+ entry 
(measured with preloaded dye) during capsaicin stimulation compared to 
baseline. Sensitization was defined as an increase in the ratio by approximately 2 
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 standard deviations above the mean. Using this endpoint, they were able to block 
NGF-sensitization in a majority of the cells tested by using 20 nM wortmannin, a 
PI3 kinase inhibitor. In a later study by this same group, they used heterologous 
expression systems to determine whether NGF exposure increased TRPV1 
expression at the membrane surface in a PI3 kinase-dependent manner. They 
concluded that TRPV1 translocation accounts for the capsaicin-specific 
sensitization with NGF. These experiments were not repeated using dorsal root 
ganglion neurons to determine if TRPV1 did translocate to the surface of primary 
cells with brief exposure to NGF.     
 In another study, Zhuang et al. used adult sensory neurons in culture to 
examine various signaling pathways that might regulate responses to NGF in 
sensory neurons (Zhuang et al., 2004). They discovered that neurons exposed to 
NGF for 10 minutes had a significant increase in pERK levels. This change was 
dependent on PI3 kinase because when preincubated with LY294002 (100μM), 
another PI3 kinase inhibitor, subsequent exposure to NGF did not alter the levels 
of pERK in neurons in culture. The authors also showed the PI3 kinase inhibitor 
blocked changes in heat hyperalgesia that develop with NGF injection into the 
paw after 15 minutes.   
 Phosphorylation of Akt in sensory neurons after stimulation with NGF also 
has been reported (Bron et al., 2003; Zhuang et al., 2004). Bron et al. showed 
that after 3 days exposure to 50 ng/ml NGF, there is a significant increase in Akt 
phosphorylation in isolated sensory neurons as measured by Western blotting 
(Bron et al., 2003). Zhuang et al. use a much shorter time course, and show that 
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 within 2 minutes of exposure to 100 ng/ml NGF, Akt phosphorylation increases 
(Zhuang et al., 2004). In addition, they show that when injected into the paw of 
an animal, NGF causes hyperalgesia within 15 minutes. The development of 
hyperalgesia is blocked by administration of the PI3 kinase inhibitor, LY294002. 
However, after 6 hours the NGF-induced hyperalgesia has disappeared in the 
group of animals not treated with LY294002, and Zhuang et al. did not measure 
phosphorylation of Akt at this time point. Therefore, the question arises whether 
Akt phosphorylation, which is shown to be active by Bron et al. for 3 days after 
NGF exposure, is truly responsible for this early hyperalgesia. Overall these 
studies are compelling and suggest that the PI3 kinase pathway is important in 
acute changes in sensory neurons in response to NGF, and that it may be 
important in regulating hypersensitivity that develops in animals in response to 
NGF. The experimental conditions described above are highly variable, and it is 
difficult to determine whether altering culture conditions or treatment conditions 
would yield consistent results. Based on their findings, the experiments contained 
in this thesis test the PI3 kinase pathway to determine if it is involved in the 
regulation of sensitivity of sensory neurons in culture. 
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  PLC signaling 
 A third signaling cascade activated by NGF binding to the TrkA receptor is 
the PLC pathway. The isoform, PLC-γ, is recruited and binds to 
autophosphorylated TrkA receptor at tyrosine 785 (Vetter et al., 1991). This 
complex catalyzes the hydrolysis of phosphatidylinositol 4,5-diphosphate (PI 4,5-
P2) to inositol 1,4,5-P3 (IP3) and diacylglycerols (DAGs). Inositol 1,4,5-P3 binds 
to multiple IP3 receptors on the endoplasmic reticulum and causes increases in 
intracellular Ca2+. DAGs bind to and activates multiple proteins, including protein 
kinase Cs (PKCs),  Muncs, guanine nucleotide exchange factors, and DAG 
kinases (Rhee, 2001; Yang and Kazanietz, 2003). Each of these signaling 
molecules downstream of DAGs is expressed in sensory neurons. Of these 
downstream effectors, PKC is implicated in the increased sensitivity of sensory 
neurons (Barber and Vasko, 1996; Gold et al., 1998; Frayer et al., 1999; Cesare 
et al., 1999; Premkumar and Ahern, 2000). Work from the Vasko laboratory 
indicates that activation of PKC either in the sensory neuronal endings of the 
spinal cord slice or in sensory neurons in culture increases release of both SP 
and CGRP.  
 There are other correlative studies that test the actions of PKC on the 
TRPV1 channel. Using electrophysiological studies, it was determined that PKC 
phosphorylation of the TRPV1 channel increases its activity (Hall et al., 1995; 
Cesare and McNaughton, 1996; Vellani et al., 2004). In a heterologous 
expression system (oocytes), NGF application caused increased currents 
through TRPV1 channels in response to noxious heat and capsaicin (Chuang et 
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 al., 2001). This increased current could be mimicked by addition of PLC to the 
preparation and blocked by the addition of anti-PLC antibody. However, it 
remains to be determined whether PLC or its downstream signaling proteins 
regulate the sensitization of sensory neurons in response to NGF. 
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  Src kinase signaling 
 A fourth pathway implicated in TrkA signaling in sensory neurons is the 
Src kinase cascade. Src is a non-receptor tyrosine kinase that is associated with 
NGF activation of the TrkA receptor (Wooten et al., 2001). Src kinase associates 
with the adapter protein, Grb2 (Meakin et al., 1999; Tsuruda et al., 2004). Grb2 is 
the same adapter that is necessary in the activation of GEFs and the Ras protein 
in the Ras/MEK/MAPK signaling pathway.  
 There may be competition for a Grb2 binding at the activated TrkA 
receptor by the Ras and Src kinase cascades. Several factors, such as the 
compliment of proteins present in sensory neurons, the simultaneous exposure 
to other growth factors, or the levels of individual growth factors influence which 
pathway will become activated in the cell in response to agonist binding. Ohmichi 
et al. showed that about half of the Shc in PC12 cells was associated to Grb2 in 
response to NGF, and this proportion of bound Shc changed depending on the 
exposure of the preparation to other growth factors (Ohmichi et al., 1994). Their 
results support the notion that lend evidence that signaling pathways diverge, 
such as at the binding site of the adapter protein Grb2, and the level of activity of 
the pathways downstream is very sensitive to slight variations in the external 
milieu.   
 Once Grb2 binds to the TrkA receptor, Src kinase can bind at its SH3 
binding domain. The kinase has been shown in PC12 cells to signal to a variety 
of proteins, including the mitogen activated protein kinase, JNK, or atypical forms 
of PKC, including PKCζ and PKCι (Wooten et al., 1994; Seibenhener et al., 
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 1999). Studies of Src in mammalian sensory neurons have just started to 
emerge. In mouse sensory neurons, blocking Src kinase activation by the 
inhibitor PP2 blocks the NGF-induced increase in Ca2+ influx that occurs with 
capsaicin stimulation (Zhang et al., 2005). These studies suggest that the acute 
effects of NGF, such as altering sensitivity to capsaicin stimulation, could be 
mediated by the Src kinase signaling cascade.  
 In another study by Igwe et al., they showed that IL-1β-induced secretion 
of SP could be inhibited by inhibitors of Src kinase (Igwe et al., 2003). 
Furthermore, increase in expression of SP by IL-1β also could be inhibited by Src 
kinase. These data suggest that Src kinase, again, may be involved in regulation 
of acute changes in neurotransmitter release, but also may be involved in 
regulation of expression of neuropeptides over a longer time course.  
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 p75 receptor and downstream signaling cascades 
 The p75 neurotrophin receptor (p75NTR) is a member of the tumor necrosis 
factor alpha (TNF-α) family of receptors that binds NGF among other 
neurotrophins (Barrett, 2000). When p75NTR binds NGF, it activates either 
apoptotic or survival promoting signaling pathways, but it is not clear what 
defines the outcome with receptor activation (Huang and Reichardt, 2003). 
Although it has no intrinsic enzymatic activity, through a series of adapter 
proteins, p75NTR is known to activate neutral and acidic sphingomyleinase (N-
SMase and A-SMase, respectively) (Dobrowsky et al., 1994; Dobrowsky et al., 
1995). Early studies on the sphingomyelin signaling cascade showed that 
ceramide acts as a second messenger (Hannun, 1994), and can activate 
phosphatases, PI3kinase and atypical PKC isoforms (Dobrowsky and Hannun, 
1994; Roux, 2001)   Ceramide is further metabolized by ceramidase to form  
sphingosine (Roux et al., 2001). Sphingosine can be phosphorylated by 
sphingosine kinase, an enzyme present in dorsal root ganglion neurons (Toman 
et al., 2001; Toman et al., 2004), to form sphingosine-1-phosphate (S1P). 
Sphingosine 1-phosphate is a known ligand of S1P receptors (Taha et al., 2004). 
 There are indications that this pathway is important in regulation of the 
sensitivity of sensory neurons. Both ceramide and S1P have been shown to 
regulate the excitability of sensory neurons in response to NGF, and inhibiting 
the p75NTR with a blocking antibody inhibits NGF-induced increases in excitability 
(Zhang et al., 2002; Jiang et al., 2003; Zhang and Nicol, 2004; Zhang et al., 
2006). It has been shown in both hippocampal and sympathetic neurons that 
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 NGF treatment increases intracellular ceramide (Brann 1999; Song and de 
Chaves, 2003). In adult sensory neurons, exposure to ceramide increases the 
excitability of sensory neurons. Conversely, blocking the p75NTR with an antibody 
blocks the ceramide-induced increases in actions potentials, but this inhibition 
can be overcome with increases in ceramide concentrations used (Zhang et al., 
2002; Zhang and Nicol, 2004).  
 Sphingosine can be phosphorylated by sphingosine kinase to form 
spingosine-1-phosphate (Toman and Spiegel, 2004). Sphingosine 1-phosphate 
activates a number of enzymes implicated in regulating sensitivity of neurons, 
including phospholipase D (PLD) and PKC isoforms (Natarajan et al., 1994; 
Meacci et al., 1999; Roux et al., 2001). However, it is not known if this pathway 
regulates the NGF-induced increase in iCGRP release from sensory neurons. It 
is important to understand because the focus of most literature regarding acute 
effects of NGF focus on the TrkA neurotrophin receptors, and the P75NTR 
pathway may be a completely separate, but equally important means to control 
the sensitivity of sensory neurons.  
    
 Signaling pathways implicated in regulation of neuropeptide content 
 In studying release of neuropeptides from sensory neurons, it is important 
to consider the expression levels of SP and CGRP because increased content 
will lead to increases in stimulated release (Malcangio et al., 1997; 
Fehrenbacher, 2005).  
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  It is well established that NGF increases expression both SP and CGRP in 
neonatal and adult dorsal root ganglion cells in culture (Adler et al., 1984; 
Lindsay and Harmar, 1989; Lindsay et al., 1989). In these studies, neurons were 
removed and cultured immediately with NGF. They found NGF (25-100ng/ml) 
increased cellular content of CGRP and substance P (SP), and increased in the 
mRNA, after 1-3 days in culture. Furthermore, if NGF was not added, there was a 
significant loss of peptides after 2-4 days. These data indicate NGF may be 
necessary for the maintenance of expression of these peptides.   
 Multiple studies demonstrate that sciatic nerve transaction in the rat 
caused decreases in the content of neuropeptides in dorsal root ganglion. 
Application of NGF to the stump of the nerve fiber reverses the loss of peptide 
and increase its expression in DRG (Fitzgerald et al., 1985; Goedert et al., 1981; 
Inaishi et al., 1992; Verge et al., 1995). The increase in expression of peptides in 
the dorsal root ganglion neurons is also observed with CFA injection or NGF 
injection into the plantar surface of rat paws (Donnerer et al., 1992; Leslie et al., 
1995).   
 To study the cellular mechanisms of regulation of CGRP expression in 
response to NGF, the promoters for the CGRP gene must be understood.  
Knowledge of its structures helps to gain insight into the cellular mechanisms of 
regulation of CGRP expression in response to NGF (Tverberg and Russo, 1992; 
Tverberg and Russo, 1993; Durham and Russo, 2003c).  The CGRP gene has a 
minimal promoter region of approximately 150 bases upstream of the gene that is 
necessary for the activation of CGRP transcription by NGF. Mutation of this 
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 promoter region blocks transcription activity (Watson and Latchman, 1995; 
Watson et al., 1995; Freeland et al., 2000). The region contains a cyclic AMP 
response element (CRE), which is activated by cAMP response element binding 
protein (CBP). When CBP is phosphorylated by the p42/44 MAP kinase in 
response to NGF, CBP can induce transcription of a variety of proteins (Liu et al., 
1998). However, speculating how NGF might control transcription of proteins in 
DRG neurons based on activity in PC12 cells, may not be appropriate. 
 It is known that in primary sensory neurons, that NGF signals to a variety 
of pathways. In PC12 cells, the Ras/MEK/Erk cascade is essential to 
differentiation of these cells, including reduction of proliferation and increased 
neurite outgrowth (Ng and Shooter, 1993; Basu et al., 1994; Ganju et al., 1998; 
Freeland et al., 2000; Rong et al., 2003). These physiological changes which 
occur in response to NGF are attributed to Ras (Wood et al., 1992).   A question 
that remains is which intracellular signaling pathways in DRG neurons regulate 
the change in CGRP content upon exposure to NGF. The Ras/MEK/ERK 
cascade is implicated because other MAPKs have been shown to regulate the 
activation of the promoter region in PC12 cells and increase transcription. 
However, no studies directly test whether Ras induces the change in CGRP 
content in sensory neurons through the MEK/ERK cascade.  
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 GTPases and GTPase Activating Protein (GAPs) 
 
Overview of function of GTPases and GAPs 
Functions of GTPases and GAPs in neurons: Ras 
  The Ras family proteins are small GTP-binding proteins (20-40kDa) that cause 
tumor formation with inappropriate activation (Takai et al., 2001). However, their normal 
functions in neurons are still being determined. The mechanisms of Ras activation, 
inactivation, and downstream effectors are well-established. In cells, Ras cycles from an 
active to inactive state depending on whether it is bound to GDP or GTP (Fig. 3).  
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Figure 3. The Ras cycle. Guanine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs).  
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  Ras activation is involved in the effects of neurotrophic factors on sensory 
neurons. Ng et. al. demonstrated exposure of primary sensory neurons in culture to 
NGF (10-50 ng/ml) increases Ras-GTP in cells after a five-minutes (Ng and Shooter, 
1993). Bron et. al. microinjected a mutant, constitutively activated Ras or a mutant 
dominant negative Ras isoform into mouse sensory neurons, and this resulted in an 
increase and decrease of TRPV1 expression, respectively (Bron et al., 2003). 
Bonnington and McNaughton used an inhibitor of Ras activation, the Sos inhibitory 
peptide, and MEK inhibitor, U0126, which did not block sensitization of sensory neurons 
exposed to NGF as measured by Ca2+ uptake in cells (Bonnington and McNaughton, 
2003).  
 These studies did not explore changes that might occur in neurotransmitter 
content and release. Release of neurotransmitter is the primary means of 
communication by sensory neurons to the CNS. Studies on activation of Ras in sensory 
neurons and how this protein affects CGRP content and release may be very important 
in understanding how Ras signaling may regulate nociception.  
 
Regulators of Ras activity and downstream effectors in neurons 
          Major regulators of Ras activity in cells are GTPase activating proteins (GAPs) 
They accelerate hydrolysis of GTP and turn off Ras signaling (Scheffzek et al., 1997; 
Bernards, 2003). Mutations in a specific GAP, called neurofibromin, result in the human 
disease neurofibromatosis (NF) (Donovan et al., 2002). Patients with NF develop 
certain types of cancers, benign tumors (neurofibromas), and learning disabilities, which 
are attributed to deregulated Ras activity.  Discrete dermal neurofibromas arise 
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 specifically from the Schwann cell surrounding neurons and are associated with pain 
and itching (Packer et al., 2002).  
 A recently discovered, neuronal-specific GAP, called synGAP, is known to be an 
important negative regulator of Ras in neurons (Komiyama et al., 2002b; Kim et al., 
2003).  SynGAP is present in neurons of the central nervous system, such as 
hippocampal and cortical neurons, but it may be present and functioning in sensory 
neurons as well. Thus, manipulation of this regulatory protein, SynGAP, could be used 
as a mechanism to alter Ras signaling and measure changes that might occur in 
neurotransmitter content and release from sensory neurons. 
         In addition to enzymes that act directly on Ras to modify its function, such as 
GEFs and GAPs, post-translation modification of Ras, namely farnesylation, must occur 
in order for Ras to be localized at the membrane and have activity (Sebti and Hamilton, 
1997). The enzyme that regulates the addition of the lipid moiety, farnesyl, to the Ras 
protein is farnesyltransferase (FT). Farnesyltransferase is an enzyme that transfers the 
hydrocarbon chain to the C-terminal end of the Ras protein. The lipid moiety is attached 
to a cysteine residue in a specific sequence, CAAX (Sebti and Hamilton, 1997). The last 
three residues, AAX are cleaved from the protein, and the cysteine residue is 
methylated to stabilize the protein. The farnesyl group then intercalates into the 
membrane and Ras is in the correct orientation for activation by GEFs.  
 RasGTP activates specific downstream effectors in neurons, including the 
Raf/MEK/ERK pathway, phosphoinositol-3-kinase (PI3K), and phospholipase Cε 
(Cullen and Lockyer, 2002). Multiple studies implicate these pathways in regulation of 
sensitivity of sensory neurons (see above).  
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       Evidence indicates the MAPK cascade regulates expression of CGRP in 
sensory neurons. Durham et. al. identified increases in MAPK activity increased CGRP 
expression in sensory neurons of the head and neck (Durham and Russo, 2000; 
Durham and Russo, 2003). In other studies, Ma et. al. found that chronic exposure of 
primary sensory neurons in culture to morphine increased both MAPK activation and 
CGRP content. By selectively blocking MAPK in the presence of morphine, they 
blocked increases in CGRP suggesting MAPK controls CGRP expression (Ma et al., 
2001). However, there are few studies on the control of CGRP expression by other 
downstream effectors of RasGTP, such as Akt (PKB) and PKC. Many studies show 
mediators both upstream and downstream of Ras are involved in expression changes, 
but the field lacks a direct link between Ras and changes in both peptide release and 
content. The experiments in this thesis explore whether Ras activation and its 
downstream effectors control changes in the release of peptide through changes in 
content in primary sensory neurons in culture. 
 
Mechanism of action of dominant negative/ constitutively active isoforms of Ras 
 As described above, GAPs and GEFs regulate the activity of Ras (Bollag and 
McCormick, 1991; Bollag and McCormick, 1991; Donovan et al., 2002). Mutation of the 
one of the isoforms, H-Ras, at critical residues has allowed the development of 
dominant negative or constitutively active isoforms of the protein. The dominant 
negative isoform, termed Ras S17N, or just 17N, has a serine converted to an 
asparagine at residue 17 (Feig and Cooper, 1988; Stacey et al., 1991; Segal et al., 
1993). This mutation causes 17N Ras to bind with greater affinity to GDP. When the 
 42
 mutated protein binds to GEF, it does not allow the exchange of GDP for GTP. Ras17N 
and the GEF form a stable, but inactive complex that inhibits native Ras activation. 
Thus, expression of this mutant isoform is dominant although native Ras is still 
expressed. The S17N mutation of H-Ras also blocks the GTP exchange for the other 
isoforms, K-Ras and N-Ras (Matallanas et al., 2003).  
 The constitutively active isoform, Ras61L, has a glutamine to leucine mutation. 
This mutation disrupts the GTPase activity of the protein. Once Ras is activated by its 
GEF, the mutated GTPase remains active because GTP hydrolysis by the protein 
cannot occur. These two mutations provide a specific tool to increase and decrease the 
activity of Ras in neurons. The mutated proteins will be used to determine if Ras 
signaling affects the acute sensitizing actions of NGF or the upregulation of expression 
of CGRP and SP in sensory neurons.  
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 Specific Aims of the Thesis 
 The studies in this thesis will investigate the intracellular signaling 
pathways that regulate the observed effects of NGF on sensory neurons, namely 
the increased expression of peptide neurotransmitters with long exposure, or the 
increase in peptide release with just brief exposure to NGF. Understanding which 
signaling pathways control these responses of sensory neurons may lead to new 
ideas about future drug targets and therapeutics to attenuate acute and/or 
chronic pain that develops with inflammation and injury. Therefore, the specific 
aims are:    
 
               1. To determine if the Ras signaling pathway mediates NGF-induced   
            increases in CGRP content in sensory neurons.  
               
                 2. To determine which signaling effectors downstream from NGF   
                       receptors regulate the ability of NGF to augment capsaicin-evoked  
            release of CGRP  that  cannot be accounted for by changes in  
            CGRP content.  
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 MATERIALS AND METHODS 
 
Materials 
 
Unless otherwise specified, all chemicals were from Sigma-Aldrich (St. 
Louis, MO). Nerve growth factor (7S) was purchased from Harlan (Indianapolis, 
IN). LY294004, wortmannin, PP2, and PP3 were from EMD Biosciences (San 
Diego, CA). C-2 ceramide and D-erythro-sphingosine-1-phosphate were from 
Avanti Polar Lipids (Alabaster, AL). Tissue culture plates and 96-well plates for 
absorbance measurements were from Becton-Dickinson (San Jose, CA). F-12 
media, horse serum, antibiotics, proteinase K, OptiMEM I®, and Normocin-O™ 
were from Invitrogen (Carlsbad, CA). Bovine IgG protein, Bradford reagent, pre-
cast polyacrylamide gels, PVDF membranes, Laemmli buffer, HRP-conjugated 
goat anti-mouse and anti-rabbit antibodies were from Bio-Rad (Hercules, CA). 
CGRP was from Tocris (Ellisville, MO). Radiolabeled NaI (NaI125) for iodination of 
CGRP and Western Lightning® chemiluminescent HRP substrate solution were 
from Perkin-Elmer (Shelton, CT). Radiographic film was from RPS imaging 
(Michigan City, IN). LI-COR Odyssey blocking solution was from LI-COR 
Biosciences (Lincoln, NE). NeuroPorter® was from Gene Therapy Systems (San 
Diego, CA). Plasmids, antibiotics, and chemically competent E.coli were from 
Invitrogen (Carlsbad, CA). Restriction enzymes described in this section were 
from New England Biolabs (Ipswich, MA).  
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 Use of Laboratory Animals 
  
 The Animal Care and Use Committee at Indiana University School of 
Medicine, Indianapolis, IN approved all procedures used in these studies. Adult 
male Sprauge-Dawley rats were purchased from Harlan (Indianapolis, IN). Mice 
with a heterozygous mutation of sygGAP were generously donated by Dr. R. 
Huganir (Johns Hopkins University) and bred in the Indiana University Laboratory 
Animal Research Center.  
 
Isolation of adult sensory neurons from rats and mice 
 
 Adult dorsal root ganglion cultures were prepared as previously described 
(Lindsay et al., 1989; Southall et al., 2002). Adult male (150-175 g) Sprauge-
Dawley rats and age and sex-matched adult (10-15 weeks) mice were 
euthanized by CO2 asphyxiation. Dorsal root ganglia from the cervical to sacral 
levels of the entire spinal column were dissected, incubated in F-12 media 
containing 0.01% collagenase for 2 hours in 3% CO2 at 37ºC, and mechanically 
dissociated. Approximately 15,000 cells were plated into each well (22 mm 
diameter) of a 12-well culture plate or 7,500 cells were plated into each well (16 
mm diameter) of a 24-well culture plate. All culture plates were precoated the day 
prior to DRG isolation. Wells were first treated with poly-D-lysine (1 mg/10ml; 
70,000-150,000 MW) for 1 hour, rinsed once with ddH2O, and then exposed to 
laminin (1 mg/ml) overnight. The cells were maintained in F-12 media 
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 supplemented with 10% horse serum, 2 mM glutamine, 100 μg/ml normocin-O™, 
50 μg/ml penicillin, 50 μg/ml streptomycin, 50μM 5-fluoro-2’-deoxyuridine, 150μM 
uridine, and the indicated amount of NGF in ng/ml. Cells were placed in an 
incubator at 3% CO2 at 37ºC. Growth medium was changed every other day. 
Cells were used 7-11 days after plating.    
 
In Vitro Release of iCGRP from Culture of DRG Neurons  
 
 Release studies were performed on cells as previously described 
(Hingtgen and Vasko, 1994; Vasko et al., 1994). The neuronal cultures were 
washed once with HEPES buffer consisting of 25 mM HEPES, 135 mM NaCl, 3.5 
mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 3.3 mM D-glucose, and 0.1% bovine 
serum albumin, pH 7.4. The cells were maintained at 37˚C, and then incubated 
for successive 10 min intervals with 0.4 ml of the same buffer in the absence or 
presence of drugs. Basal or resting release was determined by exposing the cells 
to HEPES buffer alone, or buffer in the presence of inhibitory or activating drugs 
as indicated for each group of experiments. Drugs included U0126 (1μM), PDBu 
(10 or 100nM, as indicated), LY294004 (3μM), wortmannin (3nM), PD98059 (20 
and 200μM), U73122 (15μM), PP2 (5μM), or bisindolylmalemide I (30 or 100nM). 
Drugs not soluble in water were prepared in methylpyrrolidinone (MPL). The 
maximal concentration of MPL was 0.1% by volume as this concentration was 
the lowest measured concentration of vehicle that had no affect on iCGRP 
release from sensory neurons in culture. In all instances, the maximum 
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 concentration of drug used in experiments was included in a standard curve to 
assure that the drug did not influence the results of the radioimmunoassay. Cells 
were then exposed for a second 10 min incubation to NGF (100ng/ml) in the 
presence or absence of inhibitory drugs. To determine evoked release, the 
second incubation was followed by a 10 min incubation with the same 
concentration of a drug and/or NGF in the presence of 10 or 30nM capsaicin as 
indicated. Cells then were exposed to HEPES buffer without drugs for 10 min 
incubations to reestablish resting release. During incubations, the cells were 
maintained at 37°C. After each incubation, the buffer was removed to measure 
the amount of iCGRP using radioimmunoassays (RIAs) as described below.  
 For chronic treatment of cells with the farnesyltransferase inhibitor, FTI-
276, 10 mM stock was prepared in MPL and 10 mM DTT, which was stored at -
80˚C covered in argon. Neuronal cultures were treated for 4 days with vehicle 
(0.05% MPL with 5 mM DTT) or with FTI-276 (5μM), changing the media every 
other day. Subsequently, neurons were exposed to the indicated concentration of 
NGF in the presence or absence of FTI-276 for 4-5 more days. In vitro iCGRP 
release experiments were then performed as described above.  
 In some experiments, release values were normalized to total content. In 
order to correlate the iCGRP release from a single well to the iCGRP content of 
that well, the content of a single well was determined. After the release 
experiment, each well was incubated with 400 μl 0.1N HCl in ddH2O for 10 min 
at room temperature on an orbital shaker. An aliquot from each well was diluted 
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 and assayed for the iCGRP content of that well using radioimmunoassay as 
described above. The release value then was normalized to the content. 
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 Radioimmunoassay of Immunoreactive Calcitonin Gene-Related Peptide 
  
 The amount of immunoreactive CGRP (iCGRP) was measured using 
radioimmunoassay as previously described (Vasko et. al., 1994). Samples with 
known amounts of CGRP, or standards (0-250 fmol), were prepared for each 
assay. Standards were prepared in duplicate. Experimental samples containing 
unknown amounts of CGRP were also prepared in duplicate. The volumes of all 
standards and unknown samples were 300 μl.   Added to each sample was 25 μl 
of a 1:70,000 dilution of CGRP antibody (a generous gift from Dr. M. Iadarola, 
NIH) and 25 μl of 125I-[Tyr0] CGRP. The samples were allowed to equilibrate at 
4˚C for 16-20 hours. After equilibration, 0.5 ml of a 0.1 M phosphate buffer (pH 
7.4) containing 1% charcoal was added to each sample, and the mixture was 
centrifuged at 1,500 x g for 10 minutes using a Beckman-Coulter Allegra™ 6R 
Centrifuge (Fullerton, CA). The charcoal absorbs and binds any CGRP not bound 
to antibody. The samples were centrifuged at 3000 RPM for 10 min to pellet the 
charcoal. The supernatant contains CGRP bound to antibody. The supernatant 
was decanted to new tubes, and the radioactivity was measured in these 
samples using gamma scintillation spectrometry with a Cobra II Auto-Gamma 
from Perkin-Elmer (Shelton, CT). The amount of iCGRP in experimental samples 
was determined by 4 point least squares linear regression analysis using the 
CGRP standards. The amount of iCGRP was normalized to the protein level in 
the aliquot. The concentration of protein in an aliquot of that sample was 
measured prior to radioimmunoassay as described below for Western blotting. 
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 Western Blotting and Densitometry 
  
 To collect cells for lysis and Western blotting, they were scraped from 
wells into ice-cold lysis buffer which was a modified RIPA buffer using a rubber 
policeman and placed into eppendorf tubes. The RIPA buffer contained the 
following: 50 mM Trizma base, 150 mM NaCl, 1% NP-40, 0.25% sodium 
deoxycholate, 1 mM EDTA, 1 mM PMSF, 1 μg/ml pepstatin, 1 ug/ml leupeptin, 1 
ug/ml aprotinin, 1 mM Na3VO4, and 25 mM NaF. Cells were pelleted in a 
microcentrifuge tube at 14000 x g at 4˚C, and the supernatant was removed. The 
cells were resuspended in 25 μL of ice-cold RIPA buffer, and then cells were 
sonicated at 4˚C for 15 seconds on ice using a 550 Sonic Dismembrator from 
Fisher Scientific (Pittsburg, PA). A dilution of each sample lysate was prepared in 
ddH2O.  
 To measure the protein level in each sample, standard concentrations (0-
500 mg/ml) of bovine IgG protein were prepared in ddH2O for absorbance 
measurements. Samples of the standards or samples of the unknowns were 
mixed in clear plastic 96-well plates with 1:4 dilution of Bradford reagent 
according to the manufacturer’s instructions. When protein reacts with the 
Bradford reagent a color change occurs in direct proportion to the amount of 
protein present in the sample. After mixing, samples were allowed to incubate in 
the plate at room temperature for 2-3 minutes.   The absorbances of the samples 
were measured at 595nm using a SpectraFluor Plus spectrophotometer with 
Magellan 5.03 software from Tecan (Crailsheim, Germany). A standard curve 
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 was generated using the absorbance readings from the known protein samples, 
and linear regression analysis was used to calculate the protein concentrations 
from the absorbance measurements of the unknown samples.  
 Samples were loaded onto a 10% precast polyacrylamide gel and 
electrophoresis was performed at 75V for 1hr. Proteins were transferred onto a 
PVDF membrane at 100V for 1hr. The membrane was washed twice with ddH2O 
and then incubated in freshly prepared TBST-M for 30 minutes at room 
temperature with constant agitation. The membrane was incubated overnight at 
4°C with agitation using primary antibodies as necessary in freshly prepared 
TBST-M. The membrane was washed with TBST two times for 10 minutes each. 
The membrane was incubated for 1 hour at room temperature with agitation in 
1:1000 dilution of HRP-conjugated goat anti-mouse antibody in TBST-M. The 
membrane was washed 3 times using TBST for 10 minutes each. To detect 
RasGTP or total Ras present on PVDF membranes, Western Lightning® 
chemiluminescent HRP substrate solution was used. Membranes were incubated 
with the solution for 1 minute and then signal was detected on radiographic film. 
Signals present on film were scanned into the Adobe Photoshop 7.0 program 
(Mountain View, CA) using a Hewlett-Packard Scanjet 5470c scanner (Palo Alto, 
CA), and densitometric analysis was performed using QuantityOne® software 
from Bio-Rad (Hercules, CA). The signal from the protein of interest, in this case, 
Ras, was normalized to the signal from the loading control such as actin.  
 To measure the amount of farnesylated Ras and unfarnesylated Ras, cells 
from neuronal cultures were collected for Western blotting as described above. 
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 However, instead of using a 10% polyacrylamide gel, a 15% gel was used to 
resolve the unfarnesylated Ras from farnesylated Ras proteins. Electrophoresis 
was performed at 75V over 2 hours or until the Ras proteins had nearly reached 
the end of the gel as indicated by a pre-stained protein ladder (Invitrogen). All 
other methods for Western blotting were identical. Using the 15% gel, Ras 
appears as two bands. The band at the lower molecular weight represents 
prenylated Ras, whereas the band at the higher molecular weight is unprenylated 
Ras. Densitometry was used to measure both bands, and a ratio of the two was 
determined. The ratio was normalized to signal from lysates of cells that were not 
treated with FTI-276. The PVDF membranes from these experiments were also 
probed for actin. The expression of actin was quantified using densitometry. The 
total density of both Ras bands was normalized to the signal for actin to 
determine if there were changes in Ras expression.  The results were reported 
as a fraction of the non-treated controls.  
 
Measurement of RasGTP in Neuronal Cultures 
 
 Ras activity assays were conducted using a Ras Activation Assay Kit from  
Upstate Biotechnology (Lake Placid, NY) (Chen et al., 1997).  Cells were exposed 
to NGF ranging from 0 to 250 ng/ml for 7 days. Neurons were then collected into 
Eppendorf tubes on ice by scraping them from plates with a rubber policeman 
into ice-cold Mg2+ lysis buffer: 125 mM HEPES, pH 7.5, 750 mM NaCl, 5% Igepal 
CA-630, 50 mM MgCl2, 5 mM EDTA, 10% glycerol, 10 μg/ml aprotinin, 10 μg/ml 
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 leupeptin, 1 mM Na3VO4, and 25 mM NaF (0.5 ml of lysis buffer per 150 mm 
tissue culture plate). The cells were gently pipetted up and down to completely 
lyse them in suspension, and then lysates were cleared of nuclear debris by 
centrifugation at 4˚C and 14,000 x g for 5 minutes. Supernatants were 
transferred to new Eppendorf tubes and kept on ice. For positive and negative 
controls, either 2.5 μl of 10 mM GTPγS or 2.5 μl of 100 mM GDP, respectively, 
was added to 250 μg of protein from control samples. The samples were 
incubated at 30˚C while gently rocking for 30 minutes to allow the Ras binding to 
either GTPγS or GDP to reach equilibrium, and then the reaction was stopped by 
addition of 60 mM MgCl2. To determine the amount of RasGTP in each sample, 
10 μl of the GST fusion protein, RBD, bound to glutathione agarose beads was 
added. The samples were gently mixed on a rocker at 4˚C for 45 min. The 
agarose beads were pelleted for 10 sec at 14,000 x g and 4˚C. The supernatant 
was removed and discarded. The beads of each sample were washed three 
times with 100 μl of the Mg2+ lysis buffer. The samples then were boiled in 40 μl 
of Lamelli buffer which contained: 125 mM Tris-HCl, 10% glycerol, 10% SDS, 1 
M DTT to release bound RasGTP from the beads. After boiling, the beads were 
pelleted briefly for 1 min at 14,000 x g and the supernatant was transferred to a 
new tube for assay by Western blotting.  
 Western blotting was performed as described above for on samples 
incubated with RBD agarose to detect the portion of Ras bound to GTP. A 
second aliquot of sample that had not been incubated with RBD was used for 
Western blotting to detect total Ras. Mouse anti-Ras antibody (provided in the kit) 
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 was diluted to 1 µg/ml in freshly prepared TBST-M.  HRP-conjugated goat anti-
mouse secondary antibody was used at a 1:1000 dilution of in TBST-M. 
Detection and quantification were performed as described above. The RasGTP 
was measured relative to the total Ras protein in each sample. The values for 
each sample were normalized to the value for the sample incubated with GTPγS 
(positive control).  
   
Development of Lentivirus Expressing Dominant Negative or Constitutively Active 
Ras Isoforms 
 
            The dominant negative (dnRas, S17N isoform) and the constitutively 
active (caRas, Q61L isoform) were generous gifts of Dr. L. Quilliam, Biochemistry 
Department, Indiana University School of Medicine. Fragments containing the 
dnRas and caRas sequences were amplified by PCR from the original plasmids 
with restriction sites added that were compatible with the multiple cloning site of 
the pIRES2-EGFP vector. The sites added were EcoRI and SacII. The PCR 
primers used to add the two restriction sites were 5’-
CCGGAATTCACCATGACGGAATATAAGCTG-3’ and 5’-
ATTAGGCCGCGGTCAGGAGAGCACACACTT-3’. The PCR protocol was 95°C 
for 3 minutes, followed by 30 cycles with the following conditions 94°C for 1 
minute; 57°C for 1 minute, and then 65°C for 2.5 mintues. These cycles were 
followed by an elongation phase of 65°C for 10 minutes. Products were resolved 
on a 1% agarose gel. Figure 4 shows an agarose gel demonstrating PCR 
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 products at approximately 0.6 kb (Ras mutant) and at approximately 6.0 kb 
(undigested plasmid).  
                           
6kb
1kb
0.5kb
1 2
 
Figure 4. PCR amplification of Ras mutants inserted into the pIRES2-EGFP 
vector. The left lane is a 1kb ladder.  Lane 1 is the Ras PCR product amplified 
from vector containing the dnRas isoform. Lane 2 is the Ras PCR product 
amplified from vector containing the caRas isoform. The bright band in lanes 1 
and 2 are PCR products resulting from the amplification of the Ras insert 
(574bp), while the faint band above 6kb is likely the uncut supercoiled plasmid 
template.  
  
 After digestion with EcoRI and SacII enzymes, the PCR fragment was 
inserted into the pIRES2-EGFP vector via ligation using T4 DNA ligase according 
to the manufacturer’s instructions. The plasmids were then transformed into 
OneShot® Top10 E. coli following the manufacturer’s instructions. Colonies were 
selected based on kanamycin resistance. Plasmid DNA was isolated from 
bacterial cultures grown from original kanamycin-resistant colonies using a 
Hurricane® Mini-prep kit (Gerard Biotech, Oxford, OH). The appropriate Ras 
fragment was sequenced to ensure there were no mutations generated during 
PCR or during insertion of constructs into plasmids. The sequencing primers 
were 5’-TAACAACTCCGC CCCATTGACG-3’ and 5’-
GACGGCAATATGGTGGAAAATA-3’. Sequencing was performed at the 
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 Biochemistry Biotechnology Facility of the IU School of Medicine, and the results 
were analyzed using Chromas 2.31 chromatogram viewer software 
(Technelysium, Australia). 
 The dnRas-IRES-EGFP or a caRas-IRES-EGFP constructs were 
subcloned into an entry vector, pENTR 1A. First, the two constructs were cut 
from the pIRES2-EGFP vector using EcoRI and NotI. The pENTR 1A vector was 
cut with the same enzymes. The digested products were resolved on a low 
melting point 0.8% agarose gel. The fragments were gel purified using a S.N.A.P. 
™ Gel Purification Kit (Invitrogen) per manufacturer’s instructions. The individual 
Ras constructs were inserted into separate pENTRA 1A vectors via ligation using 
T4 DNA ligase according to the manufacturer’s instructions. The plasmids were 
then transformed into OneShot® Top10 E. coli per manufacturer’s instructions. 
Colonies were selected by kanamycin resistance, selected as described above, 
and plasmid DNA was isolated from cultures using a Hurricane® Mini-prep kit 
(Gerard Biotech, Oxford, OH).  
 The Gateway® LR Clonase™ II reaction was used to move the isolated 
dnRas-IRES-EGFP or the isolated caRas-IRES-EGFP construct into the lentiviral 
transfer vector, pCSCGW. The construct was transformed into STBl3 E. coli and 
then selection was performed using zeocin resistance. Plasmid was isolated 
using the EndoFree Plasmid Maxi Kit (Qiagen, Valencia, CA). An aliquot of 
plasmid was used for PCR to ensure the Ras insert could be amplified from the 
destination vector (Fig. 5). The same primers and PCR protocol from the above 
amplification of Ras were used. Products were resolved on a 1% agarose gel. 
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 With confirmation that the destination vector contained the Ras insert, the 
remaining plasmid was used for production of lentivirus containing dnRas-IRES-
EGFP or containing caRas-IRES-EGFP (Vector Production Facility, IU School of 
Medicine). 
                    
600bp
1 2 3 4
  
Figure 5. PCR amplification of Ras mutant isoforms inserted in the pCSCGW 
destination vector. The left lane is a 100 bp ladder, with the 600 bp position 
indicated by the arrow. Lanes 1 and 2 are amplified from vector containing the 
dnRas isoform, while lanes 3 and 4 are amplified from vector containing the 
caRas isoform. These data indicate that the Ras mutants are inserted into the 
destination vector used to produce the lentivirus.  
 
  
 To determine the quantity of lentivirus particles contained in solution 
produced by the Vector Production Facility, IU School of Medicine, the 
QuikTiter™ Lentivirus Quantitation Kit (HIV p24 ELISA) was used per 
manufacturer’s instructions (CellBioLabs, San Diego, CA). Because of the 
similarity between human immunodeficiency virus (HIV) and lentivirus, the 
quantification of lentivirus is based on quantification of the HIV-1 p24 core protein 
(Naldini, 1998). There are approximately 1.25 x 107 lentivirus particles per 1 ng 
p24 core protein, and there are approximately 103 lentivirus particles per plaque 
forming unit (pfu). A standard curve of known amounts of p24 protein was 
generated. Serial dilutions of viral solutions with unknown amounts of particles 
were prepared. All samples including standards were prepared in duplicate. 
Samples were loaded into wells pre-coated with anti-p24 antibody and allowed to 
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 equilibrate with gentle rocking at 4˚C overnight. The wells were washed, and 
cells were incubated with biotin-conjugated goat anti-p24 antibody for 1 hour at 
room temperature on an orbital shaker. Wells were washed and incubated with 
the provided streptavidin-enzyme conjugate for 1 hour at room temperature on 
an orbital shaker. Wells were washed and substrate solution was added to each 
well for 20 minutes at room temperature on an orbital shaker. The reaction was 
stopped by adding an acid solution provided in the Lentivirus Quantitation Kit and 
the absorbances of the wells were measured at 450 nm. Using the colorimetric 
ELISA assay and the standard curve, the number of viral particles in the 
unknown samples was determined using linear regression analysis, and the pfu 
were calculated.  
 
Lentivirus Infection 
 
 Cells were incubated in F-12 media with or without added NGF for 2 days 
after dissection from animals. After 2 days, cultures were exposed to lentivirus 
diluted in media at a final concentration of 150 pfu for 48 hours. After 2 days, 
media containing virus was removed and fresh F-12 media with or without added 
NGF was added to wells. Media was changed every other day for 7 days. Cells 
were visualized using a Nikon TE2000 inverted microscope with a 75W Xenon 
lamp (Japan) coupled to an Olympus camera with MagnaFire SP 2.1B software 
(Fort Gibson, OK). A filter to view green fluorescene was employed to determine  
if cells were producing EGFP. After 7 days of infection with lentivirus expressing 
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 EGFP or EGFP and Ras mutants, the expression levels of Ras were determined 
in neuronal cultures. Cells were collected and Western blotting was performed as 
described above for Ras protein in lysates. Immunoblotting was performed using 
mouse anti-Ras antibody (1:1000 dilution) (Upstate, Lake Placid, NY) or mouse 
anti-actin antibody (1:2000) (Upstate) in freshly prepared TBST-M. Secondary 
antibody was a 1:5000 dilution of HRP-conjugated goat anti-mouse antibody 
(Bio-Rad) in TBST-M. Densitometry was used to quantify the signals as 
described below. The Ras signal was normalized to the actin signal, and values 
were reported as a ratio of uninfected samples.    
 
Genotyping synGAP mice 
 
 To determine if mice were homozygous or heterozygous for synGAP, 
each animal was genotyped. Genomic DNA was isolated by digesting 3 mm 
whole tail tissue in 100 μL ddH20 in the presence of 100 μg/ml proteinase K at 55 
ºC for 3 hr. The whole cell lysate was used as template. The following primers 
sets were added to each PCR reaction to determine which alleles of the synGAP 
genes were present in each mouse, (1) synGAP forward primer 5’-
ACCTCAAATCCACACTCCTCTCCAG-3’, (2) synGAP reverse primer, 5’-
AGGGAACATAAGTCTTGGCTCTGTC-3’, and (3) the primer for neomycin 
resistence gene insert in mutants 5’-ATGCTCCAGACTGCCTTGGGAAAAG-3’ 
(Invitrogen). PCR cycles started with DNA denaturation at 95ºC for 2 minutes 
followed by 35 cycles of the following three conditions: 95ºC for 1 minute, 60ºC 
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 for 1 minute, and then 72ºC for 20 seconds. These cycles were followed by an 
elongation phase of 72ºC for 5 minutes. PCR products were resolved on a 2% 
agarose gel. If there was a single fragment at 500 bp this indicated the wildtype 
condition, while a fragment at both 300 and 500 bp indicated truncation of one 
allele of synGAP and the heterozygous condition (Fig. 6). Images were acquired 
using a Kodak EDAS 290 camera with Kodak ID 3.6 software. 
 
1 2 4 5 6 7 8 9 10 11 12 133
500bp
 
 
Figure 6. Sample agarose gel demonstrating PCR products from the DNA of 13 
different animals. Genomic DNA was used as PCR template, and PCR products 
were resolved on a 2% agarose gel. The left lane demonstrates a base pair 
ladder, with the bright band at approximately 500 bp. Lanes containing a single 
band at 500bp indicates the wildtype condition, with two normal alleles for the 
synGAP gene. Lanes containing a band at 300bp (with or without a faint band at 
500bp) indicate the heterozygous condition, as animals have one normal 
wildtype allele and one truncated allele for the synGAP gene. 
 
CellTiter 96® AQueous One Solution Assay for Cell Viability 
 
  
 To determine if treatment for 7 days with FTI-276 affects cell viability, 
which in turn could affect the measured levels of iCGRP, we measured the 
relative numbers of metabolically active cells in culture in the presence or 
absence of drug. The CellTiter 96® AQueous One Solution Assay from Promega 
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 (Madison, WI) was used to measure cell viability. In this assay, cells were 
incubated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) which is a tetrazolium compound. MTS is 
taken up by cells and bioreduced to a colored formazan product by 
dehydrogenase enzymes and NADPH or NADH in metabolically active cells. The 
formazan product is soluble in tissue culture medium, and its quantity as 
measured by the absorbance at 492 nm is directly proportional to the number of 
living cells in culture.  Absorbance was measured using a SpectraFluor Plus 
spectrophotometer with Magellan 5.03 software from Tecan (Crailsheim, 
Germany).  
 In these experiments, coated wells containing no cells were used as 
blanks for the spectrophotometer. As a positive control for cell death, cells were 
killed by 10 min exposure to 4% paraformaldehyde in PBS. Other controls 
included wells treated with media alone or vehicle (0.1% MPL). The remaining 
wells were treated with 1, 10, or 30μM FTI-276 for 7 days. Cells then were 
incubated with the MTS substrate for 4 hours according to the manufacturer’s 
instructions. Absorbance in wells exposed to FTI-276 was normalized to the 
values for wells of cells treated with media alone.  
 These procedures were repeated for cells treated for 7 days with the MEK 
inhibitor, U0126. At 492 nm there was very little absorbance in wells with no cells 
(blank) and the absolute absorbance values were similar to those in experiments 
where cells were treated with FTI-276, indicating that there was little to no cell 
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 death. Therefore, dead cells and blank wells were omitted and values were 
normalized to treatment with media alone.  
 
LI-COR Quantitative Immunohistochemistry 
  
 To confirm whether U0126 inhibited MEK activity in rat or mouse dorsal root 
ganglion neurons, neuronal cultures were exposed to either no added NGF or 30 or 
100 ng/ml NGF for 7 days in the presence of the 100nM or 10μM  U0126. Stock 
solutions of 10mM U0126 were prepared in MPL before each use, and then diluted in 
media. As a vehicle control, groups of cells were treated with vehicle 0.01% MPL alone. 
The media in the absence and presence of U0126 was changed every other day. After 
7 days, the cells were fixed at the end of the treatment course with 4% 
paraformaldehyde in PBS for 20 min. To quantitate the relative amounts of pERK 
relative to the total ERK protein, cells were permeabilized by washing 3 times for 
5 min each with 0.5% Triton X-100 in PBS. Cells were incubated overnight at 4°C 
with a 1:1 dilution of PBS and LI-COR blocking solution to decrease non-specific 
antibody binding. Cells were treated overnight at 4°C with primary antibodies to 
either p-ERK and ERK diluted 1:100 together in the blocking buffer. Primary 
antibodies, the mouse monoclonal anti-pERK and rabbit anti-ERK, were from 
Cell Signaling (Beverly, MA). Cells were washed five times in TBST. Some wells 
were not incubated with primary antibody to determine non-specific staining of 
secondary antibodies.  Secondary antibodies, goat anti-mouse antibody 
conjugated to IRDye™ 680 (Invitrogen, Carlsbad, CA) and goat anti-rabbit 
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 antibody conjugated to IRDye™ 800 (Rockland Inc, Gilbertsville, PA), were 
diluted simultaneously at 1:800 in 1:1 LiCor blocking solution in PBS. Cells were 
incubated in secondary antibodies for 2 hours in the dark. Cells were washed 5 
times in 0.5% tween-20 in PBS in the dark. Plates of cells were then scanned for 
infrared signal using an Odyssey Imager from LI-COR (Madison, WI). Focus 
offset was 3.0 mm using a 24-well template. Scan intensity was set at 5 for both 
700 nm and 800 nm wavelength channels, while scan quality was set at a 
resolution of 169 μm. Scans for the signals from both secondary antibodies were 
performed simultaneously. The background signal from cells incubated with 
secondary antibody only was subtracted from the signal from cells incubated with 
primary antibody. Signal intensity at 800 nm wavelength (total ERK) was 
normalized to the most intense signal for each experimental group to control for 
differences in staining intensities between experiments. The signal intensity at 
700 nm (pERK) was divided by the signal at 800 nm to normalize for differences 
in total ERK.  Data were expressed as a ratio of pERK to total ERK relative to the 
control group of cells.     
 
Small interfering RNA (siRNA) Treatment of Neurons 
 
 After neurons were grown for 2 days in culture dishes, the standard F-12 
media was replaced with F-12 media without antibiotics. On the fourth day in 
culture, growth media was aspired and replaced with 1 ml of OptiMEM I® serum-
free media. Cells were incubated with 100nM of the 21-mer oligos double-strand 
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 siRNA to synGAP, Ape1 (or scramble siRNA), or PKCα in 10 μl of the 
transfecting reagent, Neuroporter®. The Ape1 siRNA sequences were: 5’-
GUCUGGUAAGACUGGAGUACC-3’ and 5’-UACUCCAGUCUUACCAGACCU-
3’. The synGAP siRNA sequences were: 5’-AAAGCGGAAGAAGGACAAGUU-3’ 
and 5’-CUUGUCCUUCUUCCGCUUUUU-3’. The PKC-α siRNA sequences were: 
5’-GGACGACACGGAAUGACUUUU-3’ and 5’-
AAGUCAUUCCGUGUCGUCCUU-3’. 
   After a 24 hour incubation, 0.5 ml of fresh media without antibiotics was 
added to each well. After an additional 24 hours, the medium containing siRNA 
was aspirated and replaced with 1 ml of F-12 media containing antibiotics and 
the media was changed every other day. After 10 days of treatment, cells were 
exposed to the standard iCGRP release protocol as indicated (and see above for 
methods), and then cells were collected for analysis of lysates by Western 
blotting. The protocol for Western blotting was performed identically to those 
methods described above with the following alterations. For immunoblotting for 
synGAP, rabbit anti-synGAP antibody (Upstate, Lake Placid, NY) was used at a 
dilution of 1:500 in TBST-M. Goat anti-rabbit secondary antibody (Bio-Rad, 
Hercules, CA) was used at a dilution of 1:2000 in TBST-M. For immunoblotting 
for PKCα, mouse anti-PKCα (Upstate) was used at a dilution of 1:1000 in TBST-
M. Goat anti-mouse secondary antibody (Bio-Rad) was used at a dilution of 
1:5000 in TBST-M. 
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 Immunocytochemistry 
  
 Cells were fixed by incubating in 4% paraformaldehyde in PBS for 20 min 
at room temperature, and then permeabilized by washing five times with 0.5% 
Triton-X 100 in PBS. Cells were incubated overnight at 4˚C with blocking buffer 
(1:1 dilution of Odyssey Blocking Buffer in PBS). Cells were incubated overnight 
at 4˚C on an orbital shaker with goat anti-peripherin primary antibody from Santa 
Cruz Biotechnology (Santa Cruz, CA) diluted 1:250 in blocking buffer. Cells were 
washed with TBST five times for 10 min each wash. Cells were incubated for one 
hour in the dark at room temperature on an orbital shaker with a 1:1000 dilution 
of donkey anti-goat secondary antibody conjugated to AlexaFluor488™ or 
AlexaFluor585™ from Invitrogen (Carlsbad, CA). Cells were washed 5 times for 
10 min each with TBST protected from light. Fluorescent images of neurons in 
Figure 7 were acquired on a Leica DM LB microscope (Bensheim, Germany) with 
a Krypton-Argon laser attached to a Spot CCD camera from Diagnostic 
Instruments (Sterling Height, MI). Images were collected and overlaid using 
Adobe Photoshop 7.0 (Adobe, Mountain View, CA). Fluorescent images of 
neurons stained for synGAP in Figure 24 were acquired at the Indiana Center for 
Biological Microscopy using a Bio-Rad MRC-1024MP Laser Scanning 
Confocal/Multiphoton scanner (Hercules, CA) attached to a Nikon Diaphot 
inverted microscope with a Nikon X60 1.2-NA water-immersion objective (Fryer, 
Huntley, IL). Fluorescence excitation was provided by a Krypton-Argon (488, 
568, 647 nm) laser. Images were collected in black and white to maximize 
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 resolution and pseudocolored and overlaid using Adobe Photoshop 7.0 (Adobe, 
Mountain View, CA).     
 
Statistical Analysis 
  
 All data was analyzed using Prism 3.0 by GraphPad. All graphs are presented 
as the mean ± S.E. Stastistical significance was established using one-way ANOVA 
with Tukey’s posttest, or two-way ANOVA with a Bonferroni’s posttest as indicated. The 
posttests were chosen because they were the most stringent, and would produce the 
fewest number of Type I errors (rejecting the null hypothesis of no difference among 
groups when, in fact, the null hypothsis is true). N = number of wells per condition from 
at least three separate harvests of cells from dorsal root ganglion of animals. The 
significance level was set at p< 0.05. 
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 RESULTS 
 
Cellular Signaling Regulating the NGF-induced increase in iCGRP expression in 
primary sensory neurons 
 
NGF exposure for 7 days increases the cellular content of iCGRP in rat sensory 
neurons in culture 
 Previous work demonstrated that NGF increases substance P and CGRP 
content in sensory neurons (Lindsay and Harmar, 1989; Noguchi et al., 1995; Verge et 
al., 1996; Schuligoi and Amann, 1998; Miki et al., 1998).  These increases in 
neuropeptide content are important in physiological responses in the whole animal 
(Winter, 1988). Therefore, we characterized the effects of NGF on the expression of 
iCGRP in sensory neurons in culture (Lindsay et al., 1989; Hingtgen and Vasko, 1994; 
Burkey et al., 2004). As can be seen in Figure 7A, after 7-10 days, neuronal cultures 
derived from dorsal root ganglia are a mixed population of cells. The arrowhead points 
to a representative cell body of a sensory neuron, whereas the arrow points to a support 
cell. In general, the cell bodies of neurons are larger than non-neuronal cells in culture 
and appear granular.    
 To visualize the neurons in culture, cells were incubated with goat anti-peripherin 
antibody followed by a fluorescently labeled secondary antibody. The primary antibody 
is selective for the neuronal-specific protein, peripherin, and this antibody staining is 
used to distinguish neurons from non-neuronal cell types (Ferri et al., 1990). Using a 
fluorescent microscope, the neuronal cell bodies and an extensive network of neuronal 
processes can be seen in Figure 7B.        
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  To confirm that long-term exposure to NGF increases expression of iCGRP in 
adult sensory neurons in culture, cells were grown for 7 days in the absence or 
presence of NGF. As can be seen in Figure 8, cells grown in the absence of added 
NGF contain 3.4 ± 0.3 fmol iCGRP per μg protein. The expression of the iCGRP in 
sensory neurons significantly increases to 6.6 ± 0.5 when grown in 30 ng/ml NGF and 
8.1 ±  0.6 fmol when grown in 100 ng/ml NGF. The expression of iCGRP was not 
different when comparing the two concentrations of added growth factor. These studies 
agree with literature demonstrating an upregulation of CGRP in vivo in sensory neurons 
after administration of NGF either by endoneurial injection or injection of the 
neurotrophin into the hindpaw (Schicho and Donnerer, 1999; Ruiz and Banos, 2005).  
 Because previous studies of primary sensory neurons in vitro reported total 
peptide content as the amount per well of cells, rather than per μg of protein as reported 
here, the effects of NGF on total protein expression were examined. As shown in Figure 
9, the overall expression of protein in sensory neuronal cultures did not change with 
increasing concentrations of NGF.  The protein level in 0, 30, and 100ng/ml of added 
NGF was 2.7 ± 0.7, 3.0 ± 0.8, and 3.2 ± 0.7 μg per μl of buffer respectively. These 
results show that the effects of NGF on iCGRP content are not secondary to a non-
specific change in protein expression in cells.  
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Figure 7. Isolated rat dorsal root ganglion neurons after 7 days in culture grown in 30 
ng/ml NGF as described in Methods. (A) Brightfield view demonstrating cell bodies of 
sensory neurons and non-neuronal cells (— 50μm). The arrowhead points to a cell 
body of a sensory neuron, whereas the arrow point to a non-neuronal cell. (B) 
Fluorescent microscope images of sensory neurons in culture after antibody staining for 
peripherin, a neuronal-specific protein, which allows visualization of cell bodies and 
neuronal processes.    
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Figure 8. NGF (30ng/ml) and (100ng/ml) for 7 days increases expression of 
iCGRP in  isolated sensory neurons in culture compared to cells with no added 
NGF (0 NGF). An (*) indicates a significant increase in iCGRP expression 
compared to 0ng/ml NGF (p<0.05, n=12, from 12 separate experiments using 3 
wells of cells per condition. Data was analyzed using one-way ANOVA with 
Tukey’s post-hoc test). The content of iCGRP measured after growing cells in 30 
and 100ng/ml NGF were not significantly different.  
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Figure 9. NGF does not alter total protein expression in sensory neuronal 
cultures. No difference in total protein expression was observed at any 
concentration (n=12, from 12 separate harvests, using one-way ANOVA).  
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 Activation of Ras and the MEK/ERK pathway in neuronal cultures exposed to 
NGF for 7 days 
 In PC12 cells, effectors downstream of Ras, such as ERK, are involved in 
changes in the activity of promoters of neuropeptides, such as CGRP (Durham and 
Russo, 2003a; Dai et al., 2002; York et al., 1998).  Based on these data, studies were 
performed to determine whether the Ras/MEK/ERK cascade mediated the ability of 
NGF to increase the content of iCGRP in sensory neurons.  
 For this work, studies examined whether growing neurons in the presence of 
varying concentrations of NGF altered the level of RasGTP and pERK measured in 
sensory neuronal cultures. Then the Ras pathway was manipulated in cultures of 
isolated sensory neurons by using pharmacological inhibitors of the Ras pathway,  by 
overexpressing mutant Ras isoforms into neurons by lentivirus infection, by using 
siRNA directed against synGAP, and by using neurons from mice lacking synGAP. 
Employing multiple methods to manipulate Ras strengthened the interpretation of the 
role of Ras in NGF-induced alterations of iCGRP release and expression in sensory 
neurons.  
 Neuronal cultures were exposed to increasing concentrations of NGF for 7 
days. Cells were collected, lysed, and the RasGTP levels were measured as 
outlined in Methods. As positive and negative controls, an aliquot of the cell 
lysate was incubated with either GTPγS or GDP, respectively, to maximize and 
minimize the amount of RasGTP in samples. The RasGTP measured in samples 
was normalized to the maximum amount of RasGTP detected in the positive 
control. 
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  As shown in Figure 10, there was no change in the ratio of RasGTP to 
total Ras in neurons grown in 1, 3, 10 or 30 ng/ml NGF compared to no added 
NGF. Neurons in no added NGF demonstrated a ratio of RasGTP to Ras of 0.35 
± 0.11, while the ratios for neurons grown in 10 and 30 ng/ml NGF were 0.34 ± 
0.03 and 0.42 ± 0.09, respectively. The value for the negative control was 0.34 ± 
0.04. However, when NGF was increased to 100 or 250 ng/ml, there was a 
significant increase in the ratio. Neurons grown in 100 ng/ml NGF had a ratio of 
0.57 ± 0.08 and neurons grown at 250 ng/ml NGF had a ratio of 0.71 ± 0.11. 
These studies indicated that after 7 days exposure to 100 or 250 ng/ml NGF, 
more RasGTP is present in cells in culture. It is interesting when no NGF is 
added to the F-12 media that the level of RasGTP in cells is similar to the 
negative control. This suggests that in a quiescent state, the Ras pathway is not 
activated in these cells. 
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Figure 10. NGF exposure for 7 days increases RasGTP levels in sensory neurons in 
culture. Neurons were exposed to increasing concentrations of NGF as indicated for 7 
days. The amounts of RasGTP and total Ras were measured in cell lysates. As a 
positive control, samples were spiked with GTPγS to maximize RasGTP levels. All 
values were normalized to the maximum amount of RasGTP possible . An (*) indicates 
a significant increase in RasGTP compared to 0 NGF (p<0.05, n= 3 from 3 separate 
harvests, using one-way ANOVA with Tukey’s post-hoc test).    
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  To further explore whether the Ras/MEK/ERK pathway regulates the 
NGF-induced increases in iCGRP content in sensory neurons, the 
phosphorylation of ERK was measured in cultures grown in various concentration 
of NGF for 7 days. After treatment, neurons were immediately fixed and the level 
of phosphorylated ERK (pERK) relative to the total amount of ERK was 
measured using Li-Cor as described in Methods. The relative levels of pERK 
compared to total ERK are reported. Due to variability of the absolute values 
from experiment to experiment, the ratios were normalized to the values 
measured in neurons exposed to no added NGF after each experiment. As 
shown in Figure 11, 30 ng/ml NGF did not significant increase the ratio of pERK 
to total ERK, with a normalized value of 1.20 ± 0.02. However, the ratio 
significantly increased when neurons were grown in 100 or 250 ng/ml NGF, with 
a ratio of 1.63 ± 0.08 and 1.66 ± 0.10, respectively. The total amount of ERK did 
not change in with increasing concentrations of NGF (personal communication, 
Dr. Judith Richter). These experiments demonstrated that chronic exposure to 
NGF increases the levels of pERK in neuronal cultures. 
 The data showing an increase in pERK levels at 100 and 250 ng/ml NGF 
are analogous to data showing an increase in RasGTP at these same 
concentrations of NGF (Fig. 10). These data together strongly suggest that the 
Ras/MEK/ERK pathway is activated by 7-day exposure to the higher 
concentrations of NGF.  
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Figure 11. Seven-day treatment with NGF (100 and 250ng/ml) increases the 
level of pERK relative to total ERK in sensory neurons in culture. The ratio of 
pERK/total ERK is normalized to levels measured with no added NGF (0 ng/ml 
NGF). An (*) indicates a significant increase in the ratio of pERK/total ERK 
compared to cells treated with media alone (p<0.05, n=3 from 3 separate 
harvests, using one-way ANOVA with Tukey’s post-hoc test). 
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 Expression of dominant negative Ras (dnRas) in sensory neurons attenuates 
NGF-induced increases in iCGRP expression 
 To understand whether the Ras pathway mediates the NGF-induced 
increases in iCGRP content, Ras was manipulated directly. Neurons were 
infected with 150pfu of lentivirus expressing either a dominant negative isoform 
of Ras (17N dnRas) and EGFP, or EGFP alone (control virus). Neurons began 
expressing EGFP after 5 days of infection as determined by visualization of 
green fluorescence, but neurons were allowed to incubate for 2 more days to 
mimic time courses used in previous experiments and then photographs were 
obtained. As shown in Figure 12, neurons expressed EGFP at 7 days of infection 
with lentivirus. Approximately 70-90% of neurons in each of the fields expressed 
EGFP, and approximately 5 fields were viewed for each condition in each 
experiment, indicating that the majority of neurons were infected with lentivirus. 
EGFP expression was visible in the cell bodies and in the processes of some 
neurons.  
  Neurons were placed in culture with media containing no added NGF. 
Then cells were infected with lentivirus. Two days after infection fresh media was 
added to cells containing various amounts of added NGF. Cells were incubated 
with NGF for a total of 7 days. After treatment of neurons with lentivirus and 
NGF, cells were collected and lysed. Western blot analysis of cell lysates as 
described in Methods demonstrated an increase in Ras expression in neurons 
infected with the lentivirus containing the dnRas construct (Fig. 13). Values are 
reported as a ratio of Ras expression to actin expression, and are normalized to 
 78
 control cells. Controls were uninfected sensory neuronal cultures (1.0 ± 0.0). 
Cells infected with the control virus containing only EGFP had a ratio of 0.7 ± 0.3, 
which was not significantly different than control. However, Ras expression was 
approximately 3 times the amount in lysates from cells that were uninfected or 
infected with lentivirus containing only EGFP, with a ratio of 3.0 ± 0.5 (Fig. 13). 
These data, showing high expression of EGFP in cells in culture and increased 
expression Ras in cell lysates from neuronal cultures, indicated there was an 
overexpression of the dnRas protein, including in the sensory neuronal 
population of these mixed cultures.  
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200μm 
50 μm 
 
 
 
 
 
Figure 12. Neurons after 7d infection with 150pfu of lentivirus expressing EGFP 
with dnRas insert. Neurons were visualized using an inverted microscope with 
filter to visualize EGFP. The left top and left bottom panels show a brightfield 
view of neurons at 10X and 40X, respectively. The right top and right bottom 
panels are the same fields viewed with a filter to visualize EGFP. Neurons in 
brightfield are identified by their round cell bodies, while fibroblasts have a long 
spindle shape. Both support cells, such as fibroblasts, and neurons express 
EGFP.       
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Figure 13. Cells from neuronal cultures infected with lentivirus expressing dnRas 
have increased expression of Ras protein. (A) Representative Western blot of 
protein from cells with (1) no infection, (2) infection with control lentivirus 
expressing EGFP only, or (3) infection with lentivirus expressing dnRas with 
EGFP. Immunoblotting was performed with a pan-Ras monoclonal antibody and 
anti-actin monoclonal antibody. (B) Summary data from Western blots 
demonstrating an increase in Ras expression in neuronal cultures infected with 
lentivirus expressing dnRas. Cells from these cultures have an approximate 3-
fold increase in Ras expression. Infection with control virus does not affect the 
expression of Ras in neurons (n=3, from 3 separate harvests, using one-way 
ANOVA with Tukey’s post-hoc test).  
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  The overexpression of Ras in these experiments was dramatic. Ras is 
known to regulate the activity of downstream transcription factors.  Therefore, the 
protein content of samples was measured to determine if overexpression of 
dnRas altered overall protein expression relative to infection with a virus 
containing empty vector but still expressing EGFP (control virus). Protein was 
measured in cell lysates using a Bradford assay as described in Methods. In 
these experiments, infection with the control virus or virus expressing dnRas did 
not alter protein levels in cell lysates (Fig. 14). 
 To determine dnRas altered the expression of iCGRP in neurons in 
response to NGF, iCGRP content was measured and normalized to the total 
amount of protein in the sample (Fig. 15). As shown previously, exposing 
neurons to 30 and 100 ng/ml NGF for 7 days increased the level of iCGRP 
expressed in sensory neurons in culture (Fig. 15). Control neurons expressed 2.0 
± 0.4 fmol iCGRP per μg protein, while neurons grown in 30 and 100 ng/ml NGF 
expressed 7.9 ± 0.7 and 7.5 ± 0.7 fmol iCGRP per μg protein, respectively, which 
was a significant increase from control. When neurons were exposed to the 
control virus, results were similar. Neurons grown in no added NGF expressed 
3.0 ± 0.3 fmol iCGRP per μg protein, while neurons grown in 30 and 100 ng/ml 
NGF expressed 9.1 ± 0.9 and 7.5 ± 0.8 fmol iCGRP per μg protein, respectively. 
However, when neurons were infected with lentivirus expressing dnRas, there 
was a significant decrease in iCGRP content in neurons exposed to 30 or 100 
ng/ml NGF. Neurons grown in no added NGF in the presence of dnRas 
expressed 2.0 ± 0.3 fmol iCGRP per μg protein. In neurons grown in 30 and 100 
 82
 ng/ml NGF, they expressed 5.3 ± 0.6 and 4.0 ± 0.4 fmol iCGRP per μg protein, 
respectively. This was significantly lower expression than neurons exposed to 
control virus or no virus.   However, it is important to note that the effect of NGF 
was not completely blocked by 150pfu of lentivirus. There remained a significant 
increase in the level of iCGRP, albeit smaller, in neurons expressing dnRas after 
long-term exposure to NGF.  These data indicated that expression of the dnRas 
in neurons attenuates the NGF-induced increase in iCGRP expression. 
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Figure 14. Infection with lentivirus expressing EGFP alone or EGFP with 17N 
dnRas does not alter protein levels measured in cell lysates. In these 
experiments, cells were exposed to media alone, control lentivirus, or virus 
expressing 17N dnRas. They were subsequently exposed to NGF ranging from 
0, 30 or 100ng/ml. Neurons were collected and the protein levels assayed. There 
was no difference under any condition (n=3, from 3 separate harvests. Data was 
analyzed using one-way ANOVA). 
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Figure 15. Expression of dnRas inhibits the NGF-induced increase of iCGRP 
expression in sensory neurons in culture. Neurons were exposed to media (white 
bars), virus expressing EGFP (hatched bars), or virus expressing dnRas and 
EGFP (black bars). After infection, they were exposed to increasing 
concentrations of NGF as indicated, and then cells were collected to measure 
iCGRP content. An (*) or (†) indicates a significant increase in content when 
neurons were exposed to 30 or 100ng/ml NGF compared to 0 NGF for each of 
the three conditions (media, control virus, or dnRas virus treatment). An (#) 
indicates a significant decrease in the NGF-induced augmentation of iCGRP at 
30 and 100ng/ml NGF compared to uninfected cells or cells treated with control 
virus (p<0.05, n=3, from 3 separate harvests. Data were analyzed using two-way 
ANOVA with Bonferroni’s post-hoc test).   
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 Expression of constitutively active Ras (caRas) in sensory neurons increases in 
iCGRP expression 
 If Ras activation by NGF is sufficient for the increase of iCGRP expression 
in neurons in response to NGF, then infecting neurons with constitutively active 
Ras (caRas) also should increase the neuropeptide content even in the absence 
of NGF. Neurons were infected with 150 pfu of lentivirus expressing EGFP only 
or caRas with EGFP. Cells were incubated with virus in media for 48 hours, and 
then media was replaced with fresh F-12 containing no virus. On the seventh 
day, cells were collected and lysed to measure iCGRP content. 
 Figure 16A represents a brightfield view of dorsal root ganglia cells in 
culture and the same field viewed with a filter to visualize EGFP. Neurons 
expressed EGFP mostly in cell bodies. The number of cells infected with 
lentivirus as determined by EGFP expression was similar to the number of cells 
infected with virus containing dnRas (see above). As demonstrated by the 
Western blot, which is normalized to an actin loading control, lysates from 
neurons infected with virus expressing caRas with EGFP (lane 2) expressed 
higher levels of Ras than neurons infected with control virus alone.  
 The iCGRP content in lysates from cells infected with control virus or virus 
expressing caRas are shown in Figure 17. The average values from two different 
experiments are presented. The values were derived from duplicate 
measurements from each experiment. While this series of experiments is not 
complete, it appeared that caRas increased the iCGRP content in the absence of 
NGF. Experiments are currently being performed to complete these studies. If 
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 caRas increases expression of iCGRP, then Ras activation is both necessary 
and sufficient for upregulation of iCGRP.  
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A 
200μm 
        
 
B 
       
                                  
1 2
Figure 16. Characterization of neuronal cultures infected with lentivirus 
expressing EGFP or EGFP with caRas. (A) Neurons infected with virus were 
visualized using an inverted microscope with filter to visualize EGFP. The left 
panel shows a brightfield view of neurons at 10X, and left panel is the same field 
viewed with a filter to visualize EGFP. (B) Cell lysates from neuronal cultures 
infected with lentivirus expressing dnRas have increased expression of Ras 
protein. Representative Western blot of protein from cells with (1) infection with 
control lentivirus expressing EGFP only, or (2) infection with lentivirus expressing 
caRas with EGFP. Immunoblotting was performed with a pan-Ras monoclonal 
antibody and anti-actin monoclonal antibody.   
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Figure 17. The iCGRP content in cell lysates from neurons infected with control 
virus or virus expressing caRas. Neurons were grown in culture in the absence of 
NGF, and were infected with virus for 7 days. After 7 days neurons were 
collected and lysed to measure iCGRP content. The means are derived from 
measurements from two different experiments. There is a trend for increased 
expression of iCGRP in the presence of the virus expressing caRas, but the 
experiment must be replicated to draw conclusions.  
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 FTI-276 attenuates increases in iCGRP expression with chronic NGF exposure  
 While expression of dnRas and caRas are specific ways to inhibit or 
activate Ras signaling, respectively, it is possible that these manipulations could 
affect iCGRP expression through other mechanisms. For instance, simply 
overexpressing protein levels could alter signaling pathways and lead to incorrect 
conclusions about the native function of Ras in NGF signaling. Therefore, cells in 
culture were treated with a farnsyltransferase inhibitor, FTI-276, as another way 
to manipulate Ras-mediated signaling. As described in the Introduction, the Ras 
protein is post-translationally processed and a farnesyl lipid moiety is added to 
the carboxy terminal end of the molecule (Sebti and Hamilton, 1997). By blocking 
the enzyme that catalyzes the addition of farnesyl, using FTI-276, Ras cannot 
localize to the membrane and its activity is decreased.  
 The half-life of the Ras protein is approximately 24hr  (Politi and 
Senderowicz, 2001). Therefore, treatment with FTI-276 for 4 days would theoretically 
reduce Ras by greater than 90% because the existing Ras would be degraded, 
and fanesylation of newly formed Ras would be inhibited. Consequently, cells 
were treated 4 days with 5μM FTI-276, and then cells were exposed to NGF in 
the presence or absence of inhibitor for 4-5 more days. This concentration was 
chosen because it is approximately 100x the IC50 for farnesylation of Ras in 
various cell lines (Sebti and Hamilton, 1997). Neurons were collected and iCGRP 
content was measured by radioimmunoassay, whereas inhibition of farnesylation 
was confirmed by Western blotting. 
 90
  Figure 18A shows a representative Western blot from sensory neuronal 
cultures treated with FTI-276. The unfarnesylated Ras (top band) was resolved 
from the farnesylated Ras (bottom band). To quantify the effectiveness of FTI-
276, the ratio of the density of the top band to bottom band was calculated.  
 In untreated neurons, there was no difference in the ratio at any 
concentration of NGF. Values are reported as a ratio of unprenylated to 
prenylated Ras, and are normalized to control values. At 0, 30, and 100 ng/ml 
NGF the ratios are 1.0 ± 0.0, 0.7 ± 0.2, and 1.0 ± 0.1, respectively. These values 
are not different. However, when cells were exposed to 5μM FTI-276 and NGF, 
the ratio increased from 1.6 ± 0.5 at 0 ng/ml added NGF to 2.7 ± 0.2 and 2.5 ± 
0.7 in 30 and 100 ng/ml NGF, respectively. This indicates there was a significant 
increase in the ratio, or a decrease in farnesylated Ras, when neurons were 
treated with FTI-276 and NGF compared to FTI-276-untreated controls (Fig. 
18B).  
 Because cells were incubated with FTI-276 for 7 days, it is possible that 
the level of Ras protein was altered. Altering levels of the Ras protein could 
change its activity, and could bias the interpretation of the data. Therefore, we 
measured total levels of Ras protein in these samples. When Ras (including 
farnesylated and unfarnesylated protein) was normalized to actin, the total 
amount of Ras expressed in sensory neurons does not change (Fig. 19). These 
data also indicated that there were not significant increases in total Ras 
expression in response to 30 or 100 ng/ml NGF after 7 days.  
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  In sensory neurons treated with FTI-276 in the presence of NGF, there 
was a significant reduction in neurotrophin-induced upregulation of iCGRP (Fig. 
20). Neurons with no added NGF expressed 3.0 ± 0.1 fmol iCGRP, and neurons 
with no added NGF in the presence of 5μM FTI-276 expressed 1.8 ± 0.1 fmol 
iCGRP per μg protein. These two values were not significantly different from one 
another. When 30 ng/ml NGF was added, cells expressed 6.3 ± 0.2 and 3.8 ± 0.5 
fmol iCGRP per μg protein in the absence and presence of FTI-276, respectively. 
Again, these two measurements were not significantly different from one another. 
However, both measurements were significantly increased from neurons with no 
added NGF. At 100 ng/ml NGF, measurements were 9.9 ± 1.7 and 6.7 ± 1.3 fmol 
iCGRP per μg protein in the absence and presence of FTI-276, respectively. 
These values were significantly higher than those with no added NGF, and the 
values at 100 ng/ml NGF were significantly different than one another. These 
data indicate that NGF increases the expression of iCGRP in these neurons and 
FTI-276 inhibits the neurotrophin-induced increases at higher concentrations of 
NGF.   
 Because of the long duration of treatment with FTI-276, the cells in culture 
may contain less iCGRP because there are fewer cells present. The viability of 
cells was measured using an MTS assay. This assay requires living cells to 
break down a substrate to a colorimetric product through energy-dependent 
enzymes. Dead cells cannot catalyze the reaction, and would be reflected in 
lower absorbance at a designated wavelength. In Figure 21, cells were treated 
with a fixative to kill them. They were unable to convert the substrate and the 
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 absorbance measured was not higher than background values. As shown in 
other treatment groups, FTI-276 incubation for 7-10 days did not affect viability 
up to 30μM compared to cells treated with media alone or vehicle (Fig. 21). 
 Together these data showed Ras expression did not change in cells 
treated chronically with FTI-276, and FTI-276 the NGF-induced increases in 
iCGRP expression. There were no changes in cell viability which also could be 
another uncontrolled variable in these experiments. Incubation with the drug 
reduced the increase in iCGRP expression in sensory neurons in response to 7 
day treatment with NGF. These data indicate Ras is involved in regulation of 
iCGRP content in neurons. 
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Figure 18. FTI-276 increases the ratio of unprenylated Ras to prenylated Ras in 
neuronal cultures. Cells were treated with vehicle or FTI-276 (5μM) as described 
in Methods. (A) Representative Western blot demonstrating the level of 
unprenylated Ras (top band) relative to prenylated Ras (bottom band), and the 
actin loading controls as indicated. (B) Summary densitometry data from 3 
separate experiment using FTI-276. An (*) indicates a significant increase in the 
ratio of unprenylated to prenylated Ras compared to control (0 NGF only) 
(p<0.05, n=3 from 3 separate harvests, using one-way ANOVA with Tukey’s 
post-hoc test).    
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Figure 19. Expression of Ras in neuronal cultures is not altered by treatment with 
vehicle or FTI-276 (5μM) nor by treatment with 30 or 100 ng/ml NGF for 7 days. 
Neurons were treated with increasing amounts of NGF in the presence or 
absence of FTI-276. Summary data from densitometry measurements of 
Western blots for total Ras protein normalized to actin. There was no significant 
difference among any of the conditions in the relative amounts in sensory 
neurons in culture (n=3, from 3 separate harvests, using one-way ANOVA with 
Tukey’s post-hoc test).  
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Figure 20. FTI-276 reduces the NGF-induced increase in iCGRP content in 
neurons exposed to 100 ng/ml NGF. Neurons were treated with vehicle (white 
bars) or FTI-276 (5μM, black bars) in the presence or absence of increasing 
concentrations of NGF as indicated. An (*) indicates an increase in iCGRP 
relative to treatment with no NGF. An (†) indicates significantly lower iCGRP 
content compared to vehicle control treated with 100 ng/ml NGF (p<0.05, n=12, 3 
separate harvests, using two-way ANOVA with Bonferroni’s post-hoc test). 
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Figure 21. Cell viability of cultures from dorsal root ganglia is not affected by 
treating with FTI-276 for 7 days. Neurons were treated as indicated. Wells 
containing media but not cells were used as blanks. For controls, wells of cell 
were treated with media alone (media). After 7days, one group of cells was 
treated with paraformaldyhyde as a positive control for cell death. The neurons 
were then subjected to an MTS assay and absorbance was measured at 492 nm 
(see Methods). Data were normalized to control cells (media). The blank and 
dead cells had significantly lower absorbances compared to untreated cells. 
There were no differences among untreated cells and cells treated with FTI-276 
(p<0.05, n=12 from three separate harvests, using one-way ANOVA with Tukey’s 
post-hoc test). 
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 SynGAP, a neuronal-specific RasGAP, is expressed in rat primary sensory 
neurons in culture 
 Ras activation is tightly regulated at the membrane by proteins that 
hydrolyze GTP to shut off signaling to MEK and ERK. The negative regulatory 
proteins are referred to as GTPase activating enzymes, or GAPs. SynGAP is a 
GTPase activating enzyme than has been demonstrated in neurons of the central 
nervous system, such as mouse hippocampal and cortical neurons. The enzyme 
accelerates the rate of reaction for hydrolysis of GTP, and inactivates RasGTP 
signaling to downstream cascades (Fig. 3).  
 Previously, the presence of synGAP in peripheral neurons had not been 
demonstrated. For these studies, dorsal root ganglion neurons derived from rats 
were grown for 7 days in the presence of 30ng/ml NGF. After fixing cells using 
paraformaldehyde, immunohistochemical studies were performed using 
antibodies for both synGAP and peripherin. Fluorescently labeled secondary 
antibodies were used against the primary antibodies. SynGAP (red) and 
peripherin (green) colocalized in sensory neurons (yellow) (Fig. 22). SynGAP 
was expressed in the processes of neurons in culture. There did not appear to be 
synGAP expression in non-neuronal support cells, which were present in these 
cultures.  
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Peripherin 
synGAP 
merge 
Figure 22. Dorsal root ganglion neurons in culture express the neuronal 
RasGAP, synGAP. Neurons in culture were fixed and stained using antibodies 
directed against peripherin and synGAP. Peripherin is localized in cell bodies and 
processes of neurons (top). SynGAP (middle) is localized heavily in processes 
with some staining in cells bodies. Colocalization shows synGAP is present in 
neurons that co-express peripherin. (—) represents 50 μm, fields are views from 
40X lens.  
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 After chronic exposure to 100 or 250 ng/ml NGF, neurons from mice with a 
heterozygous deletion of synGAP have increased iCGRP content compared to 
neurons from wildtype littermates   
 Mice that have a heterozygous deletion of the synGAP gene have been 
developed by the laboratory of RL Huganir (Kim et al., 2003). In neurons that 
have decreased expression of synGAP, Ras is more active. In previous studies 
using hippocampal neurons from synGAP heterozygous animals, downstream 
targets of Ras such as MEK and ERK show increased activation (Komiyama et 
al., 2002). Thus, these mice provide another means to manipulate the Ras 
signaling cascade in sensory neurons to examine the role of this small G-protein 
in NGF-induced expression of iCGRP. 
 Using dorsal root ganglion neurons from mice with a heterozygous 
deletion of synGAP, the question was asked whether the genetic alteration would 
alter the expression of iCGRP in cells exposed to NGF for 7 days. Neurons from 
synGAP heterozygous animals and their wildtype littermates were exposed to 
increasing amounts of NGF for 7 days, and the iCGRP content in these neurons 
was measured (Fig. 23). As can be seen in Figure 23, 100ng/ml NGF there was 
a significant increase in the expression of iCGRP compared to the littermate 
controls. These data suggested that neurons from mice with a heterozygous 
deletion of synGAP were more responsive to NGF compared to neurons from 
wildtype mice, suggesting that the Ras pathway is important in the regulation of 
iCGRP expression in sensory neurons in culture.  
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  An interesting finding from these experiments is that neurons from mice 
appear to have more iCGRP per microgram of protein compared to cell neurons 
derived from dorsal root ganglia from rats. On average, neurons from rats 
express approximately 2.5 fmol iCGRP per microgram protein while neurons 
from mice express about 3 times that amount. More importantly, neurons from 
wildtype mice do not have a robust increase in iCGRP expression with NGF 
treatment. 
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Figure 23. Compared to littermate controls, dorsal root ganglion neurons from 
synGAP heterozygous mice have increased levels of iCGRP expression in 
response to 100 and 250 ng/ml NGF.  Neurons from wildtype animals (black 
bars) do not have increased expression of iCGRP when exposed to NGF as 
observed in neurons from rats. However, when neurons from synGAP mice 
(hatched bars) are exposed to NGF they demonstrate a significant increase in 
expression compared to their littermate controls. An (*) indicates a significant 
increase in iCGRP content compared to wildtype neurons (p<0.05, n=4, from 4 
separate harvests, using two-way ANOVA with Bonferroni’s post-hoc test).  
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 Incubation of neuronal cultures with MEK inhibitor, U0126, attenuates the NGF-
induced increases in iCGRP expression 
 RasGTP activates Raf kinase, which phosphorylates and activates MEK 
(see Fig. 2 and Introduction). As a different means to manipulate the downstream 
effectors of Ras in neurons, the MEK inhibitor U0126 was used. The drug inhibits 
the activation of MEK by blocking phosphorylation and activation by Raf-1 kinase 
at an IC50 of less than 100nM (Kohno and Pouyssegur, 2003). Thus, U0126 was 
used to determine if signaling molecules downstream from Ras were important in 
the regulation of NGF-induced changes in neuropeptide expression. 
 Rat neurons in culture were exposed to 0, 30, or 100 ng/ml NGF for 7 
days in the absence or presence of (Fig. 24). Neurons were collected and the 
iCGRP content was measured in cell lysates. In neurons with no added NGF, 
cells expressed 3.1 ± 0.5 and 2.1 ± 0.7 fmol iCGRP per μg protein in the absence 
and presence of U0126, respectively. These measurements were not 
significantly different. In neurons exposed to 30 ng/ml NGF, cells expressed 5.6 ± 
0.9 and 3.2 ± 0.4 fmol iCGRP per μg protein in the absence and presence of 
U0126, respectively. As described in previous experiments, the U0126-untreated 
cells at 30 ng/ml NGF demonstrated a significant increase in iCGRP expression 
compared to the cells with no added NGF. However, the neurons treated with 
U0126 and 30 ng/ml NGF did not demonstrate a significant increase in iCGRP 
expression relative to NGF-untreated neurons. In neurons exposed to 100 ng/ml 
NGF, cells expressed 7.0 ± 1.0 and 4.3 ± 0.6 fmol iCGRP per μg protein in the 
absence and presence of U0126, respectively. As in previous experiments, the 
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 U0126-untreated neurons demonstrated a significant increase in iCGRP 
expression compared to cells with no added NGF. Furthermore, U0126 
significantly decreased the expression of iCGRP in the presence of 100 ng/ml 
NGF (Fig. 24). Notably, 100ng/ml NGF significantly increased iCGRP content 
compared to 0ng/ml NGF even in the presence of U0126. There are at least two 
explanations for this finding. It is possible that at high levels of the neurotrophin, 
iCGRP transcription may involve MEK-independent processes. Alternatively, 
1μM U0126 may not be a high enough concentration of the drug to block the 
increase of iCGRP expression by  100 ng/ml NGF. 
 As with FTI-276, the viability of rat neurons treated for 7 days with U0126 
was measured to ensure long-term exposure did not harm cells in culture. 
Treatment with U0126 did not cause cell death in cultures as measured by MTS 
assay (Fig. 25).  
 Throughout the experiments using 1μM U0126, it was assumed the drug 
was inhibiting the activation of MEK in neurons from rats. Although U0126 is a 
relatively selective MEK inhibitor (English and Cobb, 2002), experiments also 
were performed to confirm that U0126 at the concentration utilized inhibited the 
phosphorylation of ERK. Because ERK is specifically activated by MEK, is a valid 
indicator of MEK inhibition. Neurons from rats were exposed to 100ng/ml NGF for 
7 days in the presence or absence of U0126 (Fig. 26). NGF significantly 
increased pERK relative to total ERK compared to non-treated neurons, whereas 
U0126 significantly attenuated the effect of NGF. These data indicated U0126 
partially attenuates the NGF- induced increases in pERK in rat sensory neurons 
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 in culture, suggesting that this concentration of U0126 does not produce a 
complete inhibition of MEK.  
 In Figure 23, neurons from synGAP heterozygous mice showed an 
increase in iCGRP expression when they were exposed to 100ng/ml NGF 
compared to neurons from wildtype littermates. To determine whether this 
increase was dependent on MEK activity, neurons from synGAP heterozygous 
mice and their littermate controls were exposed to 100ng/ml NGF in the presence 
or absence of U0126 (1μM) for 7 days. The cells were collected, and iCGRP 
content was measured in lysates. As in the previous studies, there was no 
increase in the iCGRP expression in neurons from wild-type mice, whereas  
there was a significant increase in the amount of iCGRP from neurons exposed 
to 100ng/ml NGF in heterozygous mice. This increase was abolished by 
incubation with 1μM U0126 (Fig. 27), showing that the NGF-induced increase in 
iCGRP express is through MEK activation in mouse sensory neurons. 
Furthermore, these data were strikingly similar to those obtained by using FTI-
276 in rat neurons (Fig. 20). In both cases there is a significant decrease in the 
NGF-induced upregulation of iCGRP content in sensory neurons. These 
experiments together strongly implicate the Ras/MEK/ERK pathway in the 
regulation of iCGRP expression by NGF in mouse and rat sensory neurons.  
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Figure 24. The MEK inhibitor, U0126 (1μM), significantly decreases NGF-induced 
upregulation of iCGRP content in sensory neurons in culture. An (*) indicates a 
significant increase in iCGRP content compared to 0ng/ml NGF. An (#) indicates 
a significant decrease in iCGRP content within an NGF-treatment groups 
compared to U0126-untreated ccells. An (†) indicates a significant increase in 
iCGRP content compared to neurons at 0ng/ml NGF treated with U0126 (p<0.05, 
n=6 from 6 separate harvests. Data were analyzed with two-way ANOVA with 
Bonferroni's post-hoc test).  
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Figure 25. U0126 treatment for 7 days does not alter cell viability in cultures of 
dorsal root ganglion neurons. Cells were treated with the indicated amount of 
NGF in the absence (solid columns) or presence (hatched columns) of 1μM 
U0126. After 7 days, cultures were then subjected to an MTS assay per 
manufacturer’s instructions. Absorbance was measured at 492 nm (see 
Methods). Data were normalized to untreated cells (0ng/ml NGF). 
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Figure 26. U0126 blocks the increase in pERK observed after 7 day treatment 
with 100ng/ml NGF. Rat sensory neurons were exposed for 7 days to 100ng/ml 
NGF in the presence (hatched bars) or absence (solid bars) of 1μM U0126. 
Neurons were then fixed and the levels of pERK relative to total ERK were 
measured (see Methods). The data are presented relative to control values (0 
ng/ml NGF, U0126-untreated neurons). An (*) indicates a significant increase in 
the ratio of pERK/total ERK relative to control. An (#) indicates a significant 
decrease in the NGF-induced unregulated of iCGRP expression in neurons 
compared to U0126-untreated neurons (p<0.05, n=12 from 3 separate harvests, 
using two-way ANOVA with Bonferroni’s post-hoc test).  
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Figure 27. U0126 blocks the NGF-induced increase in iCGRP content in neurons from 
synGAP heterozygous mice. Neurons from synGAP heterozgyous mice (hatched bars) 
or their wildtype littermate (black bars) were exposed to either 0 or 100ng/ml NGF as 
indicated. Where indicated, groups of neurons were simultanesouly exposed to U0126 
(1μM) for 7 days. The iCGRP content was measured in these neurons and normlaized 
to the amount of protein in the sample. An (*) indicates a significant increase in iCGRP 
content compared to neurons that were not treated with NGF (p<0.05, n=4 from 4 
separate harvests, using two-way ANOVA with Bonferroni’s post-hoc test). 
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 Effects of Acute Exposure to NGF on the Capsaicin-evoked Release of iCGRP 
from Dorsal Root Ganglion Neurons in Culture 
 
 
 NGF increases the release of iCGRP from capsaicin-stimulated neurons 
 Acute exposure to NGF has been shown to increase the capsaicin-stimulated 
release of iCGRP independent of changes in content (Fehrenbacher, 2005). As shown 
in Figure 28, we were able to replicate this finding. The capsaicin-evoked release in the 
absence of NGF is 148.1 ± 16.42, while 10 min exposure to 100 ng/ml NGF prior to and 
throughout capsacin treatment causes more than a doubling in the release of iCGRP 
from sensory neurons to 323.3 ± 40.2 fmol/well/min (Fig. 28). This difference is not due 
to changes in content as the levels of iCGRP do not change with just 10 min treatment 
of NGF (Fehrenbacher 2005).  These data suggest that acute exposure to NGF 
activates intracellular signaling cascades, and these post-translational events occur 
which alter neuronal sensitivity to capsaicin stimulation. These data compliment 
previous work that shows acute exposure to NGF increase the excitability of sensory 
neurons (Shu and Mendell, 1999; Bonnington and McNaughton, 2003; Bron et al., 
2003; Zhang and Nicol, 2004; Zhuang et al., 2004). Controversy remains, however, as 
to the intracellular signaling that mediates the sensitivity of sensory neurons in response 
to treatment with NGF.  
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Figure 28. Brief exposure to NGF enhances capsaicin-evoked iCGRP release 
from neurons in culture. Resting release of iCGRP is indicated in the absence of 
capsaicin (cap) stimulation. Cells were exposed to HEPES buffer alone or to 
100ng/ml NGF for 10 min. Next, cells were exposed to HEPES buffer containing 
capsaicin (30nM) with or without NGF for 10 min (stimulated release). NGF does 
not affect the amount of resting release from neurons in these experiments. An 
(*) indicates a significant increase in the stimulated release of iCGRP from 
neurons treated with NGF compared to non-treated controls (p<0.05, n=36, from 
12 separate harvests, using one-way ANOVA with Tukey’s post-hoc test).  
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 Expression of dnRas does not alter the degree of NGF-induced increases in 
capsaicin-evoked iCGRP release from sensory neurons 
 It has been shown that the Ras/MEK/ERK pathway is necessary for NGF-
induced increases in cobalt uptake by neurons exposed to capsaicin (Bron et al., 
2003). This and other studies suggest that the Ras/MEK/ERK pathway mediates 
acute sensitization of sensory neurons with brief exposure to NGF.  Since we 
demonstrated that acute NGF increases capsaicin-evoked release of iCGRP, we 
examined whether the Ras/MEK/ERK pathway mediates this phenomenon. In 
the first series of experiments, we asked whether the NGF-induced increase in 
capsaicin-evoked release from neurons is altered when cells express dnRas. 
Because the expression of dnRas alters total content of iCGRP in neurons (Fig. 
15), the capsaicin-evoked release of iCGRP was normalized to the total amount 
of neuropeptide measured to reflect changes in the sensitivity of neurons.  
 When neurons treated with media only were exposed to 30nM capsaicin, 
they released approximately 6.0 ± 1.5 percent of the total cellular iCGRP content 
When separate wells of neurons were exposed to NGF for 10 min prior to and 
throughout the capsaicin stimulation, the amount of iCGRP released doubled to 
12.3 ± 2.2 percent of the total content (Fig. 29). This magnitude of change was 
observed in all treatment groups (media alone, control virus, or virus expressing 
dnRas). In cells expressing control virus, acute NGF exposure increased release 
from 7.5 ± 1.4 to 15.1 ± 1.0 percent. In cells expressing dnRas, release 
increased from 4.3 ± 0.6 to 7.8 ± 1.1 percent of the total content of iCGRP. 
Hence, dnRas did not affect the magnitude of sensitization by NGF. These data 
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 suggest that acute NGF sensitization in neurons is not affected by Ras activity in 
these neurons.  
 However, in cells treated with virus expressing dnRas, the capsaicin-
evoked release from neurons was lower from both NGF-treated and non-treated 
groups when compared to release from neurons treated with control virus.  This 
indicated an overall decrease in capsaicin-evoked release when Ras activity was 
decreased. Because the effect was observed using the stimulating agent, 
capsaicin, it is possible that the decrease in evoked release was a result of 
decreased expression or sensitivity of TRPV1 in response to overexpression of 
dnRas (see Discussion).  
 Table 1 shows the resting release from sensory neurons treated with 
media alone, control virus, or virus expressing dnRas. Also reported in Table 1 
are values for resting release from cells exposed to 100 ng/ml NGF for 10 
minutes. In contrast to the capsaicin-evoked release, there were no significant 
changes in the resting release of iCGRP from sensory neurons in culture infected 
with lentivirus compared to resting release from cells treated with media alone 
(Tab. 1). These data indicate the neither infection with lentivirus nor brief 
exposure to NGF alters the resting release of iCGRP from sensory neurons in 
culture. 
 113
 n = 9
0
10
20
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
media
control 
virus dn Ras
*
*
*
†
†
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
NGF (100ng/ml) + + +
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
cap (30nM) + + ++++
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e 
as
pe
rc
en
t o
f t
ot
al
 c
on
te
nt
(fm
ol
/w
el
l/1
0m
in
)
 
 
 
 
 
Figure 29. The increase in capsaicin-evoked iCGRP release by NGF is not 
altered by expression of dnRas. Neurons were treated with media alone (white 
bars), control virus (hatched bars), or virus expressing dnRas (black bars). After 
7 days, a standard release assay was performed. Neurons were exposed to 
30nM capsaicin with or without brief pretreament (10min) with 100 ng/ml NGF. 
An (*) indicates a significant increase in capsaicin-evoked release in the 
presence of NGF compared to its non-treated control. An (†) indicates a 
significant decrease in capsaicin-evoked release (with or without NGF) compared 
to neurons treated with control virus (p<0.05, n=9 from 3 separate harvests, 
using one-way ANOVA with Tukey’s post-hoc test).    
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 Resting iCGRP Release (Percentage of Total Content) 
                             
                            no infection            control virus             dnRas 
 
    no NGF           0.16 ± 0.07             0.12 ± 0.03           0.15 ± 0.04 
    NGF                0.26 ±  0.09             0.09 ± 0.01           0.26 ± 0.06 
 
 
 
 
 
 
 
Table 1. The resting release of iCGRP from sensory neurons in culture is not 
altered when neurons are infected with lentivirus expressing EGFP alone (control 
virus) or expressing EGFP with dnRas (dnRas). The values are reported as a 
percentage of the total iCGRP content expressed in neurons. Resting release in 
the presence of HEPES buffer alone (no NGF) or HEPES buffer with 100 ng/ml 
NGF for 10 min are presented. There were no differences among any of the 
values (mean ± SE, n = 9 from three separate harvests two-way ANOVA with 
Bonferroni’s post-hoc test).   
 
 
 
 
 
 
 
   
 115
 FTI-276 alters the capsaicin-evoked release of iCGRP from sensory neurons 
 In the experiments above, manipulation of the Ras pathway by incubation 
with FTI-276, a farnesyltransferase inhibitor, decreased the expression of iCGRP 
in response to NGF (Figs. 18 and 20). This suggested that the Ras pathway 
regulates the expression of iCGRP in response to NGF. Thus, we asked whether 
incubation with FTI-276 could alter the NGF-induced increase in capsaicin-
evoked iCGRP release from sensory neurons to determine if the Ras pathway 
might be involved in regulating the increase in iCGRP release in response to 
brief exposure to the neurotrophin.  
 Neurons were treated with FTI-276 (5μM) for four days because the half-
life of the Ras protein is approximately 24hr  (Politi and Senderowicz, 2001). Control 
neurons were treated with vehicle. After 4d, greater than 90% of the existing Ras 
would be degraded, and fanesylation of newly formed Ras would be inhibited. 
After treatment, neurons were subjected to a standard release protocol. Neurons 
from each treatment group were exposed to 100ng/ml NGF for 10 min prior to 
and throughout the capsaicin-evoked release. As can be seen in Figure 30, 
vehicle-treated neurons showed the characteristic increase in capsaicin-evoked 
release when exposed to NGF acutely. Unexpectedly, the capsaicin-evoked 
release from FTI-276-treated neurons was significantly higher compared to 
capsaicin-evoked release from vehicle-treated neurons even in the absence of 
acute treatment with NGF. Because FTI-276 increased capsaicin-evoked release 
dramatically on its own, this agent could not be used to examine whether 
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 inhibiting Ras alters the NGF-induced increase in transmitter release. In these 
experiments with FTI-276, the basal release was not altered (Table 2). 
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Figure 30. The inhibitor, FTI-276, increases the capsaicin-evoked release of 
iCGRP from sensory neurons in culture. Neurons were treated as previously 
described with vehicle or FTI-276 (5μM) as indicated. After treatment, the 
capsaicin-evoked release was measured in the presence or absence of 10 
minute treatment with NGF (100ng/ml). The capsaicin-evoked release is shown 
from four conditions:  vehicle treated (white bar), NGF treated (grey bar), FTI-
treated (black bar), and FTI-treated neurons with acute NGF treatment (hatched 
bar). When vehicle-treated neurons were exposed to NGF acutely, the capsaicin-
evoked release was increased. However, when neurons are treated with FTI-
276, the capsaicin-evoked release is increased from control. An (*) indicates a 
significant increase in capsaicin-evoked release compared to control (p<0.05, 
n=9 from 3 separate harvests, using one-way ANOVA with Tukey’s post-hoc 
test). 
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                         Resting iCGRP Release as a Percentage of Total Content 
                                (fmol/well/10min) 
 
                                      vehicle- treated                  FTI-276 treated  
 
    no NGF                       0.12 ± 0.04*                       0.14 ± 0.02 
    NGF                            0.13 ± 0.02                         0.18 ± 0.03  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. The resting release of iCGRP from sensory neurons in culture is not 
altered when neurons are treated with FTI-276 (5μM). The values are reported as 
a percentage of the total iCGRP content in neurons. Resting release in the 
presence of HEPES buffer alone (no NGF) or HEPES buffer with 100 ng/ml NGF 
for 10 min are presented. There were no differences among any of the values 
(*mean ± SE, n = 9 from three separate harvests, two-way ANOVA).                                  
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 The NGF-induced increase in the capsaicin-evoked release of iCGRP from 
synGAP heterozygous neurons is not different compared to release from wildtype 
littermates 
 The capsaicin-evoked release from neurons isolated from synGAP 
heterozygous mice was tested to determine if neurons were sensitized by brief 
exposure to 100 ng/ml NGF.  The rationale for testing the effects of NGF on 
capsaicin-evoked release was to test the hypothesis that neurons from 
heterozygous animals have an increased capsaicin-evoked release upon brief 
exposure to NGF secondary to increased Ras/MEK/ERK activation in cells with 
less expression of synGAP. 
 Neurons from wildtype and synGAP heterozygous mice were harvested 
and grown in culture with 30ng/ml NGF, and the resting and capsaicin-evoked 
release of iCGRP was measured from wildtype and synGAP heterozygous 
neurons. Groups of neurons from both genotypes were exposed to NGF for 10 
minutes prior to and during capsaicin stimulation. When wildtype neurons were 
exposed to 100 ng/ml NGF for 10 minutes prior to and throughout capsaicin-
evoked release, there was a significant increase in the iCGRP outflow from 
neurons from 5.6 ± 1.0 percent of total iCGRP content to 8.9 ± 1.9 percent (Fig. 
31). The same trend was observed in neurons from synGAP heterozygous 
animals. In the presence of acute NGF, release increased from 6.5 ± 0.9 percent 
to 11.2 ± 1.3 percent. No difference was observed between the degree of NGF 
sensitization when comparing neurons from heterozygous neurons and their 
littermate controls. Furthermore, there was no alteration of resting release in 
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 heterozygous neurons compared to wildtype controls. These data taken with the 
above experiments showing that expression of dnRas does not alter the NGF-
induced increase in iCGRP release from sensory neurons suggest that the Ras 
pathway does not regulate the sensitivity of sensory neurons to capsaicin with 
brief exposure to NGF. 
 121
 0
5
10
15
iC
G
R
P
re
le
as
ed
(p
er
ce
nt
 to
ta
l c
on
te
nt
)
wild type heterozygous
†
†
n=12
iC
G
R
P
re
le
as
ed
(p
er
ce
nt
 to
ta
l c
on
te
nt
)
cap (30nM)
NGF (100ng/ml)
+ + + +
+ + + +
iC
G
R
P
re
le
as
ed
(p
er
ce
nt
 to
ta
l c
on
te
nt
)
iC
G
R
P
re
le
as
ed
(p
er
ce
nt
 to
ta
l c
on
te
nt
)
iC
G
R
P
re
le
as
ed
(p
er
ce
nt
 to
ta
l c
on
te
nt
)
iC
G
R
P
re
le
as
ed
(p
er
ce
nt
 to
ta
l c
on
te
nt
)
iC
G
R
P
re
le
as
ed
(p
er
ce
nt
 to
ta
l c
on
te
nt
)
iC
G
R
P
re
le
as
ed
(p
er
ce
nt
 to
ta
l c
on
te
nt
)
 
 
 
 
Figure 31. NGF augments capsaicin-evoked release of iCGRP from wildtype 
neurons and from neurons with a heterozygous mutation of synGAP. The resting- 
and 30nM capsaicin-evoked release for each condition is shown. NGF treatment 
(100ng/ml) for 10 min prior to and throughout capsaicin stimulation augments 
iCGRP release. Wildtype and heterozygous animals demonstrate the same 
degree of sensitization in response to NGF. (†) indicates a significant increase in 
capsaicin-evoked release relative release in the presence of acute NGF 
treatment. There is no difference among the resting releases under any condition 
(p<0.05 vs. release without NGF treatment, n=12 from 4 separate harvests, using 
one-way ANOVA with Tukey’s post-hoc test).  
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 siRNA decreases the expression of synGAP in rat sensory neuronal cultures, 
and increases the level of RasGTP measured in cell lysates 
 With transgenic animals, congenital changes could be masked by 
compensation that can occur in cells. Thus, in the presence of decreased 
synGAP expression, it is possible that another GAP becomes overexpressed to 
correct aberrant Ras signaling in cells. To address this concern, siRNA against 
synGAP was designed and transfected into neurons from adult rats to transiently 
decrease the expression of synGAP in sensory neurons. Using this methodology, 
we examined whether decreasing the expression of synGAP in wildtype adult rat 
neurons could alter the NGF-induced sensitization of sensory neurons.    
 Neurons were grown in culture in the presence of 30 ng/ml NGF for two 
days. The neuronal cultures then were treated with serum-free media alone, 
serum-free media containing the transfection reagent, NeuroPorter®, media 
containing NeuroPorter® with 100nM of control siRNA (apurinergic/apyridinimic 
endonuclease, APE, see Methods), or media with NeuroPorter® containing 
100nM synGAP siRNA. After 2 days, the serum-free media was replaced with 
fresh F-12 media, and media containing 30 ng/ml NGF was changed every other 
day for 6 days. APE siRNA was chosen as a control because the protein was 
under study in the laboratory, and because APE siRNA significantly depletes 
APE without affecting the release of iCGRP from neurons (data not shown).   
 Figure 32A shows a representative Western blot of cell lysates from the 
four different treatment groups, whereas Figure 32B summarizes densitometry 
results from Western blots from three separate experiments. Protein from the 
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 hippocampus was used as a positive control for Western blotting as mouse 
neurons from this brain region express synGAP (Komiyama et al., 2002c). As 
can be seen in the representative blot in Figure 32A, an immunoreactive band 
appears near 135kDa, the size of synGAP. The levels of synGAP expression in 
NeuroPorter® or APE siRNA-treated neurons after three separate experiments 
were not different from control (Fig. 32B). However, the levels of synGAP in cells 
treated with synGAP-siRNA were decreased by 60% compared to control. 
 Once we confirmed that synGAP siRNA reduced synGAP expression in 
cell lysates, cells were treated with APE or synGAP siRNA, and the levels of 
RasGTP were measured to demonstrate a functional effect of the siRNA. As 
seen in Figure 33, there was a significant four-fold increase in the level of 
RasGTP in neurons treated with synGAP siRNA compared to neurons treated 
with NeuroPorter® alone. Therefore, these results demonstrate that a decrease 
in the level of synGAP increases the level of RasGTP present in cell lysates of 
sensory neuronal cultures, suggesting that Ras signaling is increased in these 
cells.  
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Figure 32. Rat sensory neurons in culture exposed to synGAP siRNA (100nM) have 
reduced expression of the synGAP protein. (A)  Representative Western blot 
demonstrating the presence of synGAP protein in both hippocampal neurons and 
dorsal root ganglion neurons in culture.  (B) Summary data from Western blots of 
neurons treated with siRNA. The levels of synGAP are normalized to actin, and the 
values are reported as a fraction of the control level. An (*) represents a significant 
reduction of the synGAP protein relative to control levels (p<0.05, n=3 from three 
separate harvests, using one-way ANOVA with Tukey’s post-hoc test).  
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Figure 33. The level of RasGTP in neurons treated with synGAP siRNA in 
increased compared to neurons treated with NeuroPorter® alone. After treatment 
with either NeuroPorter® or 100nM synGAP siRNA, cells were collected and the 
amount of RasGTP was measured. The RasGTP present in the cells was 
normalized to the loading control GAPDH, and the results were reported as a 
percentage of the control value. An (*) indicates a significant increase in the 
RasGTP level in synGAP siRNA-treated neurons relative to its NeuroPorter® 
control (p<0.05, n=3 from 3 separate harvests, using one-way ANOVA with 
Tukey’s post-hoc test). 
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 Decreased synGAP expression augments NGF-induced increase in iCGRP 
release from neurons 
 In these experiments, we examined whether siRNA knockdown of 
synGAP in neurons derived from wildtype rats would alter the NGF-induced 
increase in capsaicin-evoked iCGRP release. Neurons were treated with synGAP 
siRNA or control siRNA as previously described. After treatment, we measured 
iCGRP release following our standard protocol. Neurons were treated for 10 
minutes with either HEPES buffer alone or buffer containing 100 ng/ml NGF. 
Then, neurons were exposed for 10 minutes to 30nM capsaicin in the presence 
or absence of NGF.  
 Treatment with siRNA did not change the resting release of iCGRP from 
neurons as there were no significant differences among the resting release 
measured from the treatment groups (Table 3). However, the capsaicin-evoked 
release is presented in Figure 34. There was a significant increase in the 
capsaicin-evoked release of iCGRP when neurons were exposed acutely to 
100ng/ml NGF. Release from neurons treated with APE siRNA increased from 
100 ± 23 fmol iCGRP/well/10min to 260 ± 30 fmol iCGRP when treated briefly 
with NGF. In neurons treated with synGAP siRNA, NGF treatment increased 
capsaicin-evoked iCGRP release from 130 ± 17 to 360 ± 45 fmol 
iCGRP/well/10min. The increased release in response to brief exposure to NGF 
was observed in both the APE siRNA-treated neurons and synGAP siRNA–
treated neurons. However, the capsaicin-evoked release from synGAP siRNA–
treated cells in the presence of NGF was slightly, but significantly greater than 
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 the NGF-induced increase in release for APE siRNA–treated neurons. The NGF-
induced increase in capsaicin-evoked release was 2.60-fold greater for neurons 
treated with APE siRNA, while the increase was 2.75-fold in neurons treated with 
synGAP siRNA. 
 While NGF causes an increase in the iCGRP release in these 
experiments, these data appear to be inconsistent with data in experiments 
measuring NGF-induced sensitization in dnRas-treated and in synGAP 
heterozygous neurons. With overexpression of dnRas in rat neurons or in 
neurons from synGAP heterozygous mice, the degree of NGF sensitization was 
not different from controls (Figs. 16 and 31). One explanation for the data in 
neurons derived from synGAP heterozygous mice is that the animals adapt to the 
increased Ras activity so that  changes in iCGRP release in the presence of NGF 
are masked by the cells ability to offset changes in Ras activity through unknown 
mechanisms (Fig. 31). Another possible explanation is that release values 
obtained in experiments using siRNA were not normalized to cellular iCGRP 
content (Fig. 32), therefore the increase in release is a result of increased 
expression of iCGRP. Thus, further experiments are needed to eliminate the 
impact  of potential content  changes on release. 
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      Resting iCGRP Release  
(fmol/well/10min) 
 
                                    APE siRNA-treated          synGAP siRNA-treated 
 
    no NGF                      16.9 ±  2.9*                       13.3 ± 1.1 
    NGF                           18.9 ±  3.1                         11.6 ± 1.3 
 
* mean ± SE, n = 16 from four separate harvests 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. The resting release of iCGRP from sensory neurons in culture is not 
altered when neurons are treated with synGAP siRNA. The release values are 
reported fmol release per well of cells over 10 min. Resting release in the 
presence of HEPES buffer alone (no NGF) or HEPES buffer with 100 ng/ml NGF 
for 10 min are presented. There were no differences among any of the values 
(two-way ANOVA).                                  
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Figure 34. The NGF-induced sensitization of capsaicin-evoked iCGRP release 
(not normalized to content) is greater in neurons treated with synGAP siRNA.  
The 30nM capsaicin-evoked release from neurons treated with either siRNA to 
APE (black bars) or synGAP (hatched bars) is shown. Where indicated, groups 
of cells are exposed to 100ng/ml NGF for 10 min prior to and throughout the 10 
min stimulation with capsaicin. An (*) indicates a significant increase in release of 
iCGRP from neurons treated with NGF acutely compared to non-treated controls. 
An (#) indicates a significant difference between iCGRP released in the presence 
of NGF when comparing APE siRNA-treated and synGAP siRNA-treated 
neurons (p<0.05, n=16, from 4 separate harvests, using two-way ANOVA with 
Bonferroni’s post-hoc test). 
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 The MEK inhibitors, U0126 and PD98059, do not alter the NGF-induced increase 
in capsaicin-evoked iCGRP release from sensory neurons in culture 
 To further explore whether the Ras/MEK/ERK pathway regulates the 
NGF-induced increases stimulated release of iCGRP from sensory neurons, the 
activation of ERK was measured after acute exposure to the trophic factor. 
Neurons were grown in 30 ng/ml NGF for 7 days, and then the cultures were 
washed once with HEPES. Each well of cells was then exposed for a total of 20 
minutes to 15, 30, 100, or 250 ng/ml NGF. Immediately after treatment with NGF, 
cells were exposed to fixative, 4% paraformaldehyde, for 20 minutes. Then cells 
were permeabilized as described in Methods, and immunocytochemistry was 
used to measure the levels of pERK and total ERK in fixed cells. As shown in 
Figure 35, neurons exposed acutely to NGF had no changes in the levels of 
pERK relative to total ERK expression (Fig. 35).  
 However, to ensure changes in the level of pERK could be detected under 
the experimental conditions using immunocytochemistry, we included a positive 
control in experiments. We examined whether a 10 minute exposure to 100nM of 
the phorbol ester, phorbol 12,13-dibutyrate (PDBu), would increase pERK 
relative to total ERK expression. We used PDBu since activation of the PKC 
pathway has been shown in other cell systems to phosphorylate ERK through 
direct activation of Raf-1 kinase (Buscher et al., 1995; Ambrosini et al., 2000). As 
can be seen in Figure 35, 100nM PDBu increased the level of pERK 3-fold in 
dorsal root ganglion cultures. Thus, the lack of an increase in levels of pERK in 
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 neurons treated with NGF for 10 minutes was not secondary to limitations of 
detection.    
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Figure 35. Ten-minute treatment with NGF does not alter the level of pERK 
relative to total ERK in sensory neurons in culture. Neurons were grown for 7 
days in 30ng/ml NGF. On the 7th day, neurons were washed with HEPES buffer, 
and then were treated for 20 min with either buffer alone (0 NGF), the indicated 
concentration of NGF, or 100nM PDBu. After the brief treatment, neurons were 
fixed immediately and levels of pERK and total ERK were measured. The ratio of 
pERK/total ERK is normalized to control levels. An (*) indicates a significant 
increase in the ratio compared to cells treated with media alone (p<0.05, n=3 
from 3 separate harvests, using one-way ANOVA with Tukey’s post-hoc test).  
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  As described in the Introduction, MEK and ERK have been implicated in 
the regulation of the effects of NGF on cells in vitro.  Although changes in pERK 
levels were not observed in response to brief NGF exposure (Fig. 35), it is 
possible that small changes may be sufficient to cause an increase in NGF-
induced augmentation of iCGRP release from neurons.  Therefore, we examined 
whether U0126 could block the NGF-induced increase in capsaicin-evoked 
iCGRP release from rat sensory neurons in culture. As shown in previous 
experiments, NGF treatment for 10 minutes prior to and throughout capsaicin 
stimulation increases the amount of iCGRP released from sensory neurons by 
approximately two-fold from 143 ± 10 to 375 ± 53 fmol iCGRP/well/10min (Fig. 
36). When cells were pretreated for 10 minutes prior to and throughout capsaicin-
evoked release with U0126 (1μM) in HEPES, and through release with the MEK 
inhibitor did not alter capsaicin-evoked release. Furthermore, when cells were 
pretreated with U0126 and then treated with U0126 and 100ng/ml NGF 
simultaneously, the MEK inhibitor did not alter the sensitizing effect of the 
neurotrophin. These results indicated MEK is not involved in the mechanism of 
NGF-induced increases in iCGRP released from sensory neurons.  
 In the above experiments, we demonstrated that PDBu increased pERK in 
neuronal cultures (Fig. 35), and it is known that PDBu augments capsaicin-
evoked iCGRP release from sensory neurons (Barber and Vasko, 1996b). These 
two events, the increase in pERK and the increase in evoked release of iCGRP 
in response to PDBu, may be related. Consequently, we tested whether the 
ability of PDBu to augment basal or capsaicin-evoked release of iCGRP release 
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 could be blocked by the MEK inhibitor, U0126 (Fig. 37). For these studies, wells 
of cells were exposed to PDBu (10nM) for 10 minutes prior to and throughout 
capsaicin-evoked release, and the PDBu treatment increased the capsaicin-
evoked iCGRP release from 225 ± 15 to 548 ± 25 fmol iCGRP/well/10min. PDBu 
also increased resting release of iCGRP from sensory neurons in culture from 15 
± 2 to 75 ± 24 fmol iCGRP/well/10min. These results agreed with previous 
experiments performed in our laboratory using embryonic dorsal root ganglion 
neurons (Barber and Vasko, 1996). Treatment with U0126 did not block the 
ability of PDBu-induced increase in iCGRP release from sensory neurons (Fig. 
37). These data indicated that phorbol ester induced increases in iCGRP release 
are not mediated by MEK activation. 
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Figure 36. U0126 does not block the NGF-induced increase in 30nM capsaicin-
evoked iCGRP release from sensory neurons in culture. The resting (white bars) 
and capsaicin-evoked (black bars) iCGRP release from neurons are shown. 
Neurons were exposed to 100ng/ml NGF for 10 min prior to and throughout 
capsaicin-evoked release as indicated. Some groups of neurons were pretreated 
for 10 min with U0126 (not shown), and then exposed to 1μM U0126 for 10 min 
prior to and throughout capsaicin-evoked release as indicated.  An (*) indicates a 
significant increase in iCGRP release from sensory neurons compared to non-
treated controls (p<0.05, n=9 from 3 separate harvests, using one-way ANOVA  
with Tukey’s post-hoc test).  
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Figure 37. U0126 does not block the PDBu-induced increase in 30nM capsaicin-
evoked iCGRP release from sensory neurons in culture. The resting (white bars) 
and capsaicin-evoked (black bars) iCGRP release from neurons are shown. 
Neurons were exposed to 10nM PDBu for 10 min prior to and throughout 
capsaicin-evoked release as indicated. Some groups of neurons were pretreated 
for 10 min with U0126 (not shown), and then exposed to 1μM U0126 for 10 min 
prior to and throughout capsaicin-evoked release as indicated.  An (*) indicates a 
significant increase in iCGRP release from sensory neurons compared to non-
treated controls. An (#) indicates a significant increase in the resting release 
compared to untreated controls (p<0.05, n=9 from 3 separate harvests, using 
one-way ANOVA  with Tukey’s post-hoc test).  
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  To confirm that 1μM U0126 is inhibiting the activation of MEK under our 
experimental conditions, studies were designed to show that this drug inhibited 
the PDBu-induced increase in phosphorylation of ERK. Because ERK is 
selectively activated by MEK, a blockade of pERK would indicate that U0126 
inhibited MEK activity.  
 When neuronal cultures are exposed to 10nM PDBu for 10 minutes there 
is a 2-fold increase in the ratio of pERK to total ERK (Fig. 38). This increase was 
partially attenuated by treating cultures with 100nM U0126 and completely 
blocked by U0126. These data indicated that the MEK inhibitor at this 
concentration blocks activation of MEK and activation and phosphorylation of 
ERK. Thus the lack of effect of U0126 on NGF-induced increases in iCGRP 
release from neurons is not due to a lack of MEK inhibition, but likely because 
NGF-sensitivity is not mediated by ERK activation. This data in combination with 
data from Figure 36 showing no inhibition of NGF-induced increases in iCGRP 
release from neurons using the same concentration of U0126 (Fig. 36) suggest 
that pERK is not a mediator of NGF-induced sensitization.  
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Figure 38. U0126 (1μM) blocks PDBu-induced upregulation of pERK in sensory 
neurons in culture. Neurons were exposed to the phorbol ester, PDBu (10nM) for 
10 min. Where indicated, groups of cells were treated throughout PDBu 
stimulation with 100nM or 1μM U0126. An (*) indicates a significant increase of 
the ratio of pERK to total ERK compared to control (no PDBu treatment) (p<0.05, 
n=9 from 3 separate harvests, using one-way ANOVA with Tukey’s post-hoc 
test).   
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  We also examined whether PD 98059, another MEK inhibitor, could block 
the ability of NGF to augment capsaicin-evoked iCGRP release from sensory 
neurons (Fig. 39). We used this alternative inhibitor as a second means to 
determine whether MEK regulates the increase in NGF-induced increases in 
capsaicin-evoked release.  
 When cells were pretreated with 20μM PD 98059, 10 times the IC50 (Pang 
et al., 1995), the drug did not attenuate the increase in capsaicin-evoked release 
with acute exposure to 100 ng/ml NGF. When the concentration of the drug was 
increased, it stimulated iCGRP release directly to a level similar in magnitude to 
stimulation with 30nM capsaicin (data not shown). Because of the lack of effect 
at the lower concentration of the inhibitor and the alteration of basal release in 
the presence of the higher concentration of drug, the experiments were not 
repeated. However, these initial data combined with data using the MEK inhibitor, 
U0126, are evidence that MEK and ERK do not regulate the NGF-induced 
increase in capsaicin-evoked iCGRP release from sensory neurons in culture.  
 140
   
 
iC
G
R
P
(fm
ol
/w
el
l/1
0m
in
)
NGF (100 
cap (30nM)
iC
G
R
P
0
100
200
300
PD 98059 
(20 M)
ng /ml)
+ + +
+ + + +
μ
iC
G
R
P
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
 
 
 
 
 
 
 
 
 
 
Figure 39. PD 98059 does not affect NGF-induced increases in 30nM capsaicin-
evoked iCGRP release from sensory neurons in culture. The resting and 
capsaicin-evoked iCGRP release from neurons are shown for each of the five 
conditions. Neurons were exposed to100 ng/ml NGF for 10 min prior to and 
throughout capsaicin-evoked release as indicated below the x-axis. One group of 
cells were pretreated for 10 min with 20μM PD 98056, and then throughout the 
release protocol as indicated (n=3, from a single harvest of neurons).  
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 The PI3 kinase inhibitors, LY294002 and wortmannin, do not alter the NGF-induced 
increase in capsaicin-evoked iCGRP release from sensory neurons 
 Because the Ras/MEK/ERK cascade is not involved mediating the ability 
of NGF to augment capsaicin-evoked release of iCGRP, we examined whether 
another signaling pathway implicated in signaling downstream from NGF could 
mediate this action. The PI3 kinase pathway is thought to control a number of 
NGF-mediated actions in sensory neurons (Bonnington and McNaughton, 2003c; 
Zhuang et al., 2004a). Zhuang et. al. found that Akt activation was increased with 
2 minute exposure to NGF, and this increase was blocked by the PI3 kinase 
inhibitor, LY294002. Bonnington and McNaughton found just 1-2 minute 
exposure to NGF induced an increase in intracellular Ca2+ upon exposure to 
capsaicin. This effect was attenuated by a PI3 kinase inhibitor, wortmannin. 
Based on these experiments, studies were designed to test whether the PI3 
kinase inhibitors, LY294002 and wortmannin, could block the NGF-induced 
increase in capsaicin-evoked iCGRP release from sensory neurons in culture.  
  In these experiments, 10 minute treatment with 100 ng/ml NGF caused a 
two-fold increase in 30nM capsaicin-evoked release, from 185 ± 45 fmol 
iCGRP/well/10min to 392 ± 57 iCGRP/well/10min. When neurons were incubated 
with the PI3 kinase inhibitors, LY294002  (3μM) or wortmaninnin (3nM), neither of 
the drugs caused a changed capsaicin-evoked release alone. In addition, at the 
concentrations used these inhibitors did not cause changes in resting release 
from neurons. Drug concentrations higher than 3μM LY294002 or 3nM 
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 wortmannin caused a significant increase in the resting release of iCGRP from 
sensory neurons (data not shown).  
 Unlike previous studies using these inhibitors, the effects of NGF on 
sensory neurons were not inhibited. The drugs did not alter the NGF-induced 
increase in iCGRP release from sensory neurons. These data suggest that the 
PI3 kinase pathway does not regulate the increase in capsaicin-evoked iCGRP 
release induced by brief exposure to 100ng/ml NGF.  
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Figure 40. Neither LY294002 (3μM) nor wortmannin (3nM) inhibits the NGF-
induced increase in 30nM capsaicin-evoked iCGRP release from sensory 
neurons in culture. The resting and capsaicin-evoked iCGRP release from 
neurons is shown for each of the six conditions. Neurons were exposed to 
100ng/ml NGF for 10 min prior to and throughout capsaicin-evoked release as 
indicated. Groups of neurons were pretreated for 10 min with the indicated 
inhibitor, and then exposed again to the same concentration of inhibitor for 10 
min prior to and throughout capsaicin-evoked release as indicated.  An (*) 
indicates a significant increase in iCGRP release from sensory neurons 
compared to NGF non-treated controls (p<0.05, n=9 from 3 separate harvests, 
using one-way ANOVA  with Tukey’s post-hoc test).  
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 The PKC inhibitor, BIM, blocks the increase in capsaicin-evoked iCGRP release 
cause by brief exposure to NGF 
 Multiple studies demonstrate that activation of PKC is involved in the 
regulation of the sensitivity of sensory neurons (Barber and Vasko, 1996; Frayer 
et al., 1999; Khasar et al., 1999; Richardson and Vasko, 2002). In addition, NGF 
exposure has been shown to activate PLCγ, which in turn liberates DAG and 
activates PKCs (Chuang et al., 2001). Interestingly, many of these studies 
showing PKC activation by NGF have been performed in cell lines or 
heterologous expression systems, and brief NGF exposure caused an increase 
in the activation of atypical PKC isoforms (Wooten et al., 1991; Wooten et al., 
2004).  
 Bonnington and McNaughton showed that the PKC inhibitor, 
bisindolylmalemide I (BIM), abolished the NGF-induced sensitization of mouse 
sensory neurons (Bonnington and McNaughton, 2003). However, Shu and 
Mendell found that BIM did not alter NGF’s ability to block capsaicin-induced 
tachyphylaxis in sensory neurons in culture (Shu and Mendell, 2001). Thus, 
controversy exists whether PKC activation is involved in the acute sensitization of 
sensory neurons by NGF. Furthermore, the involvement of PKC in the regulation 
of evoked release of iCGRP in neurons has not been tested. Therefore, we 
examined whether PKC inhibition could block the NGF-induced increases in 
capsaicin-evoked iCGRP release from neurons in culture.  
 For these studies, cells in culture were exposed to 100 ng/ml NGF in the 
absence or presence of various concentrations of BIM and basal and capsaicin-
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 evoked release was measured (Fig. 41). As in previous studies, acute exposure 
to NGF increased in the capsaicin-evoked release of iCGRP from neurons from 
140 ± 15 fmol iCGRP/well/10min to 244 ± 28 fmol iCGRP. In neurons treated 
with 100nM BIM for 10 minutes prior to NGF treatment and throughout capsaicin-
evoked release, the inhibitor abolished the the NGF-induced augmentation of 
capsaicin-evoked iCGRP release from neurons (149 ± 21 fmol 
iCGRP/well/10min).  These data implicate PKC in the regulation of the acute 
effects of NGF on sensory neurons.  
 The capsaicin-evoked release of iCGRP in the presence of BIM alone 
appeared to trend downward (73 ± 10 fmol iCGRP/well/10min), although not 
significantly different from control. Premkumar and Ahern have shown that PKC 
activates the TRPV1 channel (Premkumar and Ahern, 2000). Therefore, it is 
logical to expect that inhibition of PKC with BIM may reduce the capsaicin-
induced release of iCGRP from neurons. If this were the case, there would be no 
difference in the degree of sensitization by NGF between the BIM-treated and 
non-treated groups. Furthermore, the baseline for capsaicin-evoked release 
would shift making comparisons in the presence of drug difficult to interpret. 
Therefore, we repeated these studies using 30nM BIM (Fig. 42).  
  In these experiments, 30nM BIM did not alter the capsaicin-evoked 
release of iCGRP alone (Fig. 42). Capsaicin-evoked release was 209 ± 25 fmol 
iCGRP/well/10min. In the presence of 30nM BIM, capsacin-evoked release was 
205 ± 27 fmol iCGRP/well/10min. NGF-induced sensitization was reduced from 
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 320 ± 41 fmol iCGRP/well/10min to 247 ± 27 fmol iCGRP. In these experiments, 
BIM did not affect resting iCGRP release.    
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Figure 41. The effect of BIM (100nM) on the NGF-induced increases in 30nM 
capsaicin-evoked iCGRP release from sensory neurons in culture. The resting 
and capsaicin-evoked iCGRP release from neurons is shown for each of the four 
conditions. Neurons were exposed to 100ng/ml NGF for 10 min prior to and 
throughout capsaicin-evoked release as indicated below the x-axis. Some groups 
of neurons were pretreated for 10 min with the 100nM BIM, and then exposed 
again to the same concentration of inhibitor for 10 min prior to and throughout 
capsaicin-evoked release as indicated.  An (*) indicates a significant increase in 
iCGRP release from sensory neurons compared to NGF non-treated controls 
(p<0.05, n=9 from 3 separate harvests, using one-way ANOVA with Tukey’s 
post-hoc test).  
 148
  
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
*
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
NGF (100ng/ml)
BIM +
++
+ ++
++
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
0
100
200
300
400
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
(30nM)
basal
30nM capsaicin
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
iC
G
R
P
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
re
le
as
e
(fm
ol
/w
el
l/1
0m
in
)
 
n = 9 
 
 
 
 
 
 
Figure 42. The effect of BIM (30nM) on the NGF-induced increases in 30nM 
capsaicin-evoked iCGRP release from sensory neurons in culture. The resting 
and capsaicin-evoked iCGRP release from neurons is shown for each of the four 
conditions. Neurons were exposed to 100ng/ml NGF for 10 min prior to and 
throughout capsaicin-evoked release as indicated below the x-axis. Some groups 
of neurons were pretreated for 10 min with 30nM BIM, and then exposed again to 
the same concentration of inhibitor for 10 min prior to and throughout capsaicin-
evoked release as indicated.  An (*) indicates a significant increase in iCGRP 
release from sensory neurons compared to NGF non-treated controls (p<0.05, 
n=9 from 3 separate harvests, using one-way ANOVA with Tukey’s post-hoc 
test).  
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  Because inhibition of PKC attenuated the NGF-induced sensitization of 
sensory neurons using BIM, we began studies to ascertain which isozymes of 
PKC are involved in NGF signaling. If NGF were signaling through a specific 
PKC isoform to augment neurotransmitter release, then reducing the expression 
of that specific PKC isoform in neurons would reduce the ability of NGF to 
increase the capsaicin-evoked iCGRP release from sensory neurons.    
 To date, siRNA-knockdown has been attempted for PKCα, PKCζ, and 
PKCε in the Vasko laboratory. However, the only molecule that has been 
successful in reducing the expression of its respective isoform was siRNA 
developed against PKCα.  Consequently, we examined whether reducing 
expression of PKCα would alter NGF-induced augmentation of capsaicin-evoked 
release of iCGRP. In these experiments, cells in culture were treated with 200nM 
siRNA targeting APE (control siRNA) or PKCα. After treatment, cells were 
subjected to a standard iCGRP release protocol in the presence or absence of 
100ng/ml NGF 10 minutes prior to and throughout capsaicin stimulation. Then 
cells were lysed and immunoblotting was performed to confirm knockdown.    
 The representative Western blot (Fig. 43A) shows that the signal for PKCα 
was reduced by approximately 50%. Despite this reduction there was no 
inhibition of the sensitizing action of NGF on peptide release (Fig. 43B). The data 
represent the mean and standard deviation from triplicate measurements from a 
single harvest. This could indicate PCKα has no effect on sensitization. 
Alternatively, a 50% decrease in the protein expression may not be sufficient to 
affect NGF-induced augmentation of evoked release. 
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Figure 43. The NGF-induced sensitization of capsaicin-evoked iCGRP release 
(not normalized to content) does not appear to be different in neurons treated 
with control or PKCα siRNA.  (A) Western blot demonstrating the expression of 
PKCα and actin in neurons treated with control siRNA (left lane) or PKCα siRNA 
(right lane). (B) The 30nM capsaicin-evoked release from neurons treated with 
control siRNA or PKCα siRNA as indicated. Where indicated, groups of cells are 
exposed to 100ng/ml NGF for 10min prior to and throughout the 10 min 
stimulation with capsaicin (n=3, from a single harvest of neurons). 
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 Inhibition of Src kinase signaling in neurons blocks the increase in capsaicin-evoked 
release of iCGRP in response to brief exposure to NGF 
 Evidence in PC12 cells shows that brief exposure to NGF activates Src kinase  
(Wooten et al., 2001). Furthermore, Src kinase may activate various PKC isoforms 
(Wooten et al., 1994; Seibenhener et al., 1999). Finally, Zhang et. al. showed 
that the NGF-induced increase in Ca2+ into mouse sensory neurons was blocked 
by a Src kinase inhibitor (Zhang et al., 2005).  
 Consequently, it is possible that activation of Src kinases is the 
mechanism through which NGF could alter transmitter release from sensory 
neurons in culture. To test this notion, a Src kinase inhibitor, PP2, was used to 
determine if this signaling pathway regulates the augmented release of iCGRP in 
the presence of acute treatment with NGF. Neurons were cultured as previously 
described. Cells were subjected to a release protocol in the presence or absence 
of NGF. In addition, cells were simultaneously exposed to PP2 (10μM) or PP3 
(10μM), which is the inactive analogue of PP2 that was used for control for the 
non-specific effects of the inhibitor.  
 When neurons were exposed to 100 ng/ml NGF for 10 minutes prior to 
and throughout capsaicin-evoked release, there was a significant increase in 
capsaicin-evoked iCGRP release, from 107 ± 8 fmol iCGRP/well/10min to 169 ± 
6 fmol iCGRP (Fig. 44). Some groups were pretreated with PP2 (10μM) or PP3 
(10μM) for 10 minutes and then treated with the inhibitors prior to and throughout 
capsaicin-evoked release. In neurons exposed to PP2 or PP3, there was no 
effect on capsaicin-evoked release alone which was 99 ± 6 and 95 ± 5 fmol 
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 iCGRP/well/10min, respectively. However, the NGF-induced increase in 
capsaicin-evoked iCGRP release was significantly reduced by PP2 from 169 ± 6 
fmol iCGRP/well/10min to 109 ± 7 fmol iCGRP. PP3 had no significant effect on 
NGF-induced sensitization of release from neurons (166 ± 6 fmol 
iCGRP/well/10min). These data indicated Src kinase regulates sensitization of 
sensory neurons by NGF. 
 In these experiments, there was a small, but significant increase in the 
resting release of iCGRP from neurons treated with either PP2 or PP3 in NGF-
treated neurons. Resting release increased from 17 ± 2 fmol iCGRP/well/10min 
to 35 ± 10 fmol iCGRP in the presence of NGF and PP2 or PP3. Considering the 
increase occurred in both the PP2- and PP3-treated neurons, it is likely that the 
effect is non-specific, and perhaps an interaction between the compounds and 
NGF.    
 These experiments strongly implicate Src kinase signaling in the effects of 
NGF on release from sensory neurons. Presently, it is not known what PKC 
isoforms signal downstream of Src kinases in sensory neurons. Nor is it known 
which Src kinases may be regulating NGF sensitization. Further studies are 
needed to distinguish these elements involved in regulation of evoked iCGRP 
release from sensory neurons in the presence of NGF.   
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Figure 44. The effect of PP2 (10μM) and PP3 (10μM) on the NGF-induced 
increases in 30nM capsaicin-evoked iCGRP release from sensory neurons in 
culture. The resting (white bars) and capsaicin-evoked (black bars) iCGRP 
release from neurons are shown for each of the six conditions. Neurons were 
exposed to 100ng/ml NGF for 10 min prior to and throughout capsaicin-evoked 
release as indicated below the x-axis. Some groups of neurons were pretreated 
for 10 min with 10μM PP2 or PP3, and then exposed again to the same 
concentration of inhibitor for 10 min prior to and throughout capsaicin-evoked 
release as indicated.  An (*) indicates a significant increase in iCGRP release 
from sensory neurons compared to NGF non-treated controls. A (#) indicates a 
significant increase in resting release compared to resting release from control 
neurons (p<0.05, n=9 from 3 separate harvests, using one-way ANOVA  with 
Tukey’s post-hoc test).  
 154
 The effects of manipulating the sphingomyelinase pathway on capsaicin-evoked 
iCGRP release from sensory neurons 
 
Ceramide (10μM) does not affect capsaicin-evoked iCGRP release,  
while S1P (1 and 10 μM) increase stimulated release 
 The experiments described above test the involvement of pathways that are 
commonly associated with the TrkA receptor activation in response to acute treatment 
with NGF. However, there are studies that show the neurotrophin receptor, p75NTR 
regulates the sensitivity of sensory neurons both in vivo and in vitro. When p75NTR binds 
NGF, it activates the enzyme sphingomyelinase. This enzyme cleaves sphingomyelin 
to produce ceramide. Zhang et. al. demonstrated that ceramide, which increases with 
activation of the p75NTR, increases the sensitivity of sensory neurons as measured by 
changes in the number of action potentials fired in response to a ramp of depolarizing 
current (Zhang et al., 2002). Furthermore, the ability of acute NGF to augment the 
number of APs is attenuated by blocking the p75 receptor (Zhang and Nicol, 2004).  
 Based on these data, we designed studies to examine whether the resting and 
30nM capsaicin-evoked iCGRP release from neurons was augmented by treating 
neurons for 10 min with ceramide (100nM, 1μM and 10μM). Capsaicin-evoked release 
from control neurons was 188 ± 27 fmol iCGRP/well/10min (Fig. 45). Capsaicin-evoked 
release in the presence of 1nM, 1μM, or 10uM ceramide was 182 ± 22, 178 ± 14, and 
229 ± 46 fmol iCGRP/well/10min, respectively. There was no significant change in the 
capsaicin-evoked release using up to 10μM ceramide, suggesting ceramide does not 
play a role in the regulation of sensitivity to capsaicin.    
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  Ceramide is converted to sphingosine, by ceramidase (Roux et al., 2001). 
Sphingosine is converted to sphingosine-1-phosphate (S1P) by sphingosine kinase 
(Toman et al., 2001). Like ceramide, S1P increases the excitability of sensory neurons 
in culture (Zhang et al., 2006). Therefore, a second group of experiments was 
performed to test whether S1P increases the capsaicin-evoked release from sensory 
neurons in culture. As with studies using ceramide, the resting and 30nM capsaicin-
evoked release from sensory neurons in culture was tested in the presence or absence 
of increasing concentrations of S1P (treatment 10min prior to and through stimulation). 
Cells treated with 30nM capsaicin released 255 ± 15 fmol iCGRP/well/10min (Fig. 46). 
Vehicle, which was 0.1% MPL, did not alter capsaicin-evoked release (295 ± 18 fmol 
iCGRP/well/10min). However, both 1 and 10μM S1P caused a significant increase in 
the capsaicin-evoked iCGRP release from neurons (391 ± 23 and 402 ± 38 fmol 
iCGRP/well/10min). There were no alterations in the resting release from neurons 
exposed to these same concentrations of S1P. These data implicated S1P in the 
regulation of sensitivity of sensory neurons and support the notion that p75NTR  signaling 
and the sphingomyelinase pathway regulate sensitization of sensory neurons.  
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Figure 45. The effect of ceramide on 30nM capsaicin-evoked iCGRP release 
from sensory neurons in culture. The resting and capsaicin-evoked iCGRP 
release from neurons is shown for each of four conditions. Neurons were 
exposed to the indicated concentration of ceramide for 10 min prior to and 
throughout capsaicin-evoked release as indicated below the x-axis. There were 
no differences among any of the measurements and there were no changes in 
resting release of iCGRP from neurons (p<0.05, n=9 from 3 separate harvests, 
using one-way ANOVA ).  
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Figure 46. The effect of sphingosine-1-phosphate on the NGF-induced increases 
in 30nM capsaicin-evoked iCGRP release from sensory neurons in culture. The 
resting and capsaicin-evoked iCGRP release from neurons are shown for each of 
four conditions. Neurons were exposed to the indicated amount of S1P or vehicle 
(0.1% MPL) prior to and throughout capsaicin-evoked release as indicated below 
the x-axis. An (*) indicates a significant increase in iCGRP release from sensory 
neurons compared to NGF non-treated controls (p<0.05, n=9 from 3 separate 
harvests, using one-way ANOVA  with Tukey’s post-hoc test).  
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 Effects of sphingosine kinase inhibitor (DMS) or a neutral sphingomyelinase 
inhibitor on sensory neurons in culture 
 Since S1P augments capsaicin-evoked transmitter release, further 
experiments were designed to determine whether inhibition of enzymes upstream 
in the metabolic pathways of S1P could alter NGF-induced increases in 
capsaicin-evoked release of iCGRP from sensory neurons. For these studies, we 
used N,N-dimethyl sphingosine (DMS), which is a sphingosine kinase inhibitor 
(Natarajan et al., 1994; Zhang et al., 2006). In a similar trend to those 
experiments shown above, NGF appears to increase the 30nM capsaicin-evoked 
release from neurons from 77 ± 5 fmol iCGRP/well/10min to 105 ± 19 fmol 
iCGRP (Fig. 47). Surprisingly, when neurons were treated with DMS (10μM) for 
20 minutes prior to and throughout capsaicin-treatment, there were alterations in 
both the resting and capsaicin-stimulation release (Fig. 47). Resting release 
increased 3-fold in the presence of DMS, while 30nM capsaicin-evoked release 
was reduced to 29 ± 2 fmol iCGRP/well/10min. The capsaicin-evoked release 
was nearly abolished. Because the drug altered both the resting and the 
capsaicin-evoked release, it was difficult to interpret the results and further 
experiments using this drug were not performed.  
 We also attempted to determine whether a sphingomyelinase inhibitor 
would block NGF-induced sensitization. A neutral sphingomyelinase inhibitor (N-
Smase) (15μM) was used in the presence or absence of NGF and capsaicin 
stimulation. As with DMS, the inhibitor increased the resting release of iCGRP by 
2 to 5 times, whereas capsaicin-evoked release was not affected (Fig. 48).  
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 Because this concentration of the sphingomyelinase inhibitor had a dramatic 
effect on resting release, interpretation of experiments using capsaicin and/or 
NGF is not practical.  
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Figure 47. The effect of DMS (10μM) on NGF-induced increases in 30nM 
capsaicin-evoked iCGRP release from sensory neurons in culture. The resting 
release from two consecutive 10 min incubations and the capsaicin-evoked 
iCGRP release from neurons are shown for each of the four conditions. Neurons 
were exposed to 100ng/ml NGF for 10 min prior to and throughout capsaicin-
evoked release as indicated below the x-axis. Neurons were treated with DMS 
during the two resting incubation (20 min) and throughout capsaicin-evoked 
release as indicated (n=3 from a single harvest, mean ± SD).  
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Figure 48. The effect of neutral sphingomyelinase inhibitor (N-SMase inhibitor, 
15μM) on NGF-induced increases in 30nM capsaicin-evoked iCGRP release 
from sensory neurons in culture. The resting release from two consecutive 10 
min incubations and the capsaicin-evoked iCGRP release from neurons are 
shown for each of the four conditions. Neurons were exposed to 100ng/ml NGF 
for 10 min prior to and throughout capsaicin-evoked release as indicated below 
the x-axis. Neurons were treated with the N-SMase inhibitor during the two 
resting incubation (20 min) and throughout capsaicin-evoked release as indicated 
(n=3 from a single harvest, mean ± SD).  
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 DISCUSSION 
 
 In this thesis, the cell signaling cascades that regulate the NGF-induced 
increases in iCGRP content and stimulated release from sensory neurons were 
examined. NGF is an important inflammatory mediator and its signaling cascades in 
neurons are important to understand. First, it is well-established that NGF expression 
increases with inflammation  (Lewin and Mendell, 1994; Woolf et al., 1994; Safieh-
Garabedian et al., 1995; Falcini et al., 1996; Nonogaki et al., 1996). Second, 
injection of NGF causes an inflammatory response in the paw and increases pain 
and hypersensitivity in animals and humans, respectively (Lewin et al., 1993; 
Petty et al., 1994). Finally, inhibiting NGF signaling by a blocking antibody 
reduces thermal hyperalgesia that develops with CFA-induced inflammation of 
the rat paw (Woolf et al., 1994). Therefore, NGF regulates the sensitivity of 
sensory neurons, and is a neurotrophin that should be studied to determine the 
possible intracellular signaling cascades that regulate its effects in sensory 
neurons. Understanding the intercellular mechanisms that regulate sensitivity of 
sensory neurons will lead to a better understanding of hypersensitivity of neurons 
and of acute and chronic pain.   
 As described above, a number of studies performed previous to this work have 
shown that NGF increases the expression of neuropeptides both in vivo and in vitro 
(Lindsay and Harmar, 1989; Verge et al., 1995; Malcangio et al., 1997; Fehrenbacher 
2005). However, the intracellular signaling pathways that regulate this alteration in 
expression in response to NGF have not been characterized in primary sensory 
neurons.  Therefore, experiments described in this work were designed to determine 
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 what regulatory pathways increase expression of neuropeptides in response to NGF in 
primary sensory neurons.  
 While multiple studies show that exposure of neurons to NGF for a number of 
days increases the expression of both SP and CGRP, it should be mentioned that one 
study by Bowles et. al. did not see a difference in content of CGRP or SP in dorsal horn 
slices after 7 or 14 day treatment of animals with NGF (Bowles et al., 2004). They found 
only an increase in the capsaicin-stimulated release of CGRP after NGF treatment. It is 
not clear why Bowles et. al. observed no changes in peptide expression with NGF 
treatment while many other studies have. For instance, Malcangio et. al. used the same 
doses of NGF (1mg/kg) in vivo, and observed increases in peptide content in rat spinal 
cord tissues (Malcangio et al., 1997). Verge et. al. demonstrated that intrathecal 
administration of NGF (125ng/ul/hr) reversed the loss of neuropeptide expression in 
response to nerve injury (Verge et al., 1995). Furthermore, there is evidence in vitro that 
NGF regulates the expression of iCGRP in primary sensory neurons (Lindsay et al., 
1989; Fehrenbacher, 2005, and Fig. 2).  
 In addition to studies on signaling cascades regulating neuropeptide expression, 
experiments were performed to determine the signaling pathways important in 
regulating the increase in evoked release of iCGRP from neurons in response to brief 
exposure to NGF (Fehrenbacher, 2005). However, a more subtle finding emerged from 
the studies by Fehrenbacher. There are at least two mechanisms that result in 
increased outflow of iCGRP from neurons in response to NGF. Fehrenbacher 
demonstrated that the stimulated release of peptide from sensory neurons increased if 
the cell content of iCGRP was increased after chronic exposure to NGF. Whether the 
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 stimulus was capsaicin or high extracellular potassium, both elicited the increase in 
iCGRP release if content was increased. This suggested that there was an increase in 
expression of iCGRP, which was confirmed by our experiments (Fig. 8).   However, if 
neurons were exposed briefly (10 minutes) to NGF, and then stimulated with capsaicin, 
there was an increase in capsaicin-evoked iCGRP release. This increase is not 
dependent on alterations in expression of the neuropeptide because changes in 
neuropeptide expression do not occur within 10 minutes of NGF exposure. 
Furthermore, if the data are normalized to the total cellular iCGRP content, then the 
percentage of iCGRP released from neurons is higher in neurons exposed to NGF for 
10 minutes. These data indicate that there is both an acute and chronic effect of NGF 
on sensory neurons, and determining the regulatory molecules that mediate these 
changes is the focus of this thesis. 
 In this thesis, it is purported that the increase in release of neurotransmitters 
from sensory neurons is important in the development of hyperalgesia, allodynia, 
neurogenic inflammation, and pain. This idea is supported by studies that show 
hyperalgesia and allodynia develop when there is an increase in neurotransmitter 
release into the spinal cord. Malmberg et. al. delivered capsaicin and PGE2 
simultaneously to the thecal space, and observed increases in the EEAs released into 
the extracellular space (Malmberg et al., 1995). This increase in EEAs induced 
allodynia in animals. In a similar group of studies, Warsame et. al. measured capsaicin-
evoked SP release into the thecal space after CFA-induced inflammation of the paw 
(Warsame et al., 2004). There was a significant increase in SP release compared to 
control animals. These data suggest that increases in release of EEAs and 
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 neuropeptides from primary sensory neurons into the spinal cord contribute to the 
development of hyperalgesia and allodynia in animals. 
 The studies outlined in this thesis show that Ras is necessary for the increased 
expression of iCGRP in response to NGF in sensory neurons in culture. A significant 
increase in RasGTP levels was measured in response to chronic exposure to NGF in 
dorsal root ganglion cultures (Fig. 11).  These results confirm previous studies in PC12 
cells showing incubation with NGF increases Ras activation as measured by increases 
in RasGTP levels  (Ng and Shooter, 1993; Basu et al., 1994; Ganju et al., 1998; Egea 
et al., 2000) . However, these data were correlative and to test the direct involvement of 
the Ras/MEK/ERK pathway in regulation of iCGRP expression, cells were infected with 
lentivirus expressing dominant negative Ras. Results show that cells expressing 
dominant negative Ras have a diminished response to chronic exposure to NGF. 
Neurons expressing dnRas do not express as much iCGRP when grown in the 
presence of 30 or 100 ng/ml NGF as those infected with control virus (Fig. 15).  When 
cells express caRas, there appears to be an increase in iCGRP content even in the 
absence of neurotrophic factors. However, the data are derived from multiple 
measurements in a single experiment.  Therefore, further studies are needed to 
determine if this result will be reproducible. If the increase occurs in the absence of 
NGF, one could conclude Ras activation is sufficient for the expression of iCGRP in 
sensory neurons.  
 As shown in Figure 15, there is still an increase in iCGRP in neurons exposed to 
30 and 100 ng/ml NGF in the presence of dnRas. There are at least two possibilities to 
explain why expression is still upregulated in neurons expressing dnRas. First, the 
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 activity of Ras may not be sufficiently blocked to completely inhibit iCGRP expression in 
response to NGF. This possibility could be resolved by increasing the number of pfu 
used to infect the cells, and then measure whether iCGRP expression is blocked to a 
greater extent in the presence of NGF. However, an alternate explanation is that there 
may be redundant signaling pathways to increase iCGRP expression, such that NGF 
signaling to Ras may not be the only pathway involved in upregulation of transcription. 
A recent report by Bellamy et. al. revealed that iCGRP expression in trigeminal neurons 
could be increased by treatment of cells with nitric oxide (Bellamy et al., 2006). In their 
studies, they showed that PI3 kinase and cGMP were not required for the increase in 
peptide expression, which suggests that in some types of sensory neurons, there are 
other signaling cascades that regulate iCGRP expression. Whether this regulatory 
pathway is similar in dorsal root ganglion neurons has not been explored.  
 As another means to inhibit Ras, cells were exposed to the farnesyltransferase 
inhibitor, FTI-276 (Fig. 18). This drug blocks the addition of a farnesyl group to the 
carboxy terminus of Ras. The data in Figure 18 show there is an increase in the level of 
unfarnysylated Ras with exposure to FTI-276. Presumably, this results in improper 
localization and decreased activity. The data in Figure 20 show that FTI-276 attenuates 
the NGF-induced increase in iCGRP expression at 100 ng/ml NGF. These data 
suggest that proper localization of Ras, which affects its ability to signal in neurons, is 
necessary for NGF to signal to this protein and increase expression of CGRP. 
Interestingly, at 30 ng/ml NGF or with no added NGF there seems to be a downward 
trend in the expression of iCGRP, but the difference was not siginificant. This may 
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 suggest that even without added NGF, the Ras pathway is active and the addition of 
FTI-276 causes some level of inhibition of iCGRP expression in our experiments.  
 As another means to manipulate the Ras pathway, neurons from synGAP 
heterozygous mice were used. Neurons from these mice have a reduced expression of 
synGAP, a RasGAP that decreases activity of the Ras protein. Komiyama et. al. 
showed that decreased expression of synGAP led to activation of ERK in hippocampal 
neurons from mice (Komiyama et al., 2002). In experiments in this thesis, 100 or 250 
ng/ml NGF caused a significant increase in the iCGRP expression in dorsal root 
ganglion neurons derived from mice with a heterozygous deletion of the synGAP gene 
compared to expression of iCGRP from wildtype littermate controls (Fig. 25). These 
data suggest upregulating activity of the Ras pathway controls expression of iCGRP in 
neurons derived from mice.  However, what is interesting is that Komiyama et. al. 
showed that the Ras/MEK/ERK pathway is upregulated in tissues derived from 
heterozygous mice which were not treated with NGF (Komiyama et al., 2002). This 
would imply with no added NGF, if Ras is constitutively active, there should be a 
difference in iCGRP expression when comparing synGAP heterozygous and wildtype 
neurons. Yet, no differences were observed in content in neurons from synGAP 
heterozygous mice versus neurons from wildtype animals in the absence of NGF (Fig. 
25). The neurons must be stimulated with higher concentrations of NGF (100 or 250 
ng/ml NGF) before differences from their littermate controls are observed. One 
explanation for the discrepancy between the data in sensory neurons and hippocampal 
neurons is that the level of activity of the Ras/MEK/ERK pathway in peripheral neurons 
versus neurons from the hippocampus might be different. It also is possible that higher 
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 levels of the pERK are needed compared to those in unstimulated tissues to drive the 
expression of iCGRP in dorsal root ganglion neurons. Finally, it is possible that 
pathways other than Ras/MEK/ERK promote the expression of iCGRP. In fact, other 
studies show that synGAP may also regulate another small G-protein, Rap (Knuesel et 
al., 2005). This G-protein is not well-studied in neurons, but could play also play a role in 
the regulation of iCGRP expression in neurons.   
 The most surprising result from studies using synGAP heterozygous mice is that 
the neurons from the wildtype mice did not show an increase in iCGRP content with 
increasing concentrations of NGF after 7 days. In the literature, transgenic mice on a 
C57Bl background were used to assess the effects chronic NGF exposure to SP or 
CGRP expression. These reports show increases in neuropeptide immunoreactivity in 
response to chronic exposure to the neurotrophin (Schmidt et al., 1995; Ma and Bisby, 
1998; Dinh et al., 2004). In these cases, the concentrations of NGF were similar to 
those used in studies in this thesis. No clear explanation to date can explain this 
discrepancy in findings. The wildtype mice for all practical purposes should have an 
intact promoter and enhancer elements of the CGRP gene. It could be that this 
particular strain of mice has very efficient GAPs, and the concentrations of NGF used in 
these experiments did not cause changes in iCGRP levels in adult animals. Further 
studies could be performed to determine the reasons why neurons from these animals 
do not respond to NGF in a similar manner to C57Bl transgenic mice demonstrated in 
other studies. 
 Based on data from this thesis using dnRas and FTI-276, which both reduce 
Ras activity, it is the small GTPase is functioning to control the expression of iCGRP 
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 in sensory neurons in culture. Whether the sphingomyelinase pathway regulates 
peptide expression was not tested in experiments in this thesis. Evidence exists 
that the p75NTR is involved in the regulation of SP expression in sensory neurons 
in culture (Skoff and Adler, 2006).  When neurons in culture are exposed to NGF 
(10ng/ml) for 7 days in the presence of a blocking antibody to either the TrkA 
receptor or to p75NTR, there was a significant decrease in the amount of SP 
expressed as measured by radioimmunoassay in a manner similar to those 
described in this thesis (Skoff and Adler, 2006). This finding demonstrates a 
need for specific inhibitors of downstream signaling cascades of p75NTR that do 
not affect the resting release of neuropeptides from sensory neurons. 
 In the studies in this thesis, the signaling cascades regulating an increase in 
evoked release of iCGRP with brief exposure to NGF were examined. The Ras 
cascade was tested first. There was no difference in the degree of sensitization by NGF 
when neurons expressed dnRas compared to neurons infected with a control virus (Fig. 
29). All treatment groups showed an approximate two-fold increase in capsaicin-
stimulated iCGRP release brief exposure to NGF (Fig. 29). These results provide 
evidence that Ras does not mediate the NGF sensitization of release. However, it was 
observed that in neurons expressing dnRas there was a significant decrease in 
capsaicin-evoked release from both the control and NGF-treated neurons. A likely 
explanation is that there is an overall decrease in the expression of the neuropeptide 
due to decreased Ras activity. It is probable because we showed that dnRas decreases 
iCGRP expression in response to NGF to a similar degree (Fig. 15). However, another 
possible explanation for these findings is the dnRas expression induces a decrease in 
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 the expression of TRPV1. Although TRPV1 expression was not measured in these 
studies, it has been shown that capsaicin-sensitivity and TRPV1 expression in sensory 
neurons is increased by activation of the Ras/MEK/ERK pathway (Winter et al., 1988, 
Bron et al., 2003). Furthermore, there are multiple studies that show that the 
upregulation of TRPV1 is an underlying cause of changes in capsaicin-sensitivity in 
response to NGF (Bonnington and McNaughton, 2003; Bowles et al., 2004).  
 MEK and ERK are not mediators of the increased evoked-release of iCGRP in 
response to 20 minute stimulation with NGF (Fig. 33). There was no increase in the 
levels of pERK in response to 10 minute incubation with NGF (Fig. 31). These results 
conflict with other studies in the literature which use comparable concentrations of NGF 
to stimulate sensory neurons. First, Zhuang et. al. showed that 2 and 10 minute 
stimulations with NGF-induced a significant upregulation of pERK levels in sensory 
neuronal cultures (Zhuang et al., 2004). Bron et. al. also found a significant increase in 
pERK with brief NGF exposure (Bron et al., 2003). The major differences between their 
studies and those presented in Figure 31 are culture conditions. Neurons used in the 
studies by Zhuang et. al. and Bron et. al. are grown in culture for 24 hours or 4-5 days, 
respectively. The neurons used in their experiments are kept in serum free media for at 
least 24 hours prior to their experiments. In contrast, neurons in the studies presented in 
the current work are grown for 7 days in 30 ng/ml NGF in media with serum. In 
experiments in this thesis, we chose to use serum because physiologically neurons 
would likely be exposed to serum continuously. Furthermore, we chose to grow 
neurons in 30 ng/ml NGF for 7 days because we were still able to observe NGF-
induced sensitization while simultaneously increasing peptide content enough to 
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 measure capsaicin-evoked release. Neurons still can be sensitized by acute NGF 
exposure after just 2 days in 30 ng/ml NGF in media with serum (data not shown). 
Therefore, the differences observed between the data presented here and the data 
presented by the groups above are most likely derived from differences in exposure to 
serum with or without NGF.  
 What is important to note, is even without significant increases in pERK in 
neurons grown in serum with 30ng/ml NGF in our studies, there is still a significant 
increase in the levels of capsaicin-evoked iCGRP release when neurons are exposed 
to NGF for 10 minutes (Fig. 35). This indicates that sensitization is occurring even in the 
absence of an increase in ERK activity, or there is no correlation between NGF-induced 
increases in capsaicin-evoked iCGRP release and changes in pERK levels. 
Furthermore, this NGF-induced increase in iCGRP expression is not blocked by 
exposing neurons to 1μM of the MEK inhibitor, U0126, showing that pERK is not a 
mediator of NGF-induced increases in capsaicin-evoked release of iCGRP (Fig. 36). It 
is unlikely that the concentrations of U0126 used in these experiments (1μM) are not 
effective in blocking MEK activity because this concentration blocked the PDBu-induced 
increase in pERK in neuronal culture (Fig. 38). 
 In experiments where neurons were treated with FTI-276, and then capsaicin-
evoked release was measured, FTI-276 increased capsaicin-evoked release (Fig. 30). 
Because FTI-276 increased capsaicin-evoked release to levels greater than the amount 
of release observed under control conditions, the effect of this drug on NGF-induced 
sensitization could not be interpreted. These results suggest that FTI-276 may act non-
specifically to alter stimulated release from sensory neurons in culture. It is known that 
 172
 FTI-276 may target a variety of proteins that are prenylated by the enzyme, 
farnesyltransferase (Sebti and Der, 2003). The majority of the studies using FTI-276 
were performed in cell lines. Therefore, it is not known what proteins are targeted by this 
enzyme in primary sensory neurons besides Ras. Possible targets of FTI-276 that may 
cause the increase in capsaicin-stimulated iCGRP release from sensory neurons are 
protein tyrosine phosphatases. Some phosphatases, specifically PTP(CAAX) or PRL-1, 
2, and 3, are prenylated by farnesyltransferase, and are localized to the membrane  
(Cates et al., 1996). These proteins are expressed in neurons of the central nervous 
system, but their presence in dorsal root ganglion neurons has not been studied 
(Takano et al., 1996). In many cases, these phosphatases inhibit the actions of receptor 
tyrosine kinases by dephosphorylating them. A loss of inhibition of receptor tyrosine 
kinases after incubation with FTI-276 could lead to a gain of function in proteins that are 
negatively regulated by dephosphorylation. As proof of concept that phosphatases are 
critical in regulating sensitivity of sensory neurons, the Vasko laboratory has previously 
shown that exposing sensory neurons in culture to the phosphatase inhibitor, okadaic 
acid, causes increased evoked release of iCGRP (Hingtgen et al., 1994). As in our 
experiments using FTI-276, there was no change in the resting release of neurons 
exposed to okadaic acid. 
 It also has been shown that FTI-276 blocks the addition of a farnesyl group, but 
other lipid groups are still added. Therefore, the lipid composition of the molecule is 
changed (Sebti and Der, 2003). An example is the Rho-b protein, which is in the family 
of small GTPases. Two lipids, a farnesyl group and geranylgeranyl group, can be 
added to this protein. When the protein contains only  the geranylgeranyl group, it 
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 localizes to another location in the cell and can signal to a different complement of 
molecules (Lebowitz et al., 1997; Lebowitz and Prendergast, 1998). While there is too 
little data in neurons to draw any conclusions about what is occurring, one could 
speculate that this differential localization of proteins also occurs in neurons. These 
findings may help to explain why there is an increase in capsaicin-evoked iCGRP 
release in the presence of FTI-276. For instance, the TRPV1 receptor may be inhibited 
constitutively by phosphatases that require the addition of lipid groups post-
translationally (Chuang et al., 2001). If these phosphatases are not properly localized, 
TRPV1 could be more active. Upon capsaicin-stimulation, a more active TRPV1 
channel could result in the increase in capsaicin-evoked release.  
In addition to the expression of mutant isoforms of Ras and the use of 
farnesyltransferase inhibitors, the Ras pathway was manipulated using mice with a 
heterozygous deletion of the RasGAP, synGAP. One limitation in using these 
genetically altered mice is the neurons with a heterozygous deletion of synGAP may 
exhibit some level of compensation so that the cell develops the ability to overcome 
increased Ras activation in order to function normally. We also developed siRNA to 
decrease synGAP expression in neurons derived from normal adult animals, and 
measured release of iCGRP in response to capsaicin in the presence or absence of 
acute stimulation with NGF. In cells treated with synGAP siRNA, there was a slight 
increase in the magnitude of sensitization compared to neurons treated with a control 
siRNA (Fig. 34). The data from these experiments could be interpreted two ways. First, 
it is clear that a decrease in synGAP may lead to the increased expression of iCGRP 
especially when the neurons are grown in NGF, as these neurons were. This slight 
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 increase could be secondary to an increase in the level of CGRP expressed. In this 
group of experiments release was not measured as a percentage of total content. 
However, these data also could indicate that indeed decreased synGAP leads to 
greater sensitization, and indicate that Ras plays a role in sensitization. However, these 
data taken into account with the other experiments that discount Ras and ERK as 
mediators of sensitization, leads this author to believe that this small increase in the 
degree of sensitization is likely due to slight changes in content. To confirm this, 
experiments should be repeated and measure release as a percentage of total content.   
 Inhibitors of the PI3 kinase pathway, another cascade activated by Ras, did not 
affect the NGF-induced increase in iCGRP (Fig. 40). The two drugs used to inhibit PI3 
kinase in these studies were wortmannin (3nM) and LY294002 (3μM). The IC50 for 
wortmannin in inhibiting PI3 kinase is 6nM , and for LY294002 it is approximately 1.4μM 
(Yano et al., 1995). While the concentrations used for these experiments were near the 
IC50, using greater concentrations caused an increase in the resting iCGRP from 
neurons when they were exposed to the drug alone without any stimulating agent. For 
instance, using LY294002 at 10 or 20μM increased resting release from neurons in 
culture by 2-3 fold (data not shown). Other studies demonstrated that brief exposure to 
NGF increased the phosphorylation of Akt using immunohistochemistry (Zhuang et al., 
2004). Prior to their brief exposure to NGF, the neurons were not exposed to added 
NGF or serum in media in these experiments. However, in experiments in this thesis, 
neurons grown in serum at 30 ng/ml NGF for 7 days did not appear to have increased 
pAkt after a 10 minute exposure to NGF (personal communication, Dr. Judith Richter). 
The differences in the results are likely due to different culture conditions and NGF 
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 exposure times. Because there was no change in NGF-induced sensitization in the 
presence of LY294002 or wortmannin, and there was no change in the levels of pAkt in 
neurons exposed for 10 minutes to the neurotrophin, this pathway is not a likely 
mediator of the NGF-induced increase in capsaicin-evoked release in our experiments. 
 In contrast to the classic pathways described above, activation of Src kinase 
does appear necessary for NGF-induced sensitization of sensory neurons (Fig. 44). In 
the current studies, it was determined that a protein that does regulate the increase in 
capsaicin-evoked release of iCGRP with 10 minute exposure to NGF is Src kinase (Fig. 
44). The Src kinase inhibitor, PP2 (10μM), was used to block activity of this protein in 
neurons. The NGF-induced increase in capsaicin-evoked release was blocked 
completely at this concentration of PP2, whereas the inhibitor had no affect on 
capsaicin-evoked release in the absence of NGF or on basal release from the neuorns 
(Fig. 44). In contrast to these findings, PP3, the inactive analogue to PP2, did not affect 
the NGF-induced increase in capsaicin-evoked release and did not affect basal release. 
These results suggest that indeed Src kinase is playing a role in NGF-induced 
sensitization of sensory neurons. The findings in these current studies substantiate 
published results using sensory neurons from adult mice and heterologous expression 
systems. Zhang et. al. found that the NGF-induced increase in Ca2+ influx in HEK293 
cells expressing the TRPv1 receptor could be blocked by the Src kinase inhibitor 
(Zhang et al., 2005). The mechanism by which this increased Ca2+ occurs is not known. 
Zhang et. al. suggest that Src kinase phosphorylates the TRPV1 receptor and causes 
translocation of TRPV1 to the membrane of the HEK293 cells. This may be the case, 
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 but these results must be duplicated in specifically in sensory neurons to substantiate 
their findings in heterologous expression systems.  
 In other studies on Src kinase, Jin et. al. found that PP2 decreased capsaicin-
evoked currents in dorsal root ganglion neurons, and they showed TRPV1 and Src 
kinase co-precipitated in lysates from a heterologous expression system. These data 
suggest that Src kinase may directly phosphorylate TRPV1 (Jin et al., 2004). Other data 
show that constitutively active Src can phosphorylate and activate the TrkA receptor in 
SK-N-MC neuroblastoma cell line (Tsuruda et al., 2004). This may represent a feed 
forward mechanism where NGF activates Src possibly through binding to 
phosphotyrosines on the cytoplasmic tail of TrkA (Fig. 2). In turn, active Src may 
phosphorylates the TrkA receptor to enhance its signaling.  
 Another study demonstrated Src could augment release of neuropeptides (Igwe, 
2003). This study showed that Src regulates the increased expression and release of 
SP from dorsal root ganglion neurons in culture in response six hours of exposure to the 
cytokine, interleukin 1-β (IL-1β). The author used PP2 (100nM) to show that both 
release of neuropeptide and Src kinase activity in neurons were decreased in the 
presence of the inhibitor. What is not clear from this study using IL-1β is whether 
alterations in release of SP are a result of increased expression of the peptide alone or 
whether there is a component of SP release affected by altered excitability. It is more 
likely that IL-1β increases production of SP because it has been previously shown that 
this interleukin does not sensitize sensory neurons in culture (Nicol et al., 1997). 
 NGF-induced sensitization of iCGRP release also was blocked by the PKC 
inhibitor, BIM. These findings provide evidence that this kinase is involved in the 
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 upregulation of stimulated outflow of neuropeptides caused by NGF (Figs. 41 and 42). 
BIM is an inhibitor of the classic and novel PKCs, but not the atypical isoforms. The 
mechanism by which PKC controls NGF-induced sensitivity in sensory neurons is not 
known, but experiments suggest that PKC phosphorylates and sensitizes the TRPV1 
receptor  (Bhave and Gereau, 2004). In light of the data showing Src kinase as a 
regulator of sensitivity, it may be that PKC is downstream from Src (Fig. 2). It has been 
demonstrated in cell lines that Src kinase can phosphorylate and active PKCδ, a novel 
PKC isoform which is inhibited by BIM  (Joseloff et al., 2002).  
 Whether or not Src kinase directly modulates the release of iCGRP in response 
to brief stimulation with NGF, or indirectly through activation of PKC isoforms in sensory 
neurons is not known. Many studies have been performed on the Src kinase pathway in 
PC12 cells or in HEK heterologous expression systems (Igwe, 2003; Seibenhener et 
al., 1999; Wooten et al., 2001). The results from these experiments are mixed. As 
described above, Src kinase may directly bind to and phosphorylate the TRPV1 
receptor to increase its activity (Jin et al., 2004). However, the atypical PKCs, such as 
PKCζ and PKCι (also called PKCλ in the rat), are activated by 15 minute stimulation of 
PC-12 cells with 100 ng/ml NGF (Wooten et al., 1994; Wooten et al., 2001). While these 
studies are compelling, more studies must be completed to understand how Src 
kinases may regulate the responses to NGF in sensory neurons both in vitro and in 
vivo.   
 The literature on PKC signaling downstream of NGF is extensive. The isoforms 
of PKC implicated in NGF-induced sensitivity and hyperalgesia include PKC-ε, PKC-δ, 
and PKC-α (O'Driscoll et al., 1995; Khasar et al., 1999; Ferreira et al., 2005). The 
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 atypical isoforms, PKC-ι/λ and PKCζ, are activated by Src kinase in response to NGF. 
Futhermore, BIM, which inhibits many isoforms of PKC, blocks the NGF-induced 
increase in capsaicin-evoked iCGRP release (Figs. 41 and 42). Based on these data, it 
is likely that the classic and/or novel isoforms of PKC are involved. An attempt was 
made to selectively decrease isoforms of PKC in sensory neurons, and test the NGF-
induced sensitization of neurons (Fig. 43). PKCα expression was reduced by 50% 
using siRNA, but there not appear to be a difference in the capsaicin-evoked release of 
iCGRP in the presence of NGF. While the experiment using PKCα siRNA is a 
single harvest of neurons and needs to be replicated, the results are compelling. 
They show that PKCα is not a likely mediator of NGF sensitization of capsaicin-
evoked release from sensory neurons in culture. Other isoforms of PKC need to 
be tested to determine if any specific one can selectively block NGF-induced 
sensitization of sensory neurons.    
 In addition to testing signaling pathways that are classically linked to the TrkA 
neurotrophin receptor, such as MEK/ERK, data from these experiments demonstrate 
that S1P is involved in the regulation of evoked release (Fig. 46). While S1P could 
be produced from the activation of other pathways, it is interesting to speculate 
that the p75NTR could be involved.  As shown above in Figure 2, NGF binds to the 
p75NTR, which activates sphingomyelinase. Sphingomyelinase cleaves 
sphingomyelin to produce ceramide. Ceramide is metabolized to sphingosine, 
which can be phosphorylated by sphingosine kinase to yield S1P in the cell. S1P 
increased the capsaicin-induced release of iCGRP from sensory neurons in 
culture (Fig. 46). While our studies did not determine whether or not the p75NTR 
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 was involved in NGF-induced sensitization, further studies could be developed to 
determine if NGF does in fact alter capsaicin-evoked iCGRP release through this 
pathway.   
 In contrast to published findings, our data indicate that ceramide, the 
precursor to S1P, did not change the capsaicin-evoked release of iCGRP from 
neurons (Fig. 45). It is unclear why S1P, but not ceramide, sensitizes cells. 
Zhang and Nicol found the NGF enhances neuronal excitability through the 
p75NTR because using a p75 blocking antibody inhibits the increases in the 
number of action potentials in response to a ramp of depolarizing current (Zhang 
and Nicol, 2004). Also, the authors link NGF signaling specifically to downstream 
mediators of the p75NTR. They show sensitization of sensory neurons by the 
neurotrophin could be blocked by inhibiting the conversion of sphingosine to S1P 
using DMS, an inhibitor of sphingosine kinase (Zhang et al., 2006). However, 
these authors also have determined that ceramide sensitizes sensory neurons in 
a similar manner to S1P (Nicol et al., 1997). One possible cause for the 
differences in results from our data and data from the Nicol laboratory, namely 
that ceramide does or does not sensitize neurons, is that the endpoints of our 
experiments, capsaicin-evoked iCGRP release, and the endpoints of studies by 
Zhang and Nicol, numbers of action potentials evoked by a ramp of current, are 
not equal and cannot be compared directly. 
 It is well established that there are interactions between the p75NTR and 
the TrkA receptor. The two receptors co-precipitate in spinal cord and brain 
tissues (Huber and Chao, 1995). It is purported that the interaction between the 
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 two receptors confers specificity for NGF binding to TrkA, and increases the 
activity of TrkA when the neurotrophin is bound (Barker and Murphy, 1992; 
Benedetti et al., 1993). In the experiments described in this thesis, the receptor 
through which NGF was acting was not defined. However, both of these 
receptors, the TrkA and p75NTR, are present on sensory neurons in culture, and it 
is likely that they are interacting as shown in cell lines. Although not the focus of 
the thesis, the contribution of these receptors to the NGF-induced increase in 
capsaicin evoked release could be determined by using antibodies that either 
block or activate TrkA and p75NTR and test the ability of NGF to increase 
capsaicin-evoked release. The laboratory of LF Reichardt has published the 
development of a TrkA activating antibody (Weskamp and Reichardt, 1991), 
which could be used to determine if the increases in NGF content and evoked 
release were mediated by TrkA. Furthermore, siRNA to specifically target either 
receptor could be used, and then the ability to NGF to sensitize neurons could be 
tested. 
 Overall, the experiments presented in this thesis show that NGF activates the 
Ras signaling pathway(s) to regulate the expression of iCGRP in neurons and Src 
kinase/PKC regulate the amount transmitter released from a neurons. This differential 
signaling through neurotrophin receptors is a concept well-established in the literature.  
Mutants of the TrkA receptor have been generated that lack the ability to signal to one 
or more of the downstream pathways activated by NGF (Loeb et al., 1994; Kaplan and 
Miller, 1997; Eggert et al., 2000). These mutants, which can then be expressed in cell 
lines, have given insight into which regions of the TrkA receptor are important for 
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 activation of the Ras, PI3 kinase, and PLC pathways, and others. Eggert et. al. 
expressed wild-typeTrkA or one of five TrkA mutants into the SH-SY5Y cell line. In cells 
transfected with the wild-type TrkA, exposure to NGF slowed their proliferation and 
differentiated. This was also the case in cells transfected with TrkA mutants that no 
longer signaled to PI3 kinase. These results suggest that the PI3 kinase pathway was 
not involved in signaling cells to stop dividing and start differentiating. Conversely, when 
TrkA mutants with the inability to activate the PLC pathway were transfected into 
neurons, differentiation was blocked, which implies this pathway is involved in the 
regulation of differentiation in response to NGF. However, there may be a more 
complex story to TrkA receptor signaling that just individual pathways activated by 
specific locations on the TrkA receptor. Meakin et. al. have shown there is competition 
for binding a single location on the TrkA receptor (Meakin et al., 1999). The complement 
of proteins within the cell and the ability of those proteins to bind at the receptor at the 
time of NGF binding may dictate what signals are further propagated. 
 Based on current knowledge, NGF can activate multiple downstream 
signaling cascades. The data from experiments in this thesis indicate iCGRP 
expression after chronic exposure to NGF is regulated by a different pathway 
than alterations in capsaicin-stimulated release with brief exposure to NGF. It is 
interesting to speculate how these findings might explain what has been 
demonstrated by studies using NGF in vivo. For instance, Lewin et. al. showed 
that administration of NGF to rats resulted in a hyperalgesia with two observed 
components (Lewin et al., 1993). First there was a thermal hyperalgesia that 
developed within 15 min after NGF injection. Then a mechanical hyperalgesia 
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 developed within 24 hours of NGF. The thermal hyperalgesia that develops 
immediately could be the result of post-translation changes in the TRPV1 
receptor in response to NGF. Perhaps Src kinase is activated by NGF, which in 
turn phosphorylates and activates TRPV1. When the animal is stimulated with 
noxious heat, the primary sensory neurons release more neurotransmitter in a 
similar manner to neurons stimulated with capsaicin in the presence of NGF. 
Because the changes could be TRPV1 specific, only the thermal hyperalgesia 
would be apparent. 
 A global question that arises from these studies on the effects of NGF on 
sensory neurons is whether the neurotrophin and its signaling cascades are good 
targets for therapeutics for inflammation and chronic pain. Recent reviews 
suggest inhibition of NGF is a good strategy to decrease chronic pain (Hefti et al., 
2005; Pezet and McMahon, 2006). In these two articles, the authors argue that 
current work both in vitro and in vivo suggests NGF augments the sensitivity of 
sensory neurons to and contributes to the development of chronic pain 
secondary to injury or inflammation. During inflammation, NGF upregulates 
multiple proteins that control the sensitivity of sensory neurons, such as ion 
channels, including TRPV1 and Nav 1.8 and 1.9, and neuropeptides (see above). 
Blocking NGF signaling reduces pain associated with a number of clinical 
problems including arthritis, pain associated with cancers invading bones, and 
post-operative pain (Voilley et al., 2001; Mamet et al., 2002; Mamet et al., 2003). 
Conversely, phase II trials are complete for recombinant human NGF therapy for 
improvement of sensory neuropathy associated with HIV infection (McArthur et 
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 al., 2000). There was a significant improvement in the intensity of pain 
experienced by individuals receiving the NGF versus individuals receiving 
placebo. 
 While the molecular mechanisms responsible for physical findings and 
symptoms associated with acute and chronic pain are still being determined, it is 
clear NGF contributes to neuronal plasticity. Because the development of pain 
appears to be from various causes, such a peripheral neuropathy caused by 
diabetes, reflex sympathetic dystrophy after bone fracture, or chronic low back 
pain after repetitive use, this author no longer believes chronic pain is one type of 
disease, but it is specific to a disease process. Subsequently, it may be more 
fruitful to study sensory neurons in the context of each disease. NGF will likely be 
a central inflammatory mediator in many of these processes, and in some cases 
it will be necessary to block its effects, while in others it will be beneficial to treat 
with NGF. Using the key findings in this thesis, (1) Ras regulation of iCGRP 
expression in response to chronic NGF, and (2) Src and PKC regulation of NGF-
induced increases in evoked release of iCGRP, may be good starting points for 
further research in determining the mechanisms of development of pain in one or 
more of these disease processes.   
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